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ABSTRACT 
The discovery of the involvement of the Bcr-Abl gene in chronic myeloid leukaemia 
(CML) has led to the rapid development of targeted tyrosine kinase inhibitors (TKIs), 
such as imatinib, which specifically interrupt the abnormal protein tyrosine kinase (PTK) 
pathways of the Bcr-Abl fusion protein. Imatinib is currently used as a frontline therapy, 
with impressive outcomes at producing long-term clinical remission among many CML 
patients; however, resistance to imatinib has been reported in patients due to the 
development of Bcr-Abl mutations and/or intolerance to the drug. Potent second 
generation TKIs, namely nilotinib and dasatinib, have since been developed and approved 
to address this therapeutic challenge. Nilotinib and dasatinib have shown a great efficacy 
against leukaemic cells, with rapid and pronounced haematological and molecular 
remission rates. Therefore, nilotinib and dasatinib are now established as highly effective 
frontline therapies for CML.  
Disease control is achieved in the majority of patients and survival is excellent. 
Consequently, the recent focus on these agents has been on their toxicities. Cumulative 
data have reported an excess of serious vascular complications, including arterial 
thrombosis and peripheral arterial occlusive disease (PAOD), in patients receiving 
nilotinib when compared with other TKIs, with a resultant interest in delineating the 
pathophysiology and implications for rational modification of the cardiovascular risk.  
Cardiovascular disease is a major clinical issue and a leading cause of illness, disability 
and death burden in the world, specifically in industrialised countries. Platelets are 
essential in normal haemostasis as they prevent blood loss following trauma by blood clot 
formation and they sustain vascular integrity. They also play a crucial role in the 
pathophysiological processes of atherosclerotic plaque and arterial thrombotic disease by 
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contributing to vaso-occlusive thrombotic mechanisms that generate ischaemic traumatic 
damage in cardiovascular and peripheral blood vessel disease. The adherence of platelets 
under specific circumstances of high flow shear rates in stenotic blood arteries increases 
the responsiveness of platelet reactivity, which results in enhanced in vivo arterial 
thrombosis. 
In the context of the vasculature, the role of platelets in pro-atherothrombotic mechanisms 
is now well recognised and implicates pro-inflammatory adhesive molecules in the 
mediation of the interactions of platelets and endothelium at site of ruptured 
atherosclerosis plaques. This promotes the recruitment and adhesion of leukocytes, 
thereby leading to enhancement of atherosclerotic plaque formation and development of 
arterial thrombosis. The anti-leukaemic therapies, such as TKIs, are commonly associated 
with modifications of platelets and endothelial functions that lead to the production of 
pathological thrombi.  
The aim of this thesis was to study the effects of imatinib, nilotinib and dasatinib on 
platelet function and thrombus formation in human and mouse models using in vitro, ex 
vivo and in vivo approaches. The overarching goal was to provide a comprehensive 
analysis that would improve the understanding of potential mechanisms by which the 
TKI, nilotinib, potentiates a prothrombotic state.  
In vitro experiments demonstrated that dasatinib and imatinib, but not nilotinib, inhibited 
ADP, CRP, and collagen-induced platelet aggregation. Nilotinib also potentiated PAR-1-
mediated alpha granule release, whilst imatinib and dasatinib showed inhibitory effects on 
platelet alpha granule exocytosis following agonist stimulation. The studies also showed 
that nilotinib and imatinib had negligible effects on dense or lysosomal granule release 
from platelets in response to a soluble agonist. In the present study, we demonstrated that 
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incubation of whole blood from healthy humans or C57BL/6 mice with different 
concentrations of nilotinib, and but not dasatinib, caused no alterations in thrombus 
growth on type I collagen under in vitro flow conditions. Accordingly, pretreatment of 
C57BL/6 mice with nilotinib (25 and 50 mg/kg), but not imatinib (25 and 50 mg/kg) or 
dasatinib (2.5 and 5 mg/kg), significantly increased both platelet thrombus growth and 
stability on type I collagen under ex vivo arterial flow conditions.  
Intravital microscopy of vascular injury of mesenteric arterioles and carotid artery 
induced by ferric chloride (FeCl3) confirmed a significant increase in in vivo thrombus 
formation and stability over time in mice treated with nilotinib (25 mg/kg), but not with 
imatinib (25 mg/kg) or dasatinib (5 mg/kg). In addition, the effect of nilotinib was 
independent of platelet glycoprotein surface expression. Nilotinib selectively potentiated 
alpha granule exocytosis in humans and mice, but it did not induce spontaneous 
conversion of the major platelet integrin αIIbβ3 into its active conformation for binding to 
its ligand, fibrinogen, and mediation of platelet aggregation. We showed that the effect of 
TKIs on in vivo thrombus formation was reversible 48 hours after a single acute dose. An 
interesting discovery was that the increased ex vivo and in vivo thrombus formation by 
nilotinib TKI required pre-treatment of C57BL/6 mice until peak drug (Cmax) was 
achieved and the vessel wall and blood components were primed. 
The thesis data confirmed that whole blood from nilotinib-treated CML patients showed 
increased ex vivo platelet adhesion under flow and increased plasma levels of soluble P-
selectin (sP-selectin) and CD40L (sCD40L), as well as enhanced in vivo thrombin 
generation [as measured by thrombin peak and endogenous thrombin potential (ETP)], 
even if patients were also on daily low-dose aspirin. In contrast to nilotinib, we and others 
have demonstrated that CML patients treated with either dasatinib or imatinib show an 
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inhibition of thrombus formation when compared with normal human donors, but the 
effect of dasatinib was more pronounced. These results indicate that chronic treatment of 
CML patients with nilotinib selectively induces both endothelial and platelet activation 
and that these perturbations could predispose them to the risk of formation of pathological 
blood clots in vivo.  This risk could be further enhanced by the presence of existing 
cardiovascular risk factors.    
The studies presented in this thesis have provided the first evidence of potentiation of 
platelet and/or endothelium activation, adhesive molecule secretion and increased 
thrombin generation in response to nilotinib treatment. The results suggested that the pro-
thrombotic phenotypes of nilotinib therapy required the presence of endothelial cells to 
prime the platelets in order to trigger potentiation of in vivo arterial thrombus formation. 
Ultimately, the results from this thesis indicated that nilotinib may modulate 
atherothrombosis by multiple off target mechanisms that affect the physiological profiles 
of platelets, endothelial cells and leukocytes. 
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Tyrosine kinase inhibitors (TKIs) such as imatinib are the frontline therapy for chronic 
myeloid leukaemia (CML). While imatinib treatment has led to much clinical success, 
some patients are intolerant or become resistant. Consequently, second generation of TKIs 
including nilotinib and dasatinib were developed. Although more potent than imatinib, 
nilotinib therapy increases the risk for heart/vascular complications likely through 
thrombotic events. Therefore, this study aims to explore the mechanism(s) of how nilotinib 
may potentiate thrombotic complications using human and wild-type mouse platelets and 
by monitoring CML patients during treatment. 
1.1 PLATELET OVERVIEW 
Platelets were discovered in 1882 by Giulio Bizzozero, who described these unique 
fragments as granular, irregular and anuclear discs. Platelets are fragments derived from 
megakaryocytes and have great importance in medicine. They are involved in metabolic 
processes such as haemostasis and thrombosis [1, 2] including numerous 
pathophysiological processes such as inflammation, atherosclerosis and malignancy. 
Haemostasis is the process that arrests blood loss subsequent to vascular injury, and in 
maintaining blood in a fluid state within the blood stream [3, 4]. The haemostatic process 
is initiated by platelet adhesion to the injured area that is followed by platelet aggregation 
and the production of a pro-coagulant surface. Platelet aggregation supports the formation 
of a haemostatic thrombus that prevents blood loss at the site of blood vessel injury [5, 6].  
Thrombus formation is normally regulated and limited at all times to prevent excessive 
platelet clumping and vessel occlusion. This is triggered by platelet activation that is 
inhibited by the secretion of bioactive naturally occurring inhibitory molecules such as 
nitric oxide (NO) and prostacyclin (PGI2) derived from endothelial cells [7, 8]. Any 
marked increase in platelet reactivity that promotes the interaction and adhesion to the 
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intact blood vessel wall results in dysregulated platelet-endothelial interactions; thereby 
induces the development of cardiovascular disease (CVD) [9]. However, if platelet 
function and/or platelet count is altered by tipping the balance in one direction or another 
abnormal haemostasis can typically occur and result in an enhanced risk of haemorrhage or 
thrombosis phenomena [10]. 
1.2 PLATELET FORMATION 
Platelets are derived from mature bone marrow precursors called megakaryocytes (MKs) 
[11, 12] which arise from haematopoietic stem cells (HSCs). The production of platelets 
requires a complex sequence of modifying events that lead to the production of 1×10
11
 
platelets per day from the cytoplasmic fragmentation of MKs in every healthy individual 
[13]. The development of platelet formation occurs in response to growth factors such as 
thrombopoietin (TPO) which functions as the primary regulator of megakaryocytopoiesis 
[14]. The TPO is thought to work in association with cytokines, including interleukins (IL-
3, IL-6 and IL-11) that promote MK maturation and differentiation processes [15]. 
The MK proliferation, terminal differentiation and maturation processes are distinguished 
by deoxyribonucleic acid (DNA) endoreduplication (polyploidisation) and extension of the 
cytoplasmic mass [16, 17]. The immature MKs have high levels of ribonucleic acid 
(RNA), ribosomes and rough endoplasmic reticulum. Throughout the maturation process, 
the cytoplasm of the MK becomes more developed with formation of intricate membrane 
systems, amplification of platelet organelles (such as alpha granules, dense bodies and 
lysosomes) and synthesis of specific platelet proteins such as von Willebrand factor (vWF) 
and fibrinogen [18]. This is followed by disassembly of the centrosomes and formation of 
microtubules which move to the cell cortex [19]. The tough MK cytoplasmic mass then 
produces proplatelets with thick pseudopods. The development of elongated proplatelets 
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takes place as the microtubules and organelles expand into the proplatelet ends where 
budding platelets assemble. Eventually, mature platelets are released when the MK 
cytoplasmic fragments are converted into proplatelets  (Figure 1.1) [17]. Platelets naturally 
circulate for about 7 to 10 days before they are removed from the bloodstream by 
macrophages, mainly in the liver and spleen. This platelet clearance may be regulated, in 
part, by apoptotic processes. The normally circulating range is 150-400×10
9
/ platelets per 
litre of blood in a healthy human body [20]. 
 
Figure ‎1.1. A schematic representation of the platelet production from megakaryocytes. (A-E) Several 
stages promote megakaryocyte transition from immature cells to produce platelets. (A-B) The first stage, the 
immature megakaryocyte undergoes nuclear endomitosis, organelle synthesis and cytoplasmic maturation 
and expansion. (C-D) The next stage involves dissociation of the centrosomes and formation of 
microtubules, which move to the cell cortex and the proplatelet generation that also occurred with the 
development of thick pseudopods. Slipping of overlapping microtubules leads to proplatelet elongation as 
organelles are moved independently at proplatelet ends, where emerging platelets assemble. (E) The 
complete megakaryocyte cytoplasm is altered into a mass of proplatelets and new platelets are produced 
from proplatelet ends. Adapted from [17].   
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1.3 PLATELET ULTRASTRUCTURE 
Compared to other blood cells, platelets are tiny fragments with average diameters of 2.0 
to 5.0 µm [21, 22]. They are distinguished by a complete lack of genomic DNA, but they 
carry megakaryocyte-derived messenger RNA (mRNA) and the translational apparatus 
required for protein synthesis [23]. Platelets are dynamic in shape (Figure 1.2). Under 
resting physiological state, they have a discoid form as they circulate in the laminar blood 
stream close to the apical surface of the endothelial tissues (Figure 1.2A) [24]. Once 
platelets become stimulated platelet cytoskeleton undergoes modification from discoid 
form to a compact sphere with long dendritic extensions (Figure 1.2B) which facilitate 
adhesion through platelet activation and aggregation [20, 25].  
 
 
Figure ‎1.2. Dynamic shape of platelets. (A) Under resting conditions, platelets have a discoid form. (B) 
Platelets reshape to a compact sphere with long dendritic extensions, facilitating adhesion through platelet 
activation. Adapted from [26]. 
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Platelets are composed of four structural regions: the peripheral zone, the sol-gel zone, the 
organelle zone and the membrane systems [27] (Figure 1.3).  
 
 
Figure ‎1.3. Diagrammatic representation of platelet structure. Mature platelets have many mediators 
including α-granules, dense granules, lysosomes, glycogen and mitochondria implicated in the regulation of 
haemostasis, cell growth, thrombosis and inflammation. The open canalicular system has an important 
function in passing plasma ingredients for intake into the cells. The dense tubular system is the central site 
for calcium ion and enzyme storage. Modified from [28, 29]. 
 
1.3.1 The peripheral zone structure 
The peripheral zone in platelets consists of a unit membrane, coagulation layer, glycocalyx 
and phospholipid membrane [27]. This zone has a key role in the transport of substances 
from the surface of the platelet into the cell and in the release of alpha granule products 
secreted throughout platelet activation [30]. The glycocalyx is a dynamic surface covered 
with various glycoprotein receptors such as GPIb-IX-V complex and integrin αIIbβ3 which 
facilitate platelet adhesion and aggregation [31]. The platelet membrane contains anionic 
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phospholipids and phosphatidylserine, which facilitate and act as the place for 
configuration of the prothrombinase complex of coagulation, and the membrane of 
platelets also contains tissue factor which becomes exposed during the activation process 
with the production of microparticles therefore platelets are considered as an important 
source for tissue factor [32, 33]. Underneath the platelet plasma membrane sits an intricate 
cytoskeleton containing microtubules and microfilaments [24, 32]. The platelet 
cytoskeleton is the major inner structure of the platelet and consists of a spectrin mesh 
strengthened by interior microtubules and a firm network of crossing actin filaments. 
Therefore, the cytoskeleton is very important in sustaining the discoid morphology and in 
protecting the platelet integrity from the high shear stress while the blood flow forces the 
platelets against the endothelium [34, 35]. The cytoskeleton is further involved in the 
platelet activation process through the facilitation of shape changes and in the interactions 
that occur during the spreading of platelets over an endothelial injury [36]. 
1.3.2 The sol-gel zone 
This zone is found at the centre of the platelet as the matrix of the platelet cytoplasm. It 
consists of numerous fibre systems in a variety of situations of polymerisation and sustains 
the normal platelet appearance. It has a key role in supplying a contractile system that is 
engaged in the changes in platelet morphology, pseudopodia expansion at the onset of 
spreading, interior activation and granule emission. The sol-gel zone provides a contractile 
system that can change platelet morphology by facilitating pseudopodia expansion at the 
onset of spreading, interior activation and granule emission [37, 38]. 
1.3.3 Organelle zone 
The platelet is distinguished from other blood cells by containing essential secretory 
organelles, including  alpha granules, dense granules and lysosomes [39]. Granules are 
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highly populated in platelets which are imperative for platelet adhesion, activation and 
eventually thrombus formation. Alpha granules and dense bodies release their contents 
following platelet activation by calcium dependent secretion. However, these secretory 
organelles are very specialised for release of their contents to promote platelet activation 
and aggregation [40] 
1.3.3.1 Alpha granules  
The alpha granules comprise the majority of the platelet organelles, with approximately 50 
to 80 granules per platelet. The granules are characterised by an elliptical shape and 
measure 200 to 500 nm in diameter, with an organised interior substructure separated into 
several zones, including the membrane zone, the peripheral zone and the central zone. The 
granules are more electron dense in the central zone than in the peripheral zone and are 
produced within MK cells [38, 41]. Alpha granules contain a variety of functional proteins, 
such as coagulation proteins, anti-coagulants, growth factors (e.g. TGFβ), adhesion 
molecules (e.g. P-selectin, CD40L), chemokines and angiogenic factors [40, 42]. Some, 
but not all, proteins, including P-selectin and CD40L, are expressed and translocated to the 
surface membrane of platelets in response to stimulation. P-selectin and CD40L can also 
be cleaved by proteolytic enzymes to soluble forms and secreted directly into the plasma. 
The expression of P-selectin and CD40L, in particular, contribute to various inflammatory 
and atherosclerotic pathways that participate in different pathophysiological processes [41, 
43-45]. Platelet alpha granules also have vWF which is a large multimeric glycoprotein 
exclusively synthesised in endothelial cells and MKs. It exists in the subendothelial matrix 
and platelets and mediates platelet adhesion and aggregation at sites of vascular injury [46, 
47].  
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Alpha granules release their contents to regulate primary and secondary haemostasis. In 
primary haemostasis, fibrinogen serves as an adhesive protein and is the ligand for the 
αIIbβ3, which is enclosed within alpha granules and is cross-linked with stimulated platelets 
to stabilise thrombus growth. By releasing coagulation factors (factor V, VII, XI and XIII), 
alpha granules also participate in the coagulation cascade and mediate the formation of 
fibrin thrombi [41, 48].  
1.3.3.2 Dense granules  
Dense granules are similar to alpha granules and are also developed in the MK, but are 
present at around ten-fold less compared to alpha granules, with approximately 3-8 copies 
of dense granules in each platelet [29]. The dense granules are usually spherical in shape 
but some have an elongated shape. Unlike the alpha granules, dense granules contain non-
protein components. They can be distinguished by their high electron density, which is 
likely due to the presence of high levels of substances such as calcium, phosphate, 
magnesium, serotonin, adenosine triphosphate (ATP) and adenosine diphosphate (ADP). 
These substances are especially important in the augmentation of platelet activation, 
aggregation and thrombus formation [29, 49].  
Upon platelet stimulation, ADP and serotonin are secreted from dense granules to amplify 
the platelet activation processes via a positive feedback mechanism that contributes to 
platelet aggregation stability. ATP and calcium are also released from dense granules for 
the phosphorylation of particular tyrosine kinases, such as protein kinase C (PKC) [50, 
51].  
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1.3.3.3 Lysosomes 
Platelet lysosomes like alpha and dense granules are also developed in megakaryocyte. 
They are fewer in number relative to the alpha and dense granules and each platelet 
contains about 1-3 lysosomes. Platelet lysosomes contain several acid hydrolases such as 
glycosidases, proteases and cathepsins [52, 53]. Although the real function of lysosomes in 
platelet remains unclear, previous studies have suggested that these granules possess 
important membrane proteins which may contribute to regulation of calcium in platelets 
and other cells in human and mouse [54]. 
1.3.4 The membrane systems 
The platelet membrane is a complex structure composed of a phospholipid bilayer [55]. 
Small, abundant indentations are present on the platelet surface. A platelet contains two 
distinct membrane systems: the open canalicular system (OCS) and the dense tubular 
system (DTS) [56, 57]. The OCS is formed by many tortuous invaginations of the platelet 
surface that are interspersed along its structure. It increases the direct association between 
the interior platelet surface to provide a route for accessing plasma ingredients and 
substances for intake into the cells and it may act as a conduit for chemical and particulate 
substances in connection with the discharge reaction. It is the main site for calcium ion 
storage. It is also the site of cyclooxygenase, an enzyme that converts membrane derived 
arachidonic acid to unstable endoperoxide precursors of prostaglandins and thromboxanes 
[57-59]. Previous research has suggested a specific physical connection between the two 
platelet channel systems and proposed that the platelet membrane may provide an 
important function in cell activation via directly communicated signals received from 
plasma through the OCS to elements of the DTS containing Ca
2+
 and the enzymes capable 
of synthesising prostaglandins and thromboxanes [27, 60]. The platelet  membrane also 
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has glycoprotein receptors for various proteins such as vWF, collagen and fibronectin; 
these receptors participate in shape alteration, adhesion and activation pathways [61, 62]. 
1.4 PLATELET RECEPTORS AND INTEGRINS 
Platelets are characterised by their expression of a variety of transmembrane receptors on 
their surfaces. The most functional important of the platelet transmembrane receptors are 
the leucine-rich repeated (LRR) receptors GPIb-IX-V and the integrins (αIIbβ3, α2β1, α5β1, 
α6β1). G-protein coupled receptors (GPCRs) include the protease-activated receptor (PAR-
1) and (PAR-4)-thrombin receptors, P2Y1 and P2Y12-adenosine diphosphate purinergic 
receptor (ADP) and TPα and TPβ-thromboxane A2 receptors (TXA2). In addition, proteins 
belonging to the immunoglobulin superfamily (GPVI, FcγRIIa), C-type lectin receptors 
(CLEC-2) and tyrosine kinase receptors (thrombopoietin receptors) as well as other types 
including CD63, CD36 and the tumor necrosis factor (TNF) receptor are expressed on 
platelets. Most of these receptors and integrins have a direct role in haemostasis either 
through co-ordinating adhesive receptors upon vascular injury, platelet activation in 
response to specific agonists, or aggregating processes for interacting with other platelets 
or other blood cells that may promote thrombus development [5, 63, 64]. The biochemistry 
and critical roles of some of the more important receptors and integrins involving platelet 
function and thrombus formation are discussed in the following sections. 
1.4.1 GPIb-IX-V complex 
GPIb-IX-V consists of four subunits: GPIbα (MW 135 kDa), GPIbβ (MW 26 kDa), GPIX 
(MW 20 kDa) and GPV (MW 82kDa). Each subunit of the GPIb-IX-V complex is a type I 
transmembrane protein which consists of a leucine-rich repeat (LRR) ectodomain 
(extracellular domain), a single transmembrane helix, and a relatively short cytoplasmic 
tail. GPIbα, GPIbβ and GPIX are essential for the efficient biosynthesis of the GPIb-IX-V 
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receptor and are thoroughly related at the membrane of platelets. Classically, a lack of an 
individual subunit reduces the surface expression of the complete GPIb-IX-V complex. 
GPIbα and GPIbβ are disulphide-linked and non-covalently associated with GPIX and 
GPV to form the receptor for vWF and P-selectin which are expressed on activated 
platelets and endothelial cells [65, 66]. Approximately 50,000 copies of GPIb-IX-V 
presented in an individual platelet [67]. GPIb-IX-V structure is shown in Figure 1.4. The 
N-terminal extracellular part of GPIbα is the chief ligand-binding region of GPIb-IX-V, 
and consists of eight LLRs. It contains the binding domains partially overlapping for 
different types of proteins including vWF, the leukocyte integrin αMβ2 (Mac-1), and 
expressed P-selectin on activated platelets or activated endothelial cells [68, 69]. The C-
terminal cytoplasmic tail of GPIbα consists of 96 amino acids and is associated with 
filamin, related it to the cytoskeleton [69]. This offers prospective connections to relevant 
signalling proteins such as phosphatidylinositol 3-kinase (PI3K), Src-related tyrosine 
kinase and protein tyrosine phosphatase (PTP1b) [69, 70]. 
The association between the GPIb-IX-V complex and collagen through vWF is very 
powerful during the platelet adhesion pathways. The binding of vWF to GPIb-IX-V 
initiates a transmembrane signalling cascade that involves phosphorylation of the 
intracellular chain of GPIbβ [64, 67]. The absence or diminished expression of the GPIb-
IX-V complex on the surface of the platelets results in defective platelet adhesion 
associated with Bernard Soulier syndrome (BSS). This is a congenital bleeding disorder 
that is characterised by macrothrombocytopaenia and an inability of these platelets to 
aggregate in response to ristocetin, an antibiotic that normally causes platelets to aggregate 
in vitro by binding and activating vWF [71, 72]. GPIb-IX-V complex works as an 
‘outside-in’ signalling receptor to initiate integrin αIIbβ3 and α2β1 which mediate stable 
platelet adhesion and aggregation. Furthermore, the binding of GPIb-IX-V complex via 
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arresting vWF could result in similar activation signals such as protein phosphorylation 
[phospholipase Cγ (PLCγ), spleen tyrosine kinase (Syk)] and the synthesis of both TXA2 
and ADP, and integrin αIIbβ3 activation [64, 69, 70]. 
 
 
Figure ‎1.4. Structure of GPIb-IX-V complex. It consists of GPIbα disulphide-associated with two GPIbβ 
subunits, and non-covalently linked with GPIX and GPV. Disulphide bonds located in domains either side of 
leucine-rich repeats are represented as solid black bars. The sulphated tyrosine residues GPIbα, 
phosphorylated serine residues residues of GPIbβ and GPIX are demonstrated. The C-terminus, N-terminus, 
TM, transmembrane domain are indicated. Adapted from [73]. 
 
1.4.2 Glycoprotein VI 
Glycoprotein VI (GPVI) is a member of the immunoglobulin superfamily. It is principally 
expressed on platelets and MKs with approximately 2,000-4,500 copies of GPVI per 
resting platelet. It acts as a major signalling receptor on the platelet membrane surface for 
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collagen, thereby triggering platelet activation and aggregation upon vascular injury [74, 
75]. The GPVI receptor is associated with the GPIb-IX-V complex through a direct 
linkage between the extracellular sequences of GPVI and GPIbα. As a result, the binding 
of GPVI/GPIb-IX-V complex with extracellular matrix ligands-vWF and collagen quickly 
induces platelet integrin activation, such that αIIbβ3 that binds vWF or fibrinogen to 
mediate platelet aggregation and  integrin α2β1 that attaches to collagen [76, 77]. In 
addition, collagen-related peptide (CRP) first developed by Morton et al. [76] and it acts as 
a specific agonist that only binds to GPVI [78].  
GPVI contains two extracellular immunoglobulin domains, a mucin-like domain, a 
transmembrane domain and a short cytoplasmic tail (Figure 1.5). Formation of a salt 
bridge between an arginine residue in the transmembrane sequences of the GPVI and an 
aspartic acid residue in the transmembrane sequences of the FcRγ chain results in linkage 
of GPVI with FcRγ subunit that carry an immunoreceptor tyrosine-based activation motif 
(ITAM). Cross-linking FcRγ subunit with GPVI leads to the activation of Syk, PI3K, PKC 
and PLCγ [74, 79]. The phosphorylated FcRγ-chain-ITAM is subsequently associated with 
the Syk via SH2 domains, and Syk is phosphorylated by Src family kinases (SFKs) which 
promotes its major activation and initiates interactions with other signalling pathways [80]. 
Dysfunction or the lack of GPVI on the human platelet membrane is linked with impaired 
collagen adhesion and thrombus formation with minor bleeding issues. In contrast, 
elevation of GPVI expression is significantly associated with thrombotic events [81]. 
GPVI is indispensable for the initiation of early outside-in signalling through activation of 
the platelet integrins αIIbβ3 and α2β1, which mediate stable platelet adhesion and 
aggregation [82].  
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Figure ‎1.5. Structure of GPVI. It is composed of two extracellular immunoglobulin domains, a mucin-like 
domain, a transmembrane domain, and a short cytoplasmic tail. The proline rich region is linked to the Src 
homology domains (Fyn and Lyn). Basic region within C-terminal region is connected to calmodulin and 
associated with FcRγ-chain. Modified from [80]. 
 
1.4.3 G-protein coupled receptors 
G-protein coupled receptors (GPRCs) are important seven-transmembrane domain 
receptors which are composed of three intracellular and three extracellular loops within 
long proteins. They have a long cytoplasmic tail that is associated with protein kinase C, A 
or GPCR kinase (Figure 1.6).  
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Figure ‎1.6. Structure of G-protein-coupled receptors. They are generally composed of seven 
transmembrane domains with three extracellular and three intracellular loops in long proteins. The 
interaction of extracellular ligands promotes a conformational alteration in the receptor and allows it to 
stimulate linked G-proteins by switching a bound guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP). Activated GPCRs triggers a single transduction pathway and further intracellular signalling 
pathways. Modified from [83]. 
 
GPRCs are expressed in platelets which interact with signalling molecules that have a key 
role in regulation of platelet activation and thrombus formation [84]. Platelet agonists such 
as thrombin, ADP and TXA2 initiate several signalling pathways that promote secretion of 
platelet granule contents and generate fibrinogen binding to integrin αIIbβ3, leading to 
platelet aggregation [85, 86] (Figure 1.7). The Src kinase and Syk-independent 
phosphorylation is principally mediated downstream of the collagen receptor GPVI [80]. 
However, the GPCR is indirectly involved in the mediation of the Src kinase and Syk 
signalling as secondary mediators but a purposeful role for tyrosine kinases in signalling 
by various GPCRs is poorly understood [87]. The most important GPCRs that are involved 
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in platelet activation mechanisms includes the thrombin protease-activated receptors PAR-
1, PAR-3 and PAR-4; ADP receptors P2Y1 and P2Y12; and the TXA2 receptor TP [88].  
 
 
Figure ‎1.7. Function of G protein–coupled receptors in platelet thrombus formation. Displaying some 
signalling mechanisms associated with the stimulation of GPCRs by thrombin, ADP and TXA2 through the 
G proteins Gq, G13 and Gi to the initiation of platelet shape change, inside-out activation of integrins and 
granule secretion. The amino-terminal of protease-activated receptors (PAR)-1 and PAR-4 are cleaved by 
thrombin. As a result, various signalling pathways are initiated e.g. ADP signalling transduction pathways 
through binding of the receptors P2Y12 and P2Y1. ADP induces further Gi-mediated pathways. TXA2 binds 
its receptor TP inducing the activation via the G proteins Gq and Gi. Mobilised Ca
2+
 activates calcium, 
CalDAG-GEF, calcium and diacyl glycerol-regulated guanine nucleotide exchange factor, glycoprotein, 
prostacyclin, protein kinase C (PKC), phospholipase Cγ (PLCγ), Rap1-GTP-linking adapter molecule 
(RIAM), phosphatidylinositol-3,4,5-trisphosphate (PIP3). Adapted from [84]. 
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1.4.3.1 Thrombin protease-activated receptors 
Thrombin is known as Factor IIa, a multifunctional plasma serine protease that is 
generated in response to blood vessel injuries. It serves as an important mediator of 
haemostasis and thrombosis converting soluble fibrinogen into an insoluble form through 
its activation as the major effector protease of the coagulation cascade and the most potent 
platelet agonist [89]. Thrombin enhances platelet activation and secretion and is involved 
in supporting and stabilising thrombus formation under low and high shear conditions 
through protease-activated receptor (PAR) mechanisms [90]. PAR can promote the 
activation of PKC and PLC and lead to enhanced auto-amplification via the synthesis of 
TXA2 and the release of ADP and production of further thrombin on the surface of 
platelets [91]. Thrombin specifically binds to three protease-activated receptors PAR-1 and 
PAR-4 in humans [92], and PAR-3 and PAR-4 in mice that couple to the Gq, G12/G13 
and Gi families of heterotrimeric G proteins [93, 94]. 
PAR-1 is considered the predominant thrombin receptor mediating platelet activation in 
humans [95] with  expression of approximately 1,000-2,000 copies per platelet [96].In in 
vitro studies where PAR-1 was blocked by antibodies or specific antagonists, the 
activation of human platelets was blocked at low concentration of thrombin. In contrast, 
use of a similar blockade method against PAR-4 had no effect on human platelet 
activation, whereas when both PAR-1 and PAR-4 were blocked by antibodies, human 
platelet activation was substantially inhibited at high concentrations of thrombin. These 
observations suggest that PAR-1 is the most important thrombin receptor to mediate 
human platelet activation at a low concentration of thrombin, and that PAR-4 probably can 
modulate platelet function but only in the presence of high concentrations of thrombin 
[97]. Investigations of platelets from PAR-1 and PAR-4 knock-out mice demonstrated that 
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PAR-1 knock-out resulted in normal haemostasis and thrombosis. By contrast, PAR-4 
knock-out mice exhibited prolonged tail bleeding times and reduced thrombus growth over 
time. PAR-1 is now recognised as the principal low-dose thrombin signalling receptor in 
human platelets and PAR-4 is the chief high dose thrombin signalling receptor in both 
humans and mice [98]. 
Thrombin associates with a hirudin-like DKEYPF combining sequence on the N-terminus 
of PAR-1 supporting cleavage upon an LDPR/SFLLR sessile linked and producing a new 
short induce activating peptide sequence that leads to self-activation through a tethered 
ligand, thereby activating G-protein signalling pathways [99]. Synthetic peptides such as 
Thrombin Receptor Activating Peptide-6 (TRAP), which contains six amino acids 
(hexapeptide) of the novel N-terminal tail (SFLLRN) that is produced after thrombin 
proteolysis of its receptor, can imitate thrombin [100, 101]. TRAP is able to stimulate 
platelet activation and secretion through specifically binding PAR-1 by similar 
mechanisms to that of thrombin but without the demand for receptor proteolysis [95, 100]. 
However, thrombin is considered more efficient than TRAP at inducing the whole 
sequence of responses needed for full activation of platelets since thrombin has additional 
receptors for GPIbα [102, 103]. 
 In comparison to PAR-1, PAR-4 is distinguished by its lack of the hirudin-like DKEYPF 
binding sequence of the molecules; thus it is not as responsive to cleavage by thrombin. 
However, PAR-4 is alternatively cleaved by thrombin at the Arg-Gly link in the 
PAPRGYPGQV sequence which causes and promotes an exposure of a tethered ligand 
that binds the PAR-4 receptor and generates the activation of G-protein coupled signalling 
[104]. PAR-3 is activated by binding thrombin and is expressed in mouse platelets but 
only minimally expressed by human platelets. It has a thrombin interaction hirudin-like 
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domain that contributes to and facilitates thrombin cleavage at a LPIKTFRGAP sequence, 
creating a tethered ligand [105]. A validation study suggested that this receptor works as a 
cofactor for binding and cleaving thrombin essentially like PAR-4 in mouse platelets 
[106].  
Human platelets can be activated by thrombin through activation and cleavage of PAR-1 
and PAR-4 consisting of a series of distinctive signalling pathways that are regulated and 
mediated by activation of the Gαq, Gα12/G13 and Gαi families of heterotrimeric G 
proteins. These signalling events lead to the activation of PLCβ, PI3-kinase and the 
monomeric G proteins such as Rho, Rac and Rap1, increased cytosolic Ca
2+
 level, 
suppression of cAMP development, platelet shape changes, protein phosphorylation and 
generation of ADP and TXA2 [106, 107]. The GPIb-IX-V complex is also considered to be 
a receptor for thrombin. It is required for good thrombin responsiveness in platelets and 
may be helpful in presenting thrombin to the surface of platelets via GPIbα subunit-
binding, thereby potentially inducing platelet adhesion, secretion and aggregation [108]. 
The investigation of blockade of the thrombin-binding of GPIbα with antibodies revealed 
inhibited platelet stimulation to thrombin [109]. More interestingly, validation experiments 
suggested that thrombin involved in Src kinase-dependent phosphorylation for downstream 
platelet adhesion and activation. Thrombin was shown to stimulate tyrosine 
phosphorylation partially via Syk and extensively by downstream SFKs [87]. 
1.4.3.2 Adenosine diphosphate receptors 
Adenosine diphosphate (ADP) is stored within platelet dense granules at a high 
concentration and is secreted upon initial platelet activation. It is also released from 
damaged endothelial cells at the site of the blood vessel injury [110]. This agonist plays a 
crucial role in stimulation of platelets with a full range of initiation events including 
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platelet shape change, mobilisation of intracellular Ca
2+
, TXA2 synthesis, protein 
phosphorylation, granule secretion, integrin αIIbβ3 activation and reduction in intracellular 
cAMP concentration [110, 111]. ADP is recognised by nucleotide receptors (P2 purinergic 
receptors) consisting of the P2X ion-channel family and the P2Y GPCR family [112]. 
Briefly, ADP mediates platelet activation through binding to two P2Y receptors, P2Y1 and 
P2Y12 which link to Gαq and Gαi, respectively [110]. In brief, P2Y1 is responsible for Ca
2+
 
mobilisation, thus mediating platelet morphological changes and transient aggregation in 
response to ADP  [113, 114]. In contrast, P2Y12 plays an important role in inhibition of 
adenylyl cyclase which reduces the level of cAMP synthesis and promotes the activation 
of platelets by dephosphorylation of vasodilator-stimulated phosphoprotein which carries 
out activation of integrin αIIbβ3 and increases the cyclic Ca
2+
 flux and platelet granule 
release [114]. 
The signal transductions of P2Y1 and P2Y12 receptors have revealed an involvement of Src 
tyrosine kinase. The studies showed that the ADP-initiated platelet aggregation response 
partially depends upon Src kinase mechanisms [115, 116]. A lack of platelet shape change, 
impaired platelet aggregation was demonstrated in P2Y1 knockout mice in response to 
ADP [117]. In contrast, P2Y12
-/-
 mice demonstrated normal platelet changes but impaired 
ADP-induced aggregation. The P2Y12
-/-
 mice experienced significantly increased bleeding 
times and unstable thrombus formation [118, 119]. These results from in vivo experiments 
show that P2Y12 is a major receptor for ADP mediated platelet activation triggered through 
P2Y1. Thus, P2Y12 is the target of thienopyridine therapy drugs such as clopidogrel and 
ticlopidine which irreversibly inhibit P2Y12 action when treating cardiovascular events 
[120, 121]. 
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1.4.3.3 Thromboxane A2 receptors  
Thromboxane A2 (TXA2) is a vasoconstrictor and a powerful platelet agonist [122]. It is 
produced during platelet activation through a series of actions of cyclo-oxygenase-1 
(COX-1) stimulation in platelets and is synthesised following arachidonic acid generation. 
TXA2 amplifies platelet activation signals causing shape change, protein phosphorylation, 
secretion, and aggregation [123]. TXA2 is lipid soluble, therefore it diffuses across the 
platelet membrane to recruit more platelets for promoting platelet plug formation via 
binding to its receptor [124]. The blockade of TXA2 secretion that occurs via inhibition of 
COX-1 by aspirin results from the conversion  of arachidonic acid into prostaglandin H2 
which serves to prevent thrombotic diseases such as atherosclerosis, myocardial infarction 
and pulmonary embolism [125]. The TXA2 receptor (TP) presents two splice variants (TPα 
and TPβ), which differ only at their C-terminal domains and both are generated from a 
single gene. In human platelets, TPα has been identified at the protein level [126, 127] and 
has been suggested to possibly stimulate adenylyl cyclase, whereas the TPβ inhibits 
adenylyl cyclase [128]. When the TP receptor is activated by  prostaglandin endoperoxides 
PGG2 and prostaglandin H2 predominantly couples to Gq and G12/13, and TP receptor has 
a minimal involvement in tyrosine kinase signal transduction [129, 130].  
TP-deficient mice are unresponsive to TXA2 and show an impaired response to collagen. 
TP
-/-
 mice show delayed bleeding times and are unable to generate stable thrombi. These 
data suggest that the decreased activation of platelets in TP
-/-
 mice might contribute to a 
reduction in cardiovascular risk [131, 132]. Validation experiments have verified the 
important role of anti-TXA2 (e.g. aspirin) in contributing to the prevention of thrombotic 
diseases as observed in TP
-/-
 mice and clearly show the importance of the role of TXA2 in 
platelet thrombus formation [64]. 
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1.4.4 Integrin‎αIIbβ3  
Integrin αIIbβ3 (GPIIb/IIIa) consists of a heterodimeric complex of αIIb and β3 subunits. It is 
highly expressed on the platelet membrane at an abundance of 60,000-80,000 copies per 
human platelet [86, 133]. The αIIb subunit is solely expressed on MKs and platelets while 
the expression of β3 subunit is broader in different cells including endothelial cells, 
leukocytes, platelets and smooth muscle cells [86, 134]. These subunits are non-covalently 
bound to each other and both contain a large N-terminal extracellular sequence that is 
extensively expressed in the heterodimeric situation which results in the integrin shape of a 
spherical head, a distinct transmembrane domain and a short cytoplasmic tail domain [135] 
(Figure 1.8). Integrin αIIbβ3 plays an important role in platelet aggregation, signalling, 
spreading on the exposed ECM of the vascular damage and pathological thrombus 
development. It also interacts with the blood coagulation system and with other cell types 
including endothelial cells. Integrin αIIbβ3 binds several adhesive glycoproteins that contain 
an arginine-glycine-aspartic acid (RGD) sequence including fibrinogen (coagulation factor 
I), vWF, prothrombin (coagulation factor II), fibronectin, thrombospondin and vitronectin 
[86]. 
In the resting platelet state, the integrin is thought to be expressed in a low affinity state 
and that the conformation of αIIbβ3 switches to a high affinity state in response to specific 
agonist-induced platelet activation, such as ADP and thrombin, through ‘inside-out 
signalling’ events [86, 136]. Activated αIIbβ3 is able to bind its ligand fibrinogen, which 
essentially induces important processes including spreading and clot retraction, and 
interacts with the pro-coagulant activity system via ‘outside-in signalling’ events [133]. 
Integrin αIIbβ3 and the immunoglobulin family receptor GPVI signal through similar but 
distinct tyrosine kinase-based signalling cascades causing activation and aggregation 
development [80].  
  
 24  
 
Figure ‎1.8. Structure of integrin αIIbβ3. This cartoon demonstrating the three major conformational states 
of integrin αIIbβ3. It contains αIIb domains and β3 subunits. The conversion of integrin αIIbβ3 from low-
affinity (a bent state) into high-affinity conformation and stabilisation of high-affinity conformation (an 
extended closed headpiece state). Adapted from [137]. 
 
The Shattil team has revealed some critical keys in the activation of Src and Syk tyrosine 
kinases by integrin αIIbβ3. Src is related through its SH3 domain with the carboxy-terminal 
portion of the β3-tail [138]. Ligand-mediated clustering of integrin αIIbβ3 triggers ‘outside-
in’ signalling regulating in filopodia extension, lamellipodia formation, spreading 
aggregation and granule secretion on vascular surfaces during haemostasis and thrombosis 
[133]. Clustering of the integrin also leads to activation of Src family kinases such as Fyn 
and Lyn through autophosphorylation [138] along with activation of the downstream 
effective enzymes, PLCγ2 and PI3K as well as recruitment of adapter proteins including 
SLP-76 and Vav small GTPases [80]. Recently, SLP-76, Syk and Vav have been 
suggested to have a key role in the regulation of PLCγ2 through integrin αIIbβ3 
involvement [139]. Src kinase constitutively associated with integrin αIIbβ3 to sustain at a 
low-affinity state on resting platelets by C-terminal Src kinase, which phosphorylates a 
negatively regulating tyrosine kinase placed in the C-terminal tail of Src (Tyr-529) [140]. 
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However, through fibrinogen mediated clustering of integrin αIIbβ3, Csk separates from the 
αIIbβ3 and is substituted by the non-transmembrane protein tyrosine phosphatase, PTP-1B 
[141] which is associated with dephosphorylation of the C-terminal tail of Src (Tyr-529) 
and phosphorylation of the Src initiation loop (Tyr-418) [140]. Ultimately, the 
phosphorylation of Src and auto-phosphorylation were shown to play a key role in 
recruitment and activation of Syk [142]. In the same way, other SFKs, such as Fyn and 
Lyn, have been demonstrated to be functionally involved in initiating ‘outside-in’ 
signalling. Validation studies established that platelets deficient in Src or healthy platelets 
treated with tyrosine kinase inhibitors, failed to spread on fibrinogen. The results of these 
studies demonstrated that Syk activation and the phosphorylation of Syk substrates were 
blocked by Src kinase inhibitors. Thus, platelet spreading on fibrinogen needs 
chronological activation of Src and Syk, with involvement of integrin αIIbβ3 [140]. 
Dysfunction or lack of integrin αIIbβ3 causes Glanzmann thrombasthaenia which is a 
bleeding syndrome characterised by impaired adhesion and failure of platelet aggregation. 
In vivo experiments using β3-knockout mice or αIIb-knockout mice elucidated that β3-
deficient mice have significantly prolonged tail bleeding times and show defective 
thrombus formation. Intravital microscopy investigations also verified that the deficiency 
of β3 causes defective binding of the integrin to fibrinogen which leads to abnormal 
platelet aggregation and spontaneous haemorrhage [143, 144]. Integrin αIIbβ3 clearly has an 
important role in haemostasis and thrombosis through platelet adhesion and aggregation 
events. 
1.4.5 Integrin‎α2β1 
Integrin α2β1, also known as GPIa/IIa or CD49b/CD29, is considered the second most 
significant platelet integrin next to integrin αIIbβ3, with approximately 2000-4000 copies 
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occurring per resting platelet. It is the direct collagen adhesion receptor [145, 146] and 
contains an I-domain with high affinity for many collagen sequences including Gly-Phe-
Hyp-Gly-Glu-Arg [79]. The I-domain located between the second and third repeats of the 
seven-bladed β-propeller of the α2 subunits which like the projection of the extracellular 
sequence, has a key role as a primary ligand linking point of the integrin (Figure 1.9). The 
I-domain of the α2 extracellular domain has a conserved cation combining site called a 
metal ion-dependent activation site (MIDAS) domain of the β1-subunit which is suggested 
to have a significant function in conformational alteration of the I-domain from a locked to 
an unlocked condition through α2β1 integrin binding to collagen [147].  
 
 
Figure ‎1.9. Structure‎and‎role‎of‎integrin‎α2β1. (Right image) Inactive state of integrin α2β1 with formed 
salt bridges produced by the pair E318, R288, R310 and E336. Various domains including α2β-propeller, β-1 
I-like domain and α2 I domain are required for activation of integrin α2β1. (Left image) Active state of 
integrin α2β1 occurs once collagen binds its ligand integrin α2β1. Adapted from [148]. 
 
Integrin α2β1 was identified as the first platelet receptor for collagen and plays an 
important role in collagen-mediated platelet adhesion [145, 149]. However, in vitro studies 
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concerning inhibition of α2β1 expression by specific antibodies demonstrate contradictory 
results, ranging from major eradication of collagen mediated platelet adhesion and 
aggregation [150, 151] to minor consequences on collagen-mediated platelet adhesion 
[152, 153]. An advanced assay was developed to understand the function of α2β1 by 
utilising a novel collagen-binding experiment where the affinity states of integrin α2β1 to 
collagen were mediated by intracellular signals. GPVI-collagen binding promotes and 
increases the affinity of integrin α2β1 for collagen from a low-affinity state to intermediate 
or high-affinity states. However, Moroi and coworkers stated that α2β1 is active in the 
high-affinity condition on resting platelets [154, 155]. This finding was supported by the 
demonstration that deficiency of platelet adhesion due to GPVI-deficient-collagen could be 
reinstated by direct interaction of α2β1 via Mn
2+
 or via exogenously added specific agonists 
that lead to activation [156]. 
The primary stage of thrombus growth strictly depends on the functional interaction of 
collagen and GPVI, or vWF with GPIb-IX-V complex followed by activation and release 
of specific agonists and activation of platelet integrins. Eventually, platelet integrin α2β1, 
αIIbβ3 or others promote firm adhesion and further support GPVI-mediated signalling 
pathways, thereby inducing the pro-coagulant activity [5, 157]. 
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1.5 PLATELET FUNCTION 
The main role of platelets is to produce clot formation which stops haemorrhage and to 
prevent further blood loss and maintain vascular integrity at sites of injured blood vessel 
endothelium. However, platelets can play a significant role in the development of 
pathological thrombosis that result in excessive accumulation of platelets and fibrin at a 
ruptured atherosclerotic plaque [9, 10, 158]. 
1.5.1 The role of platelets in haemostasis  
Under normal physiological states, platelets circulate freely in the circulation. Healthy 
vascular endothelium produces potent inhibitory intrinsic pathways to platelets though 
secretion of anti-adhesive substances including NO and PGI2 which prevent tethering and 
activation of platelets in the vascular wall and inhibit adhesive platelet-endothelial 
interactions [159]. At a site of vascular endothelial cell injury, extracellular matrix (ECM), 
including collagen and vWF is released into the blood stream. A process of haemostatic 
adhesion is triggered when circulating platelets tether and adhere to these exposed proteins 
via binding their receptors on the membrane surface of platelets [160, 161].  
Activated platelets undergo a series of biochemical changes that induce the secretion of 
soluble agonists, including thrombin, ADP and TXA2, which can induce autocrine and 
paracrine platelet activation. Each agonist activates a specific GPCR on the platelet 
surface. Thrombin activates PAR-1 and PAR-4, ADP activates P2Y12/P2Y1, and TXA2 
activates TP. This results in secretion of the platelet granule contents, which has a positive 
feedback on the amplification of platelet activation and promotes the formation of 
haemostatic thrombi. Upon platelet activation, different proteins are released such as 
fibrinogen, fibronectin, platelet factor 4 (PF4), platelet derived growth factor (PDGF), P-
selectin, CD40 ligand (CD40L) and coagulation proteins [9, 162]. 
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This is followed by aggregation and formation of a haemostatic plug at the site of vascular 
injury (Figure 1.10). Activated platelets appear to secrete TF from alpha granules and open 
canalicular system into the plasma membrane but its origin and functionality are still not 
fully explained. Subsequent secretion of coagulation factors (V, VII and XIII) and tissue 
factor which induce the secondary haemostasis that triggers the activation of a coagulation 
cascade (Figure 1.11). As a result, thrombin, a potent platelet activator, is generated to 
intensify platelet activation. A soluble plasma glycoprotein, fibrinogen, is also transformed 
to fibrin by thrombin followed by FXIII cross-linking thereby enhancing thrombus 
stability. Ultimately, following recovery of vascular injury, fibrinolytic systems play a role 
in the degeneration of the formed thrombi and restore normal blood flow in the vessels 
[10, 158, 163].  
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Figure ‎1.10. Adhesion, activation and aggregation mechanisms promoting platelet function in 
haemostasis and thrombosis. Tethering and adhesion processes are mediated via the association of the 
platelet GPIb-IX-V and GPVI receptors with exposed thrombogenic molecules on the subendothelium, 
including von Willebrand factor (vWF) and collagen. The activation of intracellular calcium mobilisation, 
cytoskeletal reorganisation, integrin αIIbβ3 activation, and platelet granule release including alpha-granules 
and dense granules are followed platelet adhesion processes. Soluble agonists, including thrombin, ADP and 
TXA2 are produced from activated platelets to amplify platelet activation through binding specific receptors, 
G protein coupled receptors (GPCRs). Activated integrin αIIbβ3 binds to fibrinogen and vWF. Finally, these 
interactions highly generate platelet aggregation and initiate pro-coagulant activity. Modified from [164]. 
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Figure ‎1.11. The coagulation cascade. It is triggered by either activation of factor XII upon vessel injury 
(intrinsic pathway) or by tissue factor expression at site of damaged vessel (extrinsic pathway). Adapted 
from [165, 166]. 
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1.5.2 Platelet adhesion, activation and aggregation 
Platelet adhesion, activation and aggregation at the site of vascular surface injury are 
necessary for both the physiological process of haemostasis and thrombosis. 
1.5.2.1 Platelet adhesion 
The first stage of primary haemostatic cascade in response to vascular injury is the 
interaction of platelets with the exposed subendothelial ECM, which contains 
thrombogenic matrix mediators including collagen, vWF, laminin, fibronectin and 
thrombospondin [135, 167]. The platelet adhesion mechanism is activated by different 
pathways and is initially dictated by the native rheological conditions. Under high shear 
rate (>10 000/seconds) such as in small arteries, microvasculature, and also in vessels 
narrowed by atherosclerosis and stenotic disease [168] the initial tethering of platelets to 
the injured subendothelium is entirely mediated by the interaction of platelet surface 
GPIbα-XI-V and vWF which binds simultaneously exposed collagen [169, 170]. The 
sufficient binding of GPIbα to vWF promotes tethering and rolling of platelets onto sites of 
the damaged vascular tissues, keeping them closely associated with the exposed ECM. 
This contact upregulates integrin αIIbβ3 affinity; however, vWF-dependent association 
cannot sustain the gathering of thrombus development because it has a rapid on/off rate 
[170, 171]. Platelets adhere to fibrillar collagens via the receptor integrin α2β1 under low 
shear rate (<10 000/s) such as are found in veins and large arteries [169, 172]. The 
tethering of platelets results in binding of vWF to GPIbα-XI-V to integrin αIIbβ3 leading to 
a slowing of platelet velocity. This allows adhesive association with collagen receptor 
GPVI and integrin α2β1, which exclusively initiates stable platelet adhesion events [163, 
170]. Both collagen receptors act synergistically to reinforce each other’s action to get an 
optimal platelet adhesion process. Integrin α2β1 also acts synergistically with GPIbα, 
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which is reinforced by GPVI [173]. The step of interaction of platelets with exposed ECM 
triggers the initial platelet adhesion and enhances the low affinity state of the collagen 
receptor GPVI which undergoes a conformational modification into the high affinity state, 
thereby enhancing firm platelet adhesion [174]. 
1.5.2.2 Platelet activation 
The major signal platelet activation involves a tyrosine kinase pathways after vWF binds 
to GPIbα [70]. GPVI is clustered with fibrillar collagen [175] that activates Src tyrosine 
kinases Fyn and Lyn [176]. Fyn and Lyn phosphorylate ITAM, located within the FcRγ-
chain. This leads to phosphorylation of the FcRγ-chain resulting in recruitment and 
activation of Syk that, in turn leads to phosphorylation of the adaptor and effector proteins 
(LAT and SLP-76). These recruit a number of protein signalling molecules such as 
phosphorylation of PLCγ2 [177]. Phosphorylated PLCγ2 hydrolyses phosphatidylinositol 
4, 5-bisphosphate (PI 4,5P2). The products of the PLC catalyzation of (PI 4,5P2) are 
inositol 1, 4, 5-trisphosphate (IP3) membrane linked 1, 2-diacylglycerol (DAG) to initiate 
efficient platelet activation [80]. IP3 quickly diffuses and binds to its receptor IP3R and to 
Ca
2+ 
channels within the DTS, thereby elevating cytoplasmic Ca
2+
 levels. DAG works 
together with Ca
2+
 through linkages to phosphatidylserine to activate PKC which then 
phosphorylates serine/threonine to activate integrin αIIbβ3 [178]. The increased levels of 
DAG and Ca
2+
 in adhesive platelets lead to platelet shape changes, granule release and 
platelet aggregation [80]. In different pathways, platelet plugs can be initiated by G-protein 
dependent mechanisms (which have stimulatory and inhibitory signals for the downstream 
platelet activation); thus, the critical co-ordination between these signals is mediated by 
GPCRs binding to their ligands [178, 179]. For instance, thrombin initiates platelet 
activation by binding and cleaving the N-terminal domain of the PAR-1 and PAR-4 in 
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humans. This cleavage creates a new N-terminus, which in turn serves as a tethered ligand 
and leads to quicker and more reinforced stimulation of PLCβ via Gqα [95]. This then 
results in the production of IP3 from PIP2, leading to increased cytosolic Ca
2+
 mobilisation 
and increased activity of PKC in response to DAG [180]. Therefore, Gqα is very important 
for integrin activation, fibrinogen formation and increases in cytosolic calcium levels. Giα 
has been shown to diminish the generation of intracellular cAMP concentrations via 
suppressing adenylyl cyclase, thus initiating platelet activation [181]. G12α and G13α act 
on reforming the actin cytoskeleton, which supports the alteration of the microtubular ring 
and formation of filopodia and lamellipodia, and entirely trigger platelet shape changes, 
degranulation and spreading [130, 182]. 
1.5.2.3 Platelet secretion 
Following initial platelet activation, a number of amplification mechanisms contribute to 
the release of platelet contents from immobilised platelets to recruit further circulating 
platelets, which form an aggregation [183]. ADP and TXA2 are the predominant mediators 
involved in the extension phase of the platelet plug. ADP is secreted from platelet dense 
granules and attaches to its own receptors on the platelet surface, including P2Y1 and 
P2Y12. At the same time, TXA2 is produced via cyclooxygenase from arachidonic acid in 
the activated platelet state and binds to its receptor TP. These actions lead to platelet shape 
change, PKC activation and amplification of platelet thrombus formation [88]. Activated 
platelets release glycoprotein molecules such as P-selectin (CD62P) and CD40L which 
have an important role in mediating the interaction of platelets with leukocytes in 
particular neutrophils and monocytes [184]. Leukocytes are potentially capable of 
tethering to immobilised platelets located on the subendothelium [185] which allows 
platelet-leukocyte interaction contributing to thrombus formation in vivo [186]. 
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1.5.2.4 Platelet aggregation 
Platelet aggregation is essentially mediated by integrin αIIbβ3. Activated intracellular 
signalling pathways induce Ca
2+
 mobilisation, and trigger inside-out signalling pathways. 
The activation of integrin αIIbβ3 occurs via the conversion of the low-affinity of integrin to 
its high-affinity state. Aggregation is triggered through cross-linking of fibrinogen to the 
active conformation of integrin αIIbβ3 on activated platelets. The interaction between 
integrin αIIbβ3 and vWF also leads to thrombus formation [160, 187]. Binding of integrin 
αIIbβ3 to its ligands induces further conformational modifications that result in 
phosphorylation of tyrosine residues of the cytoplasmic integrin αIIbβ3 chain [188], platelet 
spreading and clot retraction which contribute to pro-coagulant activity via outside-in 
signalling processes. The coagulation cascade (factors V, VII, XI, and XIII) is initially 
assembled by the exposure of phosphatidylserine (PS) on stimulated platelets, to promote 
thrombin creation [189]. Exposed tissue factor from damaged endothelial cells binds factor 
VII and the intrinsic and extrinsic pathways are activated, inducing the generation of 
thrombin, which enhances platelet activation, alters fibrinogen to fibrin and supports 
thrombus stabilisation against the shear stress forces [189, 190]. 
1.5.3 Mechanisms of stable thrombus formation in C57BL/6 mice 
Wild-type mice have a comparable platelet thrombus formation mechanism to humans in 
vivo. However, some slight differences have been reported in the glycoprotein receptors 
that are constitutively activated and expressed in platelets. Mice lack PAR-1 (a thrombin 
receptor), the prominent receptor in humans. Instead, mice have PAR-4 and PAR-3 but 
PAR-4 is known as the chief receptor [97, 98]. Studies have demonstrated that human 
platelets contain three ITAM-containing transmembrane molecules, including GPVI/FcRγ-
chain, FcγRIIa and CLEC-2, whereas wild-type mice contain GPVI/FcRγ-chain and 
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CLEC-2 but lack FcγRIIa but still show normal responses to platelet activation signalling 
pathways [79, 191]. In general, despite some minor differences between mice and humans 
regarding platelet membrane receptors, the characterisation of in vivo thrombotic processes 
on the vessel wall of mice confirm a similar phenotype to that seen in humans. The use of 
mouse models has therefore been important in identification of the features of the 
molecular mechanisms underlying haemostasis and thrombosis, as well as understanding 
the effect of therapeutic agents targeting thrombus formation [192]. 
In vivo platelet thrombus growth and stability are dynamic and complex procedures, as 
shown using C57BL/6 mouse models. Murine experiments have demonstrated that several 
processes, including platelet tethering, activation and spreading, exposed ECM molecules 
(vWF, type I collagen, fibrinogen, fibronectin), inducing of calcium ion mobilisation, 
release soluble agonists (thrombin, ADP, TXA2) and platelet aggregation, are all 
implicated in mechanism of thrombus growth in response to vascular endothelium injury. 
The capture of circulating platelets from the blood stream onto the exposed ECM 
substances (e.g. vWF and collagen) initiates the first process of thrombus growth. The 
activation and aggregation of platelets increase at sites of injury, and perhaps subsequently 
due to breakdown of embolisation downstream [143, 186, 192].  
Thrombus stabilisation on the vessel wall is also regulated by many factors, such as 
platelet adhesive-ligand associations, ‘outside-in’ signalling pathways (especially integrin 
αIIbβ3), Src family kinase signalling events and secondary mediators, ADP, TXA2 and their 
receptors, P2Y12 and TP respectively [193]. Finally, several studies have confirmed the in 
vivo involvement of other platelet adhesive receptors on thrombus stability including 
CD40L and P-selectin which have important roles in mediating the interaction of platelets 
  
 37  
with other cells, in particular leukocytes and endothelial cells [68, 192]. Mechanisms of 
stable platelet thrombus growth are illuminated in Figure 1.12.  
 
 
Figure ‎1.12. Mechanisms of stable thrombus formation in C57BL/6 mice. Transmission electon 
microscope image of stimulated platelets. This figure shows the stabilisation of platelet thrombus formation 
requires several signalling pathways including engagement of platelets, platelet adhesion, platelet adhesion 
reinforcement, secretion of adhesive molecules including P-selectin and CD40L, recruitment of tissue factor-
bearing microparticles, platelet aggregation and growth of aggregates. Adapted from [192]. 
 
1.5.4 The role of platelets in arterial thrombosis 
Although the principle role of platelets is to regulate haemostasis and prevent haemorrhage 
by formation of haemostatic plugs, platelets are widely held to have a critical function in 
cardiovascular diseases such as atherosclerosis and arterial thrombosis [9, 162]. 
Dysregulated platelet-endothelial interactions are well defined as events involved in the 
pathologic mechanism of the progression of atherosclerosis. As a result, circulating 
platelets are recruited and adhere onto the endothelium in response to specific pro-
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inflammatory protein mediators. Activation of the generation of different platelet adhesive 
molecules also promotes further activation of endothelial cells by triggering positive 
feedback signals [9, 10]. Increased aggregation of platelets with fibrin at the sites of 
atherosclerotic plaque is the most prominent process for development of arterial 
thrombosis leading to obstruction of blood vessel flow and organ failure [9, 194]. 
Atherosclerosis is distinguished by the thickening and narrowing of blood vessel arteries 
due to deposition of atheromas or fibro-fatty plaques, also known as rupture of 
atherosclerotic plaques. Atherothrombosis is the growth of thrombosis that is primarily 
triggered following a rupture of an atherosclerotic plaque in the vessel intima [195-197]. 
Previous studies have reported that increased accumulation of oxidised low-density 
lipoprotein (oxLDL) in the arterial intima plays a key role in the progression of 
atherosclerosis because it initiates endothelium dysfunction [198, 199]. The presence of 
oxLDL initiates hypercholesterolemia, which causes enhanced generation of reactive 
oxygen species (ROS), thereby leading to vascular dysfunction and supporting 
atherosclerotic development. Some studies have demonstrated that oxLDL also enhances 
the recruitment and adhesion of platelets and leukocytes to the damaged endothelial lining 
through promotion of the production of potential adhesive molecules, including P-selectin 
and CD40L. Consequently, inhibitory regulators, in particular levels of bioactive NO and 
PGI2 which are produced from healthy endothelial cells, will be reduced when 
endothelium becomes dysfunctional. These negative mediators are very important for in 
vivo inhibition of platelet activation and thrombus growth [200, 201].  
The adhesion of platelets in flowing blood to the subendothelial substances is an intricate 
process involving many glycoprotein receptors and integrins and based on dynamic flow 
conditions [202-204]. Under high shear stress (>1000s
-1
) such as occurs in arterioles and 
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stenosed arteries, the thrombotic process occurs primarily by tethering and adhesion of 
platelets to exposed collagen fibres via an indirect mechanism involving a platelet 
adhesive membrane receptor GPIb-IX-V complex bound to collagen through linkage with 
vWF [163]. Receptor GPVI and integrin α2β1 interact with an adhesive ligand (type I 
collagen) on the platelet surface as a necessary process for inducing intracellular and 
extracellular signalling pathways that initiate binding of platelet integrin αIIbβ3 with 
fibrinogen and vWF substances. This leads to irreversible platelet granule secretion, 
aggregation and subsequent thrombus formation [159, 202, 205].  
Platelets are involved in the entire process of initiation and development of the 
atherosclerotic plaque, as well as in the inflammation and atherogenesis of this lesion 
[206]. As described in this thesis, platelets have a major function in vascular inflammation 
via the production of atherogenic mediators and by the association with the endothelium 
and leukocytes. Upon activation, platelets release several pro-inflammatory molecules and 
modulators such as interleukin IL-1β, IL-6 and IL-8, PF4, monocyte chemo attractant 
protein-1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α) and ‘regulated on 
activation normal T cell expressed and secreted’ (RANTES) [9, 41, 45]. The expression of 
membrane molecules, such as P-selectin and CD40L, in activated platelets and activated 
endothelial cells also regulate atherosclerotic and atherothrombotic processes [207-211] 
(Figure 1.13). 
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Figure ‎1.13. Involvement of multiple adhesive molecules in arterial thrombosis. Upon inflamed and 
activated endothelium, several adhesive molecules are expressed including P-selectin and vWF that promote 
platelet tethering and adhesion. Activated platelets release different bioactive molecules that modify the 
chemotactic and adhesive features of the endothelial cells. Following stable platelet adhesion mediated by 
the association of αIIbβ3-fibrinogen complexes with endothelial αvβ3 or intercellular adhesion molecule-1 
(ICAM-1). Platelet derived IL-1β initiates endothelial release IL-6 and IL-8, surface expression ICAM-1 and 
monocyte chemotactic protein-1 (MCP-1). CD40L released from activated platelets that binds its ligand 
CD40 on endothelial cells resulting in expression of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), 
E-selectin and P-selectin, cytokines and tissue factor. The interaction of platelets with leukocytes supports 
pro-atherogenesis by rolling leukocytes to endothelial cell-bound platelets through different steps. The 
binding of P-selectin expressed on platelet surface with its ligand, P-selectin glycoprotein ligand-1 (PSGL-1) 
on leukocytes is initially mediated by platelet-leukocyte cross-talk. Adapted from [9]. 
 
1.5.5 Adhesive molecules that mediate pro-atherothrombosis 
As indicated above, platelets are well defined as regulators of the atherogenesis processes 
which mediate the emergence of the atherosclerotic plaque and lesion instability at the late 
phases of the vascular development. These processes are highly regulated by adhesive 
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mediators, including P-selectin and CD40L, which are derived from activated platelets 
and/or endothelial cells.  
1.5.5.1 P-selectin 
P-selectin (CD62P), also named granule membrane protein 140 (GMP-140), is a cell 
surface adhesion molecule mainly present in the alpha granules of platelets and Weibel-
Palade bodies of endothelial cells. It is constitutively expressed and translocated on the 
surface of platelets and endothelial following granule secretion [212, 213]. Increased 
expression of P-selectin play an important role in the initial rolling and recruitment of 
leukocytes to the site of vascular injury or inflamed endothelium during inflammation and 
atherosclerotic plaque formation, by binding its ligand P-selectin glycoprotein ligand 
(PSGL-1) on the membrane surfaces of leukocytes. Studies have provided evidence into 
the potential function of P-selectin in regulation of atherosclerotic lesion progression and 
arterial thrombosis through promoting greater stability of the interaction between platelets 
and leukocytes, as well as endothelial cells [214].  
However, platelet-derived P-selectin, but not endothelial P-selectin, significantly promotes 
the development of neointima production after angioplasty/air dehydration damage of the 
carotid artery in mice [214]. Studies have demonstrated that mice deficient in P-selectin or 
mice with defective anti-P-selectin blocking exhibit reduced leukocyte recruitment and 
haemostasis. In addition, the development of atherosclerosis and atherogenesis is reduced 
in mice with anti-P-selectin blocking or in mice with P-selectin-deficiency [211, 215, 216]. 
Moreover, pro-atherogenic factors such as oxLDL and hypercholesterolemia induce the 
expression of P-selectin that leads to upregulation of leukocyte adhesion to platelets and 
endothelium at sites of vascular inflammation [217-219]. Upon activation of platelets 
and/or endothelial cells, the soluble form of P-selectin (sP-selectin) can be produced in 
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vivo within few minutes by proteolytic cleavage of the membrane bound form [220]. 
Increased levels of sP-selectin have been reported in different categories of cardiovascular 
diseases, such as atherosclerosis, ischaemic heart disease, stroke, peripheral arterial 
occlusive disease (PAOD) and restenosis [209, 210, 221-225]. Today, sP-selectin is 
extensively used as a useful bioactive marker of different cardiovascular events that 
involve stimulation of platelets and/or endothelial cells [222, 226, 227]. 
Multiple downstream signalling pathways are created by the interaction of P-selectin and 
different ligands that mediate the formation of atherosclerotic plaque and atherothrombosis 
[228].  Romo et al. [229] showed that the GPIbα-IX-V complex acts as a counter receptor 
for P-selectin and supposedly promoted platelet-platelet association. GPIbα was also 
suggested to reinforce platelet adhesion through interaction with P-selectin on endothelial 
cells. Interestingly, due to the intracellular localisation of vWF (the main ligand mediating 
thrombus growth) with P-selectin (the chief receptor for leukocyte adhesion), these 
proteins are present in platelets and endothelial cells and they bind to the GPIbα-IX-V 
complex, indicating that these molecules have overlapping functions in the mediation of 
arterial thrombosis.  
P-selectin induces the expression of leukocyte macrophage adhesion ligand-1 (Mac-1, 
αMβ2, CD11b/CD18), which increases inflammation and enhances tethering of platelets to 
the endothelial cell [intercellular adhesion molecule 1 (ICAM-1)] [230]. P-selectin/ PSGL1 
cross-linking activates the ‘inside-out’ localisation of integrin αMβ2 in monocytes and 
neutrophils through Src tyrosine kinase signal transduction, resulting in increased 
interaction of platelet-leukocytes and endothelial cells, further enhancing the inflammatory 
response [231]. Another consequence of exposure of P-selectin on the platelet surface is 
that it promotes the association of the circulating microparticles derived from platelets or 
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leukocytes through binding PSGL-1 and their participation in arterial thrombus formation 
and fibrin generation in vivo. Leukocytes can be stimulated once sP-selectin is cleaved 
from the surface of activated platelets or endothelial cells, via binding PSGL-1 which in 
turn produces tissue factor-microparticles that are important in pro-coagulant activity [228, 
232]. Microparticles can cross link various cells types most particularly through P-selectin, 
forming platelet-platelet, platelet-leukocyte, leukocyte-leukocyte and endothelial cell cross 
linkages that lead to the development of atherothrombotic events [233, 234]. On this basis, 
the risk of pathological thrombosis related with P-selectin is multiplied attributed to pro-
inflammatory profiles, development of atherosclerotic plaque, prothrombotic phenotypes 
and hypercoagulability. 
1.5.5.2 CD40L 
CD40 ligand (CD40L, CD154), a type I transmembrane protein receptor, is a member of 
the tumour necrosis factor superfamily [235] that is identified in immune cells, and in 
particular in T lymphocytes [236]. The function of CD40L in the immune response is that 
the expression of its receptor CD40 on surface of B cells triggers the generation of B-cells, 
blocks B-cell apoptosis and produces memory B cells [237, 238]. However, CD40L also 
exists in different cells in the vascular wall, such as endothelial cells, smooth muscle cells, 
monocytes and macrophages [239]. The pioneering studies of Henn and co-workers [240, 
241] have demonstrated that CD40L is also present in platelets. CD40L is cryptic in 
activated platelets, but is constitutively translocated to the platelet surface upon platelet 
stimulation in response to a soluble agonist; e.g. thrombin. Subsequently, the surface-
expressed CD40L is proteolytically cleaved over of a period of minutes to hours, 
producing a soluble form of CD40L (sCD40L) that exists in the blood circulation. Most of 
the sCD40L (>95%) is essentially derived from stimulated platelets. Similar to sP-selectin, 
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increased levels of sCD40L are associated with platelet activation and elevated leukocyte 
recruitment in vivo. The platelet stimulatory phenotypes essentially contribute to the 
physiological and pathological context of CD40L involvement [241, 242].  
In vivo, the development of atherogenic mediators, particularly oxLDL and 
hypercholesterolemia, is known to trigger expression of CD40L and CD40 in the vascular 
wall [219, 243, 244]. Platelet-related CD40L expression and exposure to CD40-bearing 
vascular cells induce various pro-inflammatory responses, including the secretion of 
inflammatory chemokines (e.g. MCP-1, IL-6 and IL-8) and the expression of adhesion 
molecules (ICAM-1, VCAM-1 and E-selectin) and tissue factor [240, 245]. Many studies 
have reported that most of the inflammatory mediators can be initiated by CD40L, as 
outlined above; the association of this molecule with development of atherogenic 
phenotypes. Mach and collaborators [246] demonstrated that the development of 
atherosclerotic plaque lesions was significantly inhibited in mice receiving an anti-CD40L 
blocking antibody; indicating a direct role for the CD40L/CD40 system in atherosclerotic 
plaque stability and introduced CD40L as a chief mediator of pro-inflammatory responses.  
Circulating sCD40L has a high potency for facilitating various proatherothrombotic events 
inside the vasculature. In fact, increased concentrations of sCD40L have been reported in 
many inflammatory and thrombotic events, including atherosclerosis [208], PAOD [247], 
acute coronary syndrome [248] and restenosis [249]. Elevated levels of sCD40L are 
associated with an increased risk factor for future cardiovascular disease among normal 
humans, especially women [250]. Like sP-selectin, increased circulating sCD40L is a more 
sensitive biomarker of in vivo platelet activation and pro-thrombotic events [240, 241]. 
Leroyer et al. [251] demonstrated that microparticles separated from patients with 
atherosclerotic lesion showed induction of CD40L, while another study showed that 
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platelet-derived microparticles triggered angiogenetic phenotypes in vitro and in vivo 
[252]. Platelet microparticle-derived CD40L with atherogenic profiles are linked with 
atherosclerotic plaque from patients having vascular disease, and indicate a significant 
function for CD40L in vasculature events [251]. Santilli and coworkers [253] 
demonstrated that the GPIb-IX-V complex induces the release of sCD40L in vivo through 
the production of TXA2 in patients with vascular disease. The results also indicated that 
increased levels of sCD40L significantly activated platelets in vivo and suggested that this 
contributed to accelerated atherosclerotic progression. Andre et al. [242] showed that 
CD40L acts as ligand for αIIbβ3, as well as regulating the stability of integrin αIIbβ3-
dependent platelet thrombi. The results also indicated that sCD40L is a crucial platelet 
agonist and that platelet activation is initiated by the interaction of sCD40L with αIIbβ3, 
triggering outside-in signalling by tyrosine phosphorylation of β3.  
A previous study showed the interesting finding that integrin αIIbβ3 antagonists reduced 
secretion of sCD40L from platelets in vitro. This result indicated that the generation of 
sCD40L derived from platelets and its thrombo-inflammatory reactions seem to be closely 
associated to the platelet integrin αIIbβ3 [254]. The biological association between cleavage 
of CD40L in vivo and other adhesion protein receptors and the role of these processes on 
arterial thrombus growth are not yet ascertained. In general, platelet-derived CD40L 
appears to be involved in a broad spectrum of pathological thrombosis, and increased 
levels of sCD40L also contribute to development of pro-inflammatory and thrombotic 
events [44, 255]. 
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1.6 PROTEIN TYROSINE KINASES AND THEIR EXPRESSION ON 
OR IN PLATELETS 
The various steps of platelet activation is heavily reliant on cell-signalling pathways 
dependent on protein tyrosine phosphorylation (PTP) that is mediated by specific 
enzymatic molecules called protein tyrosine kinases (PTKs) that catalyse the transfer of 
the terminal phosphate of ATP to tyrosine residues on protein substrates [256, 257]. PTKs 
consist of assorted multigene families with specific importance in pathophysiological 
events in the human body. Indeed, PTKs are involved in the mediation and regulation of 
numerous physiological responses including cell growth, proliferation, differentiation, 
metabolism, migration and apoptosis [258, 259]. PTPs positively or negatively regulate 
platelet signal transduction through many distinct mechanisms [260]. PTKs can be 
subdivided into two broad families based on their supposed structures [261, 262]. One 
family, called receptor tyrosine kinases (RTKs), is characterised by having an intracellular 
domain and an extracellular domain. This family includes platelet-derived growth factor 
receptor (PDGFR), vascular endothelial factor growth receptor (VEFGR), and the c-Kit 
receptor [257, 261]. The second family, called non-receptor protein tyrosine kinases 
(NRTKs), is characterised by a lack of extracellular sequences. NRTKs contain modular 
domains which play an important role for subcellular objectives and the regulation of 
catalytic actions. NRTKs include distinct families such as the SFK, Abelson (Abl)  and 
spleen tyrosine kinase (Syk) [257, 262]. Most of these are regulated by different receptor-
mediated pathways through activation of their catalytic activity and modifications in their 
cellular physiology [260].  
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1.6.1 Receptor tyrosine kinase 
The RTK family such as PDGFR and c-Kit is a distinct group comprising extracellular 
proteins that are stimulated by the binding of their soluble transmembrane ligands (Figure 
1.14). Most RTKs have a single polypeptide chain and are monomeric due to a lack of 
ligands [257]. The high-affinity binding of these receptors to ligands stimulates 
conformational change that activates the cytoplasmic sequences of tyrosine kinases and 
enzymatic activity, thus triggering various cellular physiological processes [256, 263, 
264].  
 
Figure ‎1.14. Receptor protein tyrosine kinase families (RTKs). This figure shows domain structures for a 
different subfamilies of RTKs. The cytoplasmic portion of the receptor is on the bottom and the extracellular 
portion is on the top. Adapted from [256, 265, 266]. 
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1.6.1.1 Platelet-derived growth factor 
Platelet-derived growth factor (PDGF) is identified as a class III RTK and has five 
extracellular Ig-like domains [261]. PDGF is a powerful mitogenic and chemotactic in 
humans [267, 268] and is crucial for mesenchymal-derived cells and for generating cell 
division during repair mechanisms [268, 269]. PDGFR is expressed on many human cells 
including capillary endothelial cells, mast cells and neuronal cells [270, 271] and platelets 
[272]. PDGF has an important role in the development of cell growth and normal 
physiological processes in humans. However, an increase in the activity of PDGF has been 
associated with many pathological mesenchymal states including malignant conditions and 
atherosclerosis [273]. It is also represented as a prospective drug target for anti-leukaemia 
therapies [274, 275].  
Platelets conserve PDGF within their α-granules upon platelet activation and/or 
aggregation. PDGF is released resulting in the negatively dependent regulation of platelet 
activation through the inhibition of thrombin and collagen-induced platelet aggregation 
[270, 271]. Ligand binding induces dimerisation and autophosphorylation of the tyrosine 
kinase of PDGFR. The autophosphorylation of receptor tyrosine provides docking 
positions for SH2 domains with substrate proteins [271, 276] resulting in phosphorylated 
PDGFR and activation of numerous related SH2 domains containing signal molecules 
which potentially promote physiological responses including the growth and motility of 
cells [271]. 
1.6.1.2 c-Kit 
c-Kit is the original cellular homologue of the viral oncogene (v-Kit) [277]. It has 
structural similarities to PDGFR as a member of the class III receptor tyrosine kinases 
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[278] and is mainly expressed on haematopoietic stem cells, mast cells and clonogenic 
myeloid and megakaryocytic progenitor cells [279]. The normal activity of c-Kit signalling 
involves the maintenance of normal haematopoiesis, lymphopoiesis, megakaryopoiesis and 
melanogenesis development [280]. Nevertheless, the deregulation of c-Kit activity is 
thought to have significant implications in different types of human cancers including 
CML [281] and acute myelogenous leukaemia (AML) [282]. Abnormal proliferation of c-
Kit occurs through a specific mutation of the c-Kit polypeptide which leads to ligand-
independent stimulation, or through autocrine activation of c-Kit [283]. The c-Kit 
ligand/stem cell factor (KL/SCF) binds to the c-Kit receptor, mediating the proliferation of 
bone marrow progenitor cells through the induction of autophosphorylation and 
stimulation of tyrosine kinase activity. The c-Kit with intrinsic kinase domain catalyses the 
phosphorylation of substrate proteins and the phosphorylation of this receptor in tyrosine 
kinase residues works as docking positions for signal transduction sequences with SH2 and 
PTB portions [284]. 
The expression of the c-Kit receptor was identified on the surface of human 
megakaryocytes which serves as the receptor for KL/SCF [285]. Recently, expression of 
the c-Kit gene was observed in human platelets using polymerase chain reaction (PCR) 
analysis. The researchers reported that a low number of c-Kit receptors were expressed per 
platelet [286]. This study is in accordance with a previous study which revealed c-Kit 
receptors expressed at a lower number on differentiated blood cells. This observation 
showed that KL/SCF-induced modulation of the secondary wave of platelet aggregation 
occurred following stimulation with certain platelet agonists [287]. As it is known that 
KL/SCF plays a role in augmenting haematopoietic proliferation, the recent observations 
additionally suggests that KL/SCF has pleiotropic effects as a potentiator of platelet 
activation. Platelets may associate with KL/SCF produced from mesenchymal cells at the 
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sites of vascular damage or in atherosclerotic events, thus supporting platelet aggregation 
and prompting the development of thrombus formation [286]. 
1.6.2 Non-receptor tyrosine kinases 
Non-receptor tyrosine kinase (NRTKs) such as SFKs and Abl are vital parts of the 
signalling pathways mediated by RTKs and other cell membrane receptors such as GPCRs 
and immune cells [256]. NRTKs have many important members including  SFKs and Abl 
[288] which are characterised by a lack of receptor-like characteristics such as 
extracellular or transmembrane domains but contain modular domains [289]. Some 
NRTKs (e.g. SFK) are secured to the cell surface membrane via amino-terminal alteration 
such as myristoylation or palmitoylation. NRTKs contain sequences that mediate protein-
protein, protein-lipid and protein-DNA communication. The SH2 and SH3 domains 
exemplify the case of protein-protein interactions [290]. In brief, the SH2 domain is a 
condensed domain consisting of ~100 residues that link to the residues of phosphotyrosine 
in a sequence specific mode. In contrast, the SH3 domain is a smaller domain of ~60 
residues that links to proline-holding domains capable of producing a polyproline type II 
helix. Some NRTKs possess an F-actin-linking domain and DNA-linking domains in 
addition to SH2 and SH3 domains such as Abl which has a nuclear localisation signal and 
exists in both the nucleus and the cytoplasm [256] (Figure 1.15).  
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Figure ‎1.15. Non-receptor protein tyrosine kinase families (NRTKs). This figure shows domain 
structures of the main subfamilies of NRTKs. The carboxyl group is on the right side and the amino group is 
on the left. Adapted from [256, 265, 291]. 
 
1.6.2.1 Src family kinases 
Src family kinases (SFKs) are proto-oncogenes of the largest subfamily of NRTKs that 
essentially exist in all metazoan cells [292, 293]. SFKs play an important role in regulating 
diverse vital cellular processes-including cell proliferation, differentiation, morphology, 
motility, adhesion and survival-through their involvement in the regulation of signal 
transduction by a varied set of cell surface receptors in the background of diverse cellular 
environments [292, 294]. There are 11 SKFs expressed in human cells specifically Src, 
Lck, Hck, Fyn, Lyn, BIk, Fgr, Yes, Yrk, Frk and Srm [295]. They have an important role 
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in signal transduction mechanisms in the human body. A defect or mutation in the SH2 
and SH3 domains of SFK significantly activates kinase activity and enhances abnormal 
Src catalytic activity, a common hallmark of various types of cancers. SFKs are promising 
targets for cancer treatment. Thus, tyrosine kinase inhibitors against SFK phosphorylation 
are being progressively developed for treatment of different types of leukaemia [296]. 
There are at least six distinct SFK members expressed on human platelets including Src, 
Lyn, Fyn, Fgr, Lck and Yes [297, 298]. SFKs have been revealed to be the major protein-
phosphorylating enzymes in platelet membranes [299], where they play various functions 
in different aspects of platelet activation [300]. For instance, Src has a key role in integrin 
‘outside-in’ αIIbβ3 signalling initiating integrin activation through its binding to the C-
terminal sequence of integrin β3 [138]. Moreover, Fyn have been proposed for mediating 
the phosphorylation of the FcRγ chain and may be essential for initiating the platelet 
GPVI/Fcγ chain ITAM-syk signalling pathways [301]. Furthermore, Wu et al. reported 
that phosphorylation of two SFK members,  Src and Lyn are implicated in GPIb-mediated 
platelet activation and they are involved with PI3-kinase and GPIb that generate an 
intricate mechanism on vWF binding to GPIb-IX-V to induce platelet activation [302]. 
Unlike Fyn and Src, Lyn is associated with a positive and negative feedback pathways and 
downregulates platelet activation [303, 304]. A recent study performed by Li et al. verified 
an important function of SFK signalling pathways in potentiating platelet granule release. 
It is suggested that SFKs play an important role in both positive and negative regulation of 
platelet activation, granule release and aggregation [303, 305]. Although different 
members of SKF have been identified to stimulate platelet activation and to be located 
downstream of platelet signalling pathways but some mechanisms involved in platelet 
function have not yet been elucidated. 
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1.6.2.2 Abl family kinases 
The Abelson (Abl) proto-oncogene is the normal cellular homologue encoded by the 
Abelson murine leukaemia virus [306, 307]. It is found in all cells throughout embryonic 
development, and is generated by maternally implicated mRNA [308]. Abl kinase is 
thought to have a significant role in the regulation of cell growth, cell adhesion and 
morphogenesis via functional association with proteins to bind the transmembrane 
signalling pathways [309].  
The structural domains of Abl is broadly similar to the Src protein kinases, such as in the 
SH3 and SH2 domains; however, there are critical differences between them (Figure 
1.16A and B). In brief, the inactivation switch of Abl is a large conformational change at 
the base of activation loop inside the kinase domain and this differs from Src kinase which 
turns over the sites of the aspartate and phenylalanine side sequences in a conserved Asp-
Phe-Gly (DFG) motif. This conformational change in the DFG motif is incompatible with 
a closing of the kinase domain which is observed in inactive Src kinase, the catalytic 
sequence of the Abl is fundamentally presented in the open conformation observed in 
active protein kinases. This dislocates in the DFG motif and the activation loop is 
importantly needed for binding tyrosine kinase inhibitors (TKIs) such as imatinib (STI-
571) [307, 310]. Additionally, the inner docking of the SH2 sequence requires the 
stimulation of a pointed bend within the C-terminal region at the bottom of the kinase 
domain. This conformational change is initiated by the interaction of the protein N-
terminal myristol by which assembles to the base of kinase domain; the creation of this 
binding emerges to be the principle function of the N-terminal cap domain. These 
significant differences explore the capability of imatinib to bind to Abl on Src kinases 
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[307]. Furthermore, Abl is known to play a critical role in oncogenesis by associating with 
breakpoint cluster region (Bcr) to form Bcr-Abl fusion gene [311] (Figure 1.16C). 
 
 
Figure ‎1.16. Comparison of domain structures of the Src and Abl families of NRTKs. (A) Src family 
kinases (SFKs ) (B) Abl family kinase (C) oncogenic fusion Bcr-Abl kinase. All these families of NRTKs 
are essentially composed of Src-homology-3 (SH3), an SH2 and a tyrosine kinase. SH3 domains bind to 
proline-rich residues. Whereas SH2 domains bind to phosphorylated tyrosine residues. The 1b link form of 
the Abl family of kinases and the c-Src and Blk kinases are myristoylated, while all other subfamilies of the 
SFKs are myristoylated and palmitoylated. The carboxyl terminus of Abl encodes a lysine-rich motif 
necessitated for nuclear localisation, DNA-binding domain, and F-actin binding domains. Rearrangement of 
Bcr gene into Abl gene resulting in a Bcr-Abl fusion gene. Modified from [312]. 
 
1.6.2.3 The Abl and Bcr interaction 
c-Abl is expressed in all types of human cells and is exclusively located in the cytoplasm 
and nucleus [313]. Major cytoplasmic c-Abl interacts with the F-actin cytoskeleton via the 
C-terminal actin-linking sequences and is associated with regulating cell-cell kinases; thus 
mediating cell development and proliferation. In contrast, the Bcr-Abl protein is entirely 
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present in the cytoplasm [314]. The Bcr protein 160 kDa [315] is ubiquitously expressed in 
haematopoietic and other tissues [316]. It consists of several diverse structural domains 
and the N-terminal domain encodes a novel serine/threonine protein kinase [317].  
In brief, the 3' end of cellular c-Abl at chromosome 9 reorganises onto chromosome 22 
where it is joined with the 5' region of the Bcr, as a result the production of Bcr-Abl gene 
that known as the Philadelphia (Ph) chromosome (Figure 1.17). It is able to enhance the 
generation of the Bcr-Abl fusion protein [318, 319]. The aberrant Bcr-Abl fusion protein 
likely activates several signalling pathways that affect haematopoietic cell proliferation 
and apoptosis together with deregulation of numerous signal transduction pathways such 
as PI3K and extracellular signal-regulated kinase (ERK) [313, 320]. In addition, an adapter 
protein termed CrKL (CrK-like) is a major prominent tyrosine kinase protein 
phosphorylated in the myeloid cells associated with CML. It is implicated in the regulation 
of cellular movement and mediation of integrin-cell adhesion [321, 322], in which CrKL 
recently was revealed to be constitutively tyrosine phosphorylated in platelets of CML 
while CrKL could not be observed in healthy platelets [323]. CrKL is suggested to be 
involved in determining the inhibition of the Bcr-Abl enzyme through measuring the 
proportion of phosphorylated versus unphosphorylated CrKL by the gel electrophoresis 
technique [314]. 
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Figure ‎1.17. Philadelphia chromosome. c-Abl at chromosome 9 translocated onto chromosome 22 where it 
is joined to the Bcr gene; as a result, the generation of Bcr-Abl fusion gene occurs that known as the 
Philadelphia (Ph) chromosome. Adapted from [316, 324]. 
 
1.6.2.4 Bcr-Abl fusion protein and chronic myeloid leukaemia 
CML is a haematopoietic stem cell malignancy distinguished by the expression of the Bcr-
Abl fusion gene [324]. Almost all adult CML cases have characteristic chromosomal 
abnormality due to a reciprocal t(9;22) (q34;q11) translocation with more than 95% of 
adult CML patients are diagnosed with the Ph chromosome. The Ph chromosome 
contributes to the existence of p210
Bcr-Abl
 [325, 326]. A validated study showed that CML-
like leukaemia was potentially developed in cultured haematopoietic murine cells treated 
with a retrovirus encoding p210
Bcr-Abl
, inducing cytogenetic disorders. The researchers 
emphatically argued that the Bcr-Abl fusion gene is an adequate source to trigger CML in 
humans [314, 327]. 
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Genetic instability is associated with disruptions in different aspects of vital cell processes 
such as proliferation, differentiation, maturation and apoptosis [328]. CML is also 
characterised by the increased production of immature granulocytes and neutrophils. CML 
is categorised into three stages including the chronic phase (CP-CML), accelerated phase 
(AP-CML) and blastic transformation (BT-CML) [326]. Approximately 40% of CML 
patients are asymptomatic at the onset of the disease. Diagnostic testing is based on an 
abnormal blood count with eosinophilia, basophilia and increased myeloid cell production 
[314]. Therefore, the investigation of CML depends on cytogenetic testing to identify the 
Ph chromosome in patient samples [314, 320]. As a consequence, most CML cases 
progress from the chronic phase to an accelerated phase or blastic crisis in 3-5 years [320]. 
The induction of CML by Bcr-Abl is a complex mechanism and widely studied. It is 
initiated by the clonal development of pluripotent haematopoietic stem cells and the 
original stage of myeloid hyperplasia is followed by conversion to acute leukaemia of 
either the myeloid or lymphoid cell line. Significantly, the myeloid lineage in CML 
undergoes uncontrolled elevation of myeloid cell divisions and experience defective 
apoptosis of these cells. The disorder of physiological regulation in this mechanism is 
caused by diminished adhesion to bone marrow stromal cells [320, 329] and the rising 
resistance to negative regulators of haematopoiesis including macrophage inflammatory 
protein 1α (MIP-1α) [330]. 
Therapeutic strategies for CML have been greatly improved through exclusively 
investigated mechanisms of CML. Clinically, the efficacy and safety of therapy is based on 
clinical remission in CML patients. There are several categories of remission in CML: a 
haematological remission (HR), a cytogenetic remission (CR), and a molecular remission 
(MR). A complete haematological remission (CHR) is recognised as the normalisation of 
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blood counts and spleen size, while complete cytogenetic remission (CCR) is realised 
when Ph+metaphase presents in 0-35% of cells. A major molecular remission is described 
by a decreasing Bcr-Abl/Bcr ratio to 3-log from the mean level prior to treatment. A 
complete molecular remission (CMR) is assessed by reverse transcriptase PCR (RT-PCR) 
to confirm the absence of Bcr-Abl chimeric mRNA [331]. CML patients were historically 
treated with chemotherapies, interferon α (INF-α) and bone marrow transplantation. These 
therapies exhibit good tolerance but there are many critical issues and complications 
following the treatment  [332]. In recent decades, TKIs have replaced conventional 
chemotherapeutic agents that are highly effective in blocking the myeloid leukaemic cells. 
Specifically, TKIs inhibit abnormal proliferation and promotes apoptosis by inhibiting 
Bcr-Abl activity [333, 334]. 
1.7 TYROSINE KINASE INHIBITORS 
Tyrosine kinase inhibitors (TKIs) have emerged within the clinical and research fields as 
effective inhibitory therapies for treatment of patients with CML [335]. Most TKIs are 
characterised by small molecules and hydrophobic complexes that specifically and directly 
inhibit the overexpression or abnormal activation of tyrosine kinase enzymes by 
exclusively linking to ATP-binding sites or substrates [335, 336]. 
Imatinib is a first generation of TKIs used as a frontline treatment for Ph-positive CML. 
[337, 338]. Despite the impressive outcomes of CML patients treated with imatinib, 
numerous CML cases have been reported as having unsuccessful responses to the imatinib 
regime during advanced stages of the disease suspected to result from either resistance or 
intolerance to imatinib. Therefore, second-generation TKIs (2G TKI), nilotinib and 
dasatinib, have been revolutionised to surmount imatinib-intolerant and imatinib-resistant 
CML [339-341]. Advanced-generation TKIs have higher efficacy and tolerance against 
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CML than the original imatinib regimen [342]. Although, these TKIs have been approved 
by the US Food and Drug Administration (FDA), these drugs remain controversial because 
of frequent toxicity development [343] and clinical events ranging from mild, moderate to 
serious adverse effects. These inhibitors have also been recently suggested to trigger other 
serious life-threatening complications, particularly when used for long-term treatment 
[344]. There is a clinical need to identify the mechanisms by which adverse side effects 
occur following TKI treatment. This would help and guide clinicians to seek alternative 
treatment strategies to reduce complications of TKI treatments.  
1.7.1 TKI imatinib  
Imatinib or imatinib mesylate, known as Gleevec in the United States or Glivec in Europe, 
is made by Novartis Pharmaceuticals Corporation [314, 345]. It was formerly known as 
signal transduction inhibitor-571 (STI-571). It is a compound in the 2-
phenylaminopyrimidine category and specific inhibitor of Bcr-Abl, c-Kit, and PDGFR 
[274]. In 2001, imatinib was officially approved by the FDA with recommended doses of 
400 mg daily (QD) for CP-CML and 600 mg QD for AP- CML and BP-CML [335, 346]. 
Previous observations performed by O’Brien, et al. reported that recently diagnosed CML 
patients demonstrated an estimated 97% CHR and 76% CCR following 19 months of 
receiving 400 mg imatinib QD [341, 347]. Furthermore, other studies have shown that 
high doses of imatinib 600 mg QD were expected to result in higher efficacy than the 400 
mg dose for treatment during AP-CML and BP-CML [338, 348]. Imatinib successfully 
inhibits cell proliferation and induces apoptosis in all phases of CML. Thus, this 
compound is approved for use after failure of other agents such as interferon-α, to 
stimulate CHR and CCR [335, 349].  
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The pharmacokinetics of imatinib shows that it is rapidly absorbed following oral 
administration with an entire oral bioavailability of 98% and a half-life of 15-20 hours 
[350, 351]. One daily dose of 400 mg at steady state sustains mean peak plasma 
concentration of approximately 4 µM to 5 µM but can reach 7.5 µM administered with 400 
mg BID [352]. The 50% inhibitory concentration (IC50) is 3.3±0.05 µM for the inhibition 
of the enzymatic activity of tyrosine kinases and leukemic cell proliferation [353]. 
Although the efficacy of imatinib for inhibition of Bcr-Abl tyrosine kinase activity in 
leukemic cell lines is broadly elucidated, many CML patients fail to respond to imatinib 
treatment at advanced stages of the disease, especially the accelerated phase and blast 
crisis [353]. Recent reports have stated that up to 30% of CML patients discontinued 
treatment with imatinib during the first five years because of resistance [354]. Several 
mechanisms of imatinib resistance have been reported, but Bcr-Abl gene mutation or 
amplification within the kinase domain and subsequent overexpression of Bcr-Abl has 
been identified as the primary mechanism of drug resistance. Mutation or amplification of 
this oncogene involves drug-protein binding, presumably resulting in interference that 
impairs the mechanism of imatinib metabolism; therefore, these patients exhibit drug 
resistance or intolerance and progress toward relapse during the chemotherapy course 
[355, 356]. Moreover, imatinib sequestration arbitrated by the serum protein α-1 acid 
glycoprotein (AGP) or imatinib efflux by multidrug pumps seem to be implicated as 
possible mechanisms of imatinib resistance [356]. 
As a consequence of Bcr-Abl over stimulation, altered cellular signalling pathways are 
activated including those responsible for cellular regulation and growth. As reviewed by 
Bixby and Talpaz, the activation of SFK by Bcr-Abl may enhance leukemic progression 
and impair tolerance to treatment. The direct association of Bcr-Abl with SFK promotes 
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the active conformation of Abl tyrosine kinase that acts to strongly modify the regulation 
of cellular enzymes [357]. In addition, phosphorylation of the SH2 and SH3 domains of 
Abl tyrosine kinase by SFK may increase the activation of Abl kinase, leading to changes 
in Abl kinase susceptibility to imatinib [357, 358]. Ultimately, the independent 
participation of SFK in activation of Bcr-Abl may also be a factor in imatinib-resistant 
patients [359]. Indeed, based on the understanding of the mechanism of imatinib as an 
effective therapeutic agent against CML, many researchers have been encouraged to 
develop and explore 2G TKIs such as nilotinib and dasatinib [360]. 
1.7.2 TKI nilotinib 
Nilotinib (trade name Tasigna, formerly AMN107, Novartis Pharmaceuticals Corporation) 
is an ATP-competitive inhibitor of Bcr-Abl. A novel oral phenylaminopyrimidine 
derivative, this compound is rationally modified and designed based on the 
crystallographic structure of imatinib [361]. In fact, nilotinib resulted from incorporation 
of alternative binding clusters for the N-methyl-piperazing moiety preserving an amide 
pharmacophore to retain hydrogen (H)-bond interactions Glu286 to Asp381 [341, 362]. 
Nilotinib was originally approved by the FDA in 2007 as a second-generation TKI to treat 
imatinib-resistant or intolerant Bcr-Abl-CP-CML and AP-CML patients [331]. The 
compound is a structural analogue of imatinib with multiple protein kinase targets 
including Bcr-Abl, c-Kit, and PDGF but has shown a 20-50 fold increase in potency over 
imatinib with respect to inhibition of tyrosine kinases [341, 362]. In vivo and in vitro 
experiments have demonstrated that nilotinib is a very effective compound against all Bcr-
Abl mutation-related imatinib resistances in CML except for the T3151 mutation in the 
Abl kinase domain which influences an essential H-bond located within the ATP-binding 
cleft [355, 363].  
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In pharmacokinetic profiles, nilotinib is quickly absorbed and reaches peak levels within 3 
hours after oral administration with a half-life of approximately 15 hours [364, 365]. 
Nilotinib has a high bioavailability which increases with meals, therefore this compound 
should be administered on an empty stomach with minimal ingestion of food for one hour 
after the dose to avoid high plasma levels, which promote increased risk of toxicity [366]. 
The mean peak plasma concentration after a single administration of nilotinib (400 mg) is 
4.6 µM at steady state [334, 367]. Also, the IC50 for the inhibition of cellular 
phosphorylation of Bcr-Abl tyrosine kinase depends on the cell type but ranges from 25-
709 nM [362, 366]. According to the FDA, the initial nilotinib dose recommended for 
CML therapy is 300 mg BID to minimise the drug adverse events. However, clinical trials 
have indicated that 400 mg BID of nilotinib is a more favourable dose to achieve CHR and 
CMR over a relatively short treatment period as compared with a dose of 300 mg BID 
[367]. The efficacy of nilotinib has been evaluated through many prospective studies. In 
one study of 321 CP-CML patients treated with nilotinib (400 mg BID) the results of a 19 
month follow up demonstrated CHR in 94% of patients and CMR in 59% of patients, 
whereas after 24 months CMR was at 78% [331]. 
Furthermore, a phase II trial was carried out by Kantarjian et al  [366]. This validation 
study aimed to assess the efficacy of nilotinib among imatinib-resistant Ph+ CML patients. 
The study included 17 CP-CML, 56 AP-CML, and 24 BP-CML patients who were 
administered nilotinib (50-1200 mg) until discontinuation as a result of complications or 
disease progression. This observation revealed a time-curve response on day 8 among 
patients given 50-400 mg BID of nilotinib. A steady state level was achieved with 400 mg 
BID, but an achievable steady state level was not observed with higher doses of the drug. 
The follow-up results of this study demonstrated that 92% and 53% of CP-CML patients 
achieved CHR and CMR respectively. In AP-CML patients with clonal assessment, 100% 
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and 90% obtained HR and CR, respectively; whereas, 72% and 48% of AP-CML patients 
without clonal assessment obtained HR and CR, respectively. Among the BP-CML 
patients, 42% and 29% gained HR and CR, respectively. This study elucidated nilotinib-
independent doses have rapid responses and adequate tolerance among CML patients with 
or without point mutations in the Bcr-Abl domain. However, two cases with T3151 
mutation resistance to nilotinib were reported. Based on these studies, the efficacy and 
response of nilotinib (400 mg BID) was of greater magnitude and occurred more rapidly 
than with imatinib, particularly in imatinib-resistant patients [364, 366]. Although, the 
effectiveness and tolerance of nilotinib against imatinib-resistant CML has been even 
greater. However, the interruption or reduction of nilotinib doses was frequently performed 
that due to the occurrence of haematologic and nonhaematologic adverse events among 
patients with nilotinib therapy. Serious vascular diseases such as PAOD and myocardial 
infarction following nilotinib treatment was reported in many cases [368, 369]. Adverse 
events (AEs) of nilotinib will be discussed in greater detail in section 1.7.6. 
1.7.3 TKI dasatinib  
Dasatinib (trade name Sprycel, formerly BMS-354825), manufactured by Bristol-Myers 
Squibb (BMS), is another potent second generation TKI. It is a multitarget TKI of Bcr-Abl 
that has been rationally proposed for treatment of CML patients particularly those with 
intolerance or resistance to imatinib [370, 371]. Dasatinib is a 2-aminothiazole-5-
carboxamide compound that is structurally distinct from imatinib. This compound has 
been shown to have a 325-fold and 16-fold greater potency than imatinib and nilotinib, 
respectively on Bcr-Abl phosphorylation [370, 372]. It is very effective on all imatinib-
resistant Bcr-Abl mutants, except T3151 [373]. Dasatinib is highly effective on c-Kit [374] 
and PDGFR  tyrosine kinases. Indeed, SFK signalling pathways are significantly involved 
in Bcr-Abl independent mechanisms supporting drug resistance especially at the 
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intracellular level if the drug causes very little SFK activation as has been reported in 
many human leukemic cells. Unlike imatinib or nilotinib, dasatinib was initially developed 
as a potent inhibitor targeting SFKs such as Fyn, Src, Lck and Yes. It has been shown to 
potentially inhibit leukemic cell proliferation, adhesion, and induce apoptosis [375]. 
In 2006, dasatinib was approved by the FDA to treat CML patients demonstrating imatinib 
resistance or intolerance [370]. The initial dose of dasatinib approved for treatment of CP-
CML based on the phase II study was 70 mg BID. However, the phase I and phase III 
studies revealed that 100 mg QD is the optimal dose for patients with CP-CML who 
exhibit imatinib resistance or intolerance and similar HR and CR activities were observed 
with both 70 mg BID or 100 mg QD. Shah et al. presented data clearly indicating that the 
70 mg BID dose was correlated with subsequent dose reduction while the 100 mg dose QD 
was usually related with less dose reductions and discontinuations. The data showed that 
the group of patients given dasatinib 100 mg QD were less frequently associated with 
adverse events (AEs) as compared with doses administered twice a day [376]. The FDA 
has recently approved dasatinib 100 mg QD for treatment of CP-CML patients and 140 mg 
once daily for treatment of patients with AP-CML and BP-CML [331]. 
Dasatinib is rapidly absorbed and peaks within 0.5 to 6 hours following oral 
administration, its half-life is 3-5 hours [370] and preclinical models indicated that 
dasatinib has lower oral bioavailability ranging from 14%-34% that is not influenced by 
meal intake [377]. IC50 of dasatinib 70 mg BID is estimated to range from 17.5-52.5 nM 
with a maximum plasma level of 90 nM. In clinical trials, dasatinib induced good 
responses and overcame imatinib resistant Bcr-Abl within a short period, suggesting that it 
may be a promising therapy for treatment of imatinib-resistant CML. Treatment with 
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dasatinib is well tolerated but the most frequently-reported adverse events among these 
subjects included fluid retention, bleeding, abdominal pain, dyspnoea and skin rash [367]. 
1.7.4 Chemical structures of imatinib, nilotinib and dasatinib 
Nilotinib is analogue of imatinib and thus they have a similar structure. In comparison, 
dasatinib is structurally different to imatinib (Figure 1.18). Nilotinib is a 
phenylaminopyrimidine derivative that was rationally generated and designed based on the 
crystallographic structure of imatinib [378]. The Abl kinase domain has two conserved 
lobes with an ATP linking sequence positioned between the N- and C-terminal domains, 
which are closely situated (A-loop) and include a conserved Asp-Phe-Gly (DFG) portion. 
These regulate catalytic activity by changing between various conditions through a 
phosphorylation-dependent pathway. The activation of Abl kinase principally requires 
autophosphorylation of the A-loop; thus the absence of the A-loop leads to insufficient 
catalytic activity and ATP binding. By understanding this mechanism has allowed 
structural development of TKIs [379]. Significantly, most mutations confer resistance to 
the imatinib doses presented in the phosphate-binding loop (P-loop) of Abl kinase which 
has been related to a bad prognosis [378]. Here, imatinib potentially inhibits the activation 
of Bcr-Abl kinase by binding to the inactive and unphosphorylated conformation of DFG-
out, diminishing catalytic activity required for ATP binding.  This inhibition of tyrosine 
kinase signalling pathways leads to diminished cell growth and proliferation [379, 380]. 
Nilotinib was developed by sustained binding to the unphosphorylated conformation of the 
Abl kinase domain, while incorporating alternative linking groups to the N-
methylpiperazine moiety and conserving an amide pharmacophore to maintain H-bond 
associations with Glu286 and Asp381. Replacement of the N-methylpiperazine moiety in 
imatinib with a phenyl group carrying trifluoromethyl and imidazole substitutions in the 
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nilotinib structure significantly decreases the number of H-bonds from six in imatinib to 
four in nilotinib. Nilotinib binds with the unphosphorylated transformation of the Abl 
tyrosine kinase domain with the P-loop folding up the ATP binding position and the A-
loop obstructing the ATP phosphate-binding position, and inhibiting the enzymatic activity 
[378]. Nilotinib has a greater inhibitory function with greater affinity for aminopyrimidine-
based ATP competitive inhibitors as compared to imatinib resulting in potential inhibition 
of Bcr-Abl kinase activity and resulting reduction of cell proliferation [341, 378].  
Dasatinib is a 2-aminothiazole-5-carboxamide compound which is structurally distinct 
from imatinib and nilotinib. It was originally developed as a dual Abl-Src tyrosine kinase 
inhibitor that could potentially inhibit all point mutations within Bcr-Abl kinase domain 
except the T3151 mutation which promotes imatinib-resistance among CML patients [339, 
375]. Dasatinib and imatinib bind similarly to the same ATP-binding sites sharing 
overlying areas but expanding in different directions [381]. Where the dasatinib 
aminothiazole pharmacophore components (which are subsequent to the aminopyrimidine 
in imatinib) create a bi-denoted H-bond association within the C=O backbone where the 
NH of Met318 and the amide-NH creates an H-bond with the side-sequence oxygen of 
Thr315. Moreover, dasatinib contains similar structural components to nilotinib, such as 
the juxtaposition of the aminopyrimidine and carboxamidine assembles [362]. The crystal 
structure of dasatinib is so complex such that it can identify many states of the tyrosine 
enzymes with fewer required contact points of Abl kinase as compared with imatinib 
[381]. The crystal structures of these TKIs reveal consistent structures with inhibitory 
mechanisms of tyrosine kinases, and all three TKIs have a higher affinity to Abl kinase 
with potential inhibition pathways against the Bcr-Abl kinase domain [339, 382].  
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Figure ‎1.18. Molecular structure of nilotinib, imatinib and dasatinib. Nilotinib is an analogue of 
imatinib. However, nilotinib is characterised by incorporating alternative linking groups to the N-
methylpiperazine moiety and conserving an amide pharmacophore to maintain four H-bond associations with 
Glu286 and Asp381. Dasatinib is structurally distinct from imatinib and nilotinib. Adapted from [378]. 
 
1.7.5 Mechanistic action of imatinib, nilotinib and dasatinib 
The principle mechanism of TKI activity was originally based on the mechanism of Bcr-
Abl tyrosine kinase activity, which is produced by gene transformation [331, 383]. TKIs 
have been targeted against the constitutive activity of Bcr-Abl tyrosine kinases and 
inhibitory regulation of cell proliferation [383]. TKIs link to ATP-binding sites through 
binding the inactive and/or active conformation of the Abl kinase, thereby disrupting the 
ATP-binding site and catalytic activity of the enzyme [384] (Figure 1.19). Imatinib binds 
the inactive conformation of the Abl kinase, blocking ATP site and inhibiting catalytic 
activity [385]. In an in vitro experiment, imatinib revealed a potential inhibition of 92-98% 
clonal leukaemic cells without impairing normal clonal cells.  
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Some of the patients who received imatinib treatment later relapsed, resulting in resistance 
[341]. Consequently, nilotinib was developed as a solution to imatinib-resistant CML and 
has a higher linking affinity than imatinib producing a >30-fold greater effectiveness. 
Nilotinib binds the ATP-binding site of Bcr-Abl leading to inhibition of the protein 
phosphorylation implicated in intracellular signalling pathways mediated by Abl [366]. 
Similar to imatinib, nilotinib also inhibits the activity of c-Kit and PDGFR and selectively 
binds the unphosphorylated conformation of Abl kinase disrupting the substrate binding 
site proximity to the A-loop. In fact, nilotinib acts as a very effective inhibitor against the 
activity of Bcr-Abl kinase and controls cell growth, producing longer survival in imatinib-
resistant CML wild-type mouse models [331, 341].  
Another approach involves using dasatinib as an ATP-competitive inhibitor that binds to 
the ATP site but extends in different directions from imatinib [331, 386]. Dasatinib is 
approved as a dual Abl/Src inhibitor that binds both the unphosphorylated and 
phosphorylated conformations of the Abl kinase domain [331, 339]. It is a potent inhibitor 
of all imatinib-intolerant or resistant Bcr-Abl mutations except the T3151 mutation. 
Dasatinib also targets c-Kit, PDGFR and SFKs by inhibiting autophosphorylation and 
regulating phosphorylation of additional targets implicated in the activation of Bcr-Abl 
mutation-independent signalling pathways linked with imatinib-resistant CML [331, 373]. 
Indeed, the activity of PTK is significantly inhibited through these mechanisms of TKIs, 
contributing to sustained haematological and cytogenetic responses in CML patients.  
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Figure ‎1.19. Mechanism of action of the Bcr-Abl TKIs. (A) The Bcr-Abl tyrosine kinase (Bcr-Abl TK) is 
constitutively active kinase that binds ATP. Transfer a phosphate from ATP to tyrosine residues on different 
substrates lead to an alteration in cellular activation which leading to CML development. (B) The imatinib 
TKI blocks the binding of ATP to the Bcr-Abl and inhibits the TK phosphorylation of Bcr-Abl-mediated 
signaling pathways. (C) In the case of imatinib resistant CML, ATP binds Bcr-Abl TK that leads to 
hyperactivity of tyrosine kinases resulting in relapse of CML. The second generation of TKI, nilotinib and 
dasatinib effectively overcome imatinib resistance via potent inhibition on Bcr-Abl TK phosphorylation in 
CML.  
 
1.7.6 Adverse events of imatinib, nilotinib and dasatinib 
TKIs have many reported type-adverse toxicities related to their therapeutic regimens. The 
severity of these toxicities varies based on TKI profiles. Most CML patients treated with 
TKIs particularly those in advanced phases of the disease have experienced mild or 
moderate or serious side effects [369]. Most TKIs trigger the same clinical AEs among 
patients. Peripheral and periorbital oedema, muscle cramps, fatigue, headaches, diarrhoea 
and abdominal pain are the most frequent AEs following TKI treatment [348, 387].  
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Among haematological AEs, the rates of myelosuppression, thrombocytopenia and 
anaemia events were higher for imatinib and dasatinib-treated patients versus nilotinib-
treated patients [344, 369]. In particular, dasatinib is as a potent SFK inhibitor [373] which 
may involve a greater rate of myelosuppression; whereas imatinib and nilotinib inhibit c-
Kit and have been implicated in myelosuppression events but at lower rates than dasatinib. 
The studies suggested that c-Kit inhibition is implicated in myelosuppression development 
but may be also associated with a combination of interactions between several tyrosine 
kinase signalling pathways and underlying leukaemic pathogenesis [344]. Recently, 
dasatinib was reported to have clinical association with bleeding issues. The MD Anderson 
Cancer Center (Houston, TX, USA) stated that 40% of bleeding events associated with 
dasatinib occurred in the absence of thrombocytopenia which is of a lower incidence than 
with imatinib and was rarely associated with nilotinib [344, 388]. SFKs such as Lyn, Fyn, 
and Src are important contributors to platelet function [389] suggesting that the inhibition 
of kinase signalling pathways may be implicated in platelet aggregation, which may 
explain the notable bleeding incidence during dasatinib therapy. Dasatinib is now known 
to have an inhibitory effect on platelet activation in vitro and in vivo [388, 390].  
Nonhaematologic AEs in nilotinib-treated patients were infrequent but included peripheral 
and periorbital oedema, vomiting, diarrhoea, and muscle spasms which were commonly 
observed in patients treated with imatinib and dasatinib. The elevation of hepatic enzyme 
levels resulting from TKI therapy regimens was documented to a lesser extent. 
Hyperbilirubinemia and increased pancreatic enzymes and fasting glucose levels were 
observed at a greater frequency in nilotinib-treated patients than in patients treated with 
imatinib and dasatinib [344, 369]. In clinical trials, it was observed that the levels of liver 
enzymes and bilirubin increased with higher doses of nilotinib [366].  
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These TKIs have also been clinically related to cardiac toxicities such as congestive heart 
failure and QT interval prolongation [369]. In clinical studies, nilotinib and dasatinib have 
been more frequently related than imatinib to these cardiac toxicities QT interval 
prolonged electrocardiogram and sudden death. Thus, patients who have electrolyte 
disturbances such as hypokalemia or long-term QT disorders should not use nilotinib 
therapy regimes and should be monitored with regular electrocardiograms [360, 391]. 
Clinical data has suggested that vascular occlusive abnormalities including PAOD, 
myocardial infarction and arterial thrombosis have been frequently reported in nilotinib-
treated CML patients (Figure 1.20) but the association between PAOD progression and 
nilotinib treatment has not been validated. This issue should be targeted for further study 
because of the potential for serious and possibly life-threatening complications [392, 393]. 
Development of vascular AEs including PAOD and sudden death was reported in 33% of 
patients treated with nilotinib. Kim et al. reported a prospective study involving 159 
patients on imatinib or nilotinib showed a higher incidence of abnormal ankle-brachial 
index (ABI) in patients on nilotinib (relative risk, 10.3) [394].  Abnormal ABI in patients 
treated with first and second line nilotinib was 26% and 35.7% respectively compared with 
6.3% for first line imatinib. An abnormal ABI is a sensitive and specific test for PAOD 
and implicates systemic atherosclerosis in arterial beds. Furthermore, a recent study 
showed that the six year follow up ENESTnd trial data demonstrated  28 (10%) of 279 
patients treated with nilotinib 300 mg BID, 44 (15.9%) of 277 patients treated with 
nilotinib 400 mg BID and seven (2.5%) of 280 patients treated with imatinib 400 mg QD 
had cardiovascular events [395]. Note that the progression of vascular events was higher 
for 400 mg dose of nilotinib compared to 300 mg dose of nilotinib in the follow up 
ENESTnd trial results. It is also suggested that nilotinib may induce vasospasm to induce 
endothelium activation in vivo and it also has been thought that nilotinib may magnify pre-
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existing pro-atherothrombosis. The mechanisms of action of nilotinib on platelets and 
thrombus formation that may elucidate prospective off targeting reliable mechanisms of 
adverse effects have not been characterised and thus represents an important research 
question. 
 
 
Figure ‎1.20. Common adverse events of Bcr-Abl TKIs. Imatinib, nilotinib and dasatinib cause the same 
clinical adverse events among patients. In particular, imatinib and dasatinib have been more frequently 
associated with bleeding and oedema. Peripheral arterial occlusive disease (PAOD) and myocardial 
infarction are occasionally seen with nilotinib therapy. 
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1.8 SUMMARY AND AIMS 
Platelets are essential for the initiation of pro-thrombotic phenotypes in humans, 
specifically those with a high risk of cardiovascular events that can have fatal outcomes 
such as myocardial infarction and PAOD. Platelets have adhesive features and are capable 
of responding to stimulus molecules that can lead to platelet activation and thrombus 
formation. Specific pharmacological agents have powerful influences on the disruption of 
platelet function and cause dysregulation of platelet interactions with exposed 
thrombogenic subendothelial constituents, leading to the development of atherothrombotic 
events. Recently, the TKIs imatinib, nilotinib and dasatinib have been approved as front-
line therapies for patients with CML with greater outcomes and durable complete of 
haematological and molecular remission, resulting in high survival rates [337, 378, 391, 
396-398]. Hence, the most recent management focus has been toward important side 
effects of these agents and how they can be prevented or minimised.  
Previous studies showed that dasatinib and imatinib treatment is related to increased risk of 
bleeding among CML patients, resulting from platelet dysfunction due to an inhibitory 
effect on platelet aggregation and thrombus formation [390, 399]. On the other hand, of 
particular relevance to nilotinib, is the emergence of vascular adverse events. Emerging 
data indicate that nilotinib, but not imatinib or dasatinib, induces a prothrombotic event; 
however, the potential mechanisms by which nilotinib may trigger adverse vascular events 
are poorly identified [392, 394, 400, 401]. The challenge is to identify those patients at risk 
of developing vascular thrombotic adverse events. Based on the literature, we hypothesise 
that nilotinib potentiates platelet-endothelial reactivity in vitro, ex vivo and in vivo and 
contributes to atherothrombotic complications in humans, particularly in patients with a 
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high risk of cardiovascular disease. In order to address this hypothesis, the following aims 
are outlined: 
1. To compare platelet reactivity profiles over a wide concentration range of TKIs in 
vitro in the presence of a range of agonists using healthy human donor platelets and 
to identify any differences in the effects of TKIs, imatinib, nilotinib and dasatinib 
on platelet profiles (Chapter 3). 
  
2. To investigate the effect of TKIs, in particular nilotinib, on platelet thrombus 
formation under in vitro and ex vivo flow, and on activated endothelium, platelets 
and coagulation state in vivo using a C57BL/6 mouse model (Chapter 4). 
 
3. To investigate the effect of these TKIs, in particular nilotinib, on platelet-mediated 
arterial thrombus formation in vivo. Using two different mouse models of FeCl3-
induced vascular injury of mesenteric arterioles and carotid artery using a C57BL/6 
mouse model (Chapter 5). 
 
4. Assess platelet activation, ex vivo platelet thrombus formation, platelet-leukocyte 
interactions, thrombogenic biomarkers and coagulation reactivity in patients with 
CML receiving nilotinib, imatinib or dasatinib treatment. Furthermore, the dose-
dependent effects of TKIs were examined on platelet adhesion and platelet 
thrombus growth on type I collagen under in vitro flow conditions using whole 
blood from healthy human donors (Chapter 6). 
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2.1 MATERIALS 
2.1.1 Chemicals and reagents 
Sodium chloride (NaCl), potassium chloride (KCl), sodium bicarbonate (NaHCO3), 
glucose, tri-sodium citrate, magnesium chloride hexahydrate (MgCl2-6H2O), disodium 
hydrogen phosphate (Na2HPO4), potassium dihydrogen orthophosphate (KH2PO4) were 
purchased from Merck, Kilsyth (Victoria, Australia). HEPES and prostaglandin E1 (PGE1), 
bovine serum albumin (BSA), paraformaldehyde, iron (III) Chloride (FeCl3), quinacrine, 
dimethyl sulfoxide (DMSO), Rhodamine G6 dye (Rh6G), acetylsalicylic acid (aspirin), 
thrombin and Protease activated receptor-1 (PAR-1, SFLLRN) were purchased from 
Sigma-Aldrich (St Louis, MO). Protease activated receptor-4 (PAR-4) agonist peptide (H-
Ala-Tyr-Pro-Gly-Lys-Phe-NH2 (AYPGKF-NH2) was purchased from GL Biochem Ltd. 
(Shanghai, China). ADP and acid-soluble collagen were purchased from Chrono-log Co 
(Havertown, PA). Type I collagen fibrils was purchased from Nycomed (Linz, Austria). 
Type I collagen-related peptide (CRP) was made and purchased from Dr. Richard Farndale 
(Cambridge University, Cambridge, UK). Ketamine was purchased from Pfizer, 
(Auckland, New Zealand) and xylazine was purchased from Ilium, Troy Laboratories Pty 
Ltd (Smithfield, NSW, Australia). 
2.1.2 Antibodies 
Anti-human CD63 antibody-unconjugated was purchased from Abcam (Redfern, NSW, 
Australia). Rabbit anti-mouse phycoerythrin (PE) and anti-rabbit fluorescein 
isothiocyanate (FITC) were purchased from Dako (Botany, NSW, Australia).  FITC-
conjugated anti-mouse CD62P antibodies, PE-mouse anti-human CD41a, PE-labeled 
mouse IgG isotype control, anti-mouse integrin β3 (CD61) and anti-mouse CD3e were 
purchased from BD Biosciences Pharmingen (Franklin Lakes, NJ). Mouse anti-human 
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CD14-FITC was purchased from Beckman Coulter (NSW, Australia). Anti-mouse 
PECAM-1 antibody (390) was obtained from Dr Steve Albelda (University of 
Pennsylvania, PA).  PE-conjugated JON/A monoclonal antibodies, anti-mouse integrin 
α2β1 (CD49b), anti-mouse GPIbα-IX-V complex (CD42b), anti-mouse GPVI (JAQ1) and 
anti-mouse CD9 antibodies were purchased from Emfret Analtics (Würzburg, Germany). 
Anti-mouse P-selectin (CD62P) blocking antibody and rat anti-mouse CD3 isotype control 
antibody were purchased from BD Biosciences Pharmingen (Franklin Lakes, NJ). 
2.1.3 Preparation of tyrosine kinase inhibitors 
Imatinib (STI-571) and nilotinib (AMN-107) were purchased from Novartis 
Pharmaceuticals as a pure powder. Both imatinib and nilotinib were dissolved in DMSO to 
give a 10 mM stock solution and stored at -20 
o
C. Dasatinib (BMS-354825) was purchased 
from Bristol Myers Squibb (BMS) as a pure powder form. It was dissolved in DMSO to a 
concentration of 10 mM and stored at -20 
o
C. Fresh dilutions were performed in phosphate 
buffered saline (PBS) pH 7.4 which was prepared by dissolving (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4) in 1000 mL total volume of Milli-Q water 
(Millipore, Australia) and was mixed well. Note, the final concentration of DMSO was 
less than 0.2% (v/v). 
2.1.4 Healthy human donors 
The collection of healthy human blood for this research project was approved by RMIT 
University Human Research Ethics Committee. Each blood donor voluntarily gave 
informed consent prior to blood collection. Eligible donors were healthy adults of both 
sexes between 18-58 years of age without known history of disease and donors must not 
have taken any anti-platelet medications such as aspirin and clopidogrel within the last 7 
days. Venous blood was obtained from healthy human volunteers using a 21-gauge 
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butterfly needle into a syringe containing 3.2% (w/v) trisodium citrate (9 parts blood to 1 
part anti-coagulant). 
2.1.5 Chronic myeloid leukemia patients 
Blood samples were obtained from chronic phase of chronic myeloid leukaemia diagnosed 
patients by the Department of Haematology, Austin Health (Heidelberg, Victoria, 
Australia), after informed consent was made in accordance with the Declaration of 
Helsinki. The Austin and RMIT University human ethics approved the study (#HEC 
HREC/14Austin/404). The characterisation of patients treated with imatinib, nilotinib or 
dasatinib are provided in Table 2.1. 
Table 2.1: Characteristics of patients treated with nilotinib, imatinib or dasatinib. 
 
CP, chronic phase, CML, chronic myeloid leukaemia, N, nilotinib, I imatinib, D, dasatinib, CHR, complete 
haematological remission. 
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2.1.6 Animal model 
Male and female (age- and sex matched) C57BL/6 mice were obtained from Animal 
Resource Centre (Perth, Western Australia). These mice were accommodated and 
monitored at RMIT University animal house facility in accordance with the National 
Health and Medical Research Council animal guidelines. Five to eight-week-old WT mice 
were used in this research project. All experiment procedures conducted on these mice 
were approved by the RMIT University animal ethics committee. (#AEC 1333). 
For ex vivo and in vivo model studies, cohorts of C57BL/6 mice were orally administrated 
by oral gavage once as a single dose with certain concentrations of TKIs according to 
mouse body weight. Mice were treated with 25 or 50 mg of imatinib or nilotinib per kg 
body weight or treated with 2.5 or 5 mg of dasatinib per kg body weight. Sham control 
mice were orally given PBS pH 7.4 alone using the same method of TKIs treated mice 
with similar corresponding doses of drugs. Sham- and TKI- treated mice were left for 4 
hours (peak drug concentration) or left for 48 hours (trough drug concentration) and had 
free access to fresh water and food supplement. 
2.2 METHODS 
2.2.1 Preparation of human platelets 
Whole blood sample obtained from either volunteers or CML patients was immediately 
collected into 3.2% (w/v) tri-sodium citrate. For centrifugation process, 50 ng/mL of PGE1 
was added to blood sample to prevent spontaneous platelet activation. Platelet rich plasma 
(PRP) was generated by centrifuging the citrated blood at 190 ×g for 10 minutes without 
brake at room temperature using Beckman Coulter Allegra X-15R centrifuge (Brea, CA). 
Washed platelets were generated from PRP by centrifugation at 1000 ×g for 15 minutes 
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without brake in the presence of 50 ng/mL PGE1. The platelet pellet then was washed 
twice in Ringer-citrate-dextrose (RCD) buffer (108 mM NaCl, 38 mM KCl, 1.7 mM 
NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose and 1.1 mM MgCl2-H2O, pH 6.5) in 
the presence of 50 ng/mL of PGE1 gently resuspended in RCD buffer. Finally, the platelet 
pellet was then resuspended in RCD buffer, pH 7.4, to give a final concentration of 
100×10
9
 platelets per litre [402]. The remaining citrated blood was further centrifuged at 
1000 ×g for 10 minutes without brake at room temperature to obtain platelet poor plasma 
(PPP) from the top layer of the centrifuged blood sample to be used as an optical baseline 
standard for platelet aggregation studies. Furthermore, plasma was isolated from whole 
blood derived from CML patients by centrifugation at 1000 ×g for 15 minutes at room 
temperature. Plasma was stored at -80
o
C until analysis [223]. 
2.2.2 Preparation of mouse platelets 
Blood was collected from C57BL/6 mice under universal anaesthesia using inhalation of 
2% isoflurane vapor from an Isotec3 vaporiser linked with two litres/minute oxygen flow 
to initiate general deeper anaesthesia. Whole blood was collected from mice by cardiac 
puncture using a 26-gauge needle with a 1-mL syringe and immediately placed into 100 
µL 3.2% (w/v) trisodium citrate in a ratio of 9 parts blood to 1 part anti-coagulant. 
Approximately from 600 to 900 µL blood was collected from each mouse. Additionally, to 
test a baseline platelet count (time=0) in nilotinib or imatinib treated mice, blood was 
collected from retro-orbital plexus by capillary tube into 3.2% (w/v) tri-sodium citrate. 
Furthermore, for evaluating the effect of aspirin dose on ex vivo thrombus formation under 
arterial flow conditions, various cohorts of mice were orally administered with 1.45 mg/kg 
of aspirin and blood was collected 4 hours later. Finally, mice were killed by cervical 
dislocation immediately following cardiac puncture. 
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PRP was obtained through centrifugation of the whole blood at 115 ×g for 8 minutes at 
room temperature without brake in the presence of 50 ng/mL of PGE1. Washed platelets 
were obtained via re-centrifuged PRP at 640 ×g for 10 minutes without brake at room 
temperature. The platelet pellet was then resuspended gently in RCD buffer, pH 7.4, at a 
concentration of 100×10
9
 platelets/liter [403]. Mouse plasma samples were generated from 
whole blood for measurement of the soluble levels of P-selectin and CD40L. Plasma was 
isolated from whole blood by centrifugation at 1000 ×g for 15 minutes at room 
temperature. Plasma was separated into eppendorf tubes and immediately frozen at -80
o
C 
until analysis [223]. 
2.2.3 Haematological parameter analysis 
Full blood examination parameters were determined in whole blood derived from TKI-
treated mice versus sham control using a Cell-Dyn Emerald automated haematology 
analyser (Abbott Diagnostics, Abbott Park, lllinois). Low, medium and high controls were 
performed initially before analysing the samples [404]. 
2.2.4 Platelet aggregation studies 
As described in section 2.2.1 for the separation of PRP from human whole blood. Platelet 
aggregation responses were recorded by measuring the changes in light transmission using 
a four channel lumi-aggregometer (Chrono-Log Co, Havertown, PA) [402]. PRP was 
normalised to 100×10
9
/L in RCD buffer, pH 7.4 using a Cell-Dyn Emerald haematology 
analyser. PRP aggregation was performed in the presence of 1 mM CaCl2 with continuous 
stirring (1000 rpm) at 37
o
C. Human PPP was set as baseline diluted 1:2 in RCD buffer, pH 
7.4. PRP was pre-incubated with different concentrations (0.05, 0.1, 1, 2.5, 5, 10, 20, 40, 
80 and 160 µM) of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C. Subsequently, 
platelet aggregation was initiated by adding certain agonist, including 1 µg/mL collagen, 
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0.5 µg/mL CRP and 5 µM ADP. The platelet aggregation response was measured as the 
maximal increase of light transmittance platelet aggregation over 10 minutes was recorded. 
2.2.5 Flow cytometry assays 
2.2.5.1 Measurement of platelet dense granule exocytosis 
Washed human platelets (100×10
9
/L; 50 µL) were pre-labelled with 100 µM quinacrine 
dye for 30 minutes in the dark at 37
o
C, allowing the platelet dense granules to take up the 
dye. The reaction was terminated by adding 1 mL RCD, pH 6.5 containing 0.2% (w/v) 
BSA and centrifuged the samples at 640 ×g for 10 minutes at room temperature without 
brake. Platelets were then incubated with or without various dose responses of nilotinib, 
imatinib or dasatinib at 37
o
C for 10 minutes. A range of platelet agonists such as 0.25-1.0 
U/mL thrombin, 1.25-5.0 µM PAR-1, 50 µM PAR-4 agonist peptide and 0.5 µg/mL CRP 
were added to samples and incubated at 37
o
C for 10 minutes to stimulate platelet 
activation and trigger dense granule exocytosis. The stimulation was stopped by adding 
300 μL of RCD buffer, pH 7.4. Immediately, platelet dense granule release was quantitated 
as the percentage of decrease in quinacrine fluorescent intensity compared to resting 
platelets using flow cytometry. The flow cytometer settings were recognised for the 
acquisition of platelets via logarithmic signal intensification. The dot-plot template was 
configured specifically for platelet-FITC/PE protocol based on characteristic side and 
forward light scatter channels and fluorescence parameters in log scale. A total of 10,000 
platelet events were analysed for each individual sample using FACS Canto II flow 
cytometry (BD Biosciences, San Jose, CA) and Weasel software Version 3.0.2 (Walter and 
Eliza Hall Institute of Medical Research, Victoria, Australia) [405]. 
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2.2.5.2 Measurement of alpha granule exocytosis 
Washed platelets (100×10
9
/L; 50 µL) were pre-incubated with or without different 
concentrations of nilotinib, imatinib or dasatinib at 37
o
C for 10 min. For murine platelet 
samples, mice were treated with PBS or 25 mg/kg nilotinib for 4 hours as described in 
section 2.1.6. Washed platelets from human or mice (100 ×10
9
/L) were activated by 
addition of 0.25 and 0.5 U/mL thrombin, 1.25-1.0 μM PAR-1, 50 µM PAR-4 agonist 
peptide and 0.25 and 0.5 μg/mL CRP for 15 minutes at 37 oC. Platelets were then fixed in 
1% (w/v) paraformaldehyde with RCD buffer pH 6.5 for a 10 min at room temperature 
followed by termination of the reaction with 1 mL of RCD buffer pH 6.5 containing 0.2% 
(w/v) BSA and the samples were centrifuged at 640 ×g for 10 minutes without brake. 
Fixed platelets were pre-labelled with 10 μg/mL P-selectin antibody (FITC-conjugated -
anti-mouse-CD62P antibody) for 30 min at room temperature in the dark. Following, 
samples were washed in RCD buffer pH 6.5 with 0.2% (w/v) BSA and centrifuged at 640 
×g for 10 minutes without brake. Lastly, platelets were then diluted with 300 μL of RCD 
buffer pH 7.4. Platelet alpha granule secretion (P-selectin expression) was recognised 
using platelet population characteristic side and forward light scatter channels. A total of 
10,000 platelet events were analysed for each individual sample using FACS Canto II flow 
cytometry and Weasel software Version 3.0.2 [406]. 
2.2.5.3 Surface expression assessment of platelet lysosomal (CD63) membrane 
50 µL of washed human platelets (100×10
9
 platelets/L in RCD, pH 6.5) were pre-
incubated with a wide range 0.05-160 µM of TKIs for 10 min at 37
o
C. Subsequently, 
platelets were activated with several platelet agonists, including 2.5 µM PAR-1 or 100 µM 
PAR-4 agonist peptide for 15 minutes at 37
o
C. The reaction was terminated by the addition 
of 1% (w/v) paraformaldehyde for 10 minutes at room temperature. Platelets were then 
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washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and centrifuged at 640 ×g for 10 minutes 
without brake. Fixed platelets were then incubated with an unconjugated primary antibody 
0.5 µg/ml anti-human-CD63 antibody for 30 min at room temperature. The labelled 
platelets were then washed with 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged 
at 640 ×g for 10 minutes without brake, followed incubation with a secondary antibody 1 
μg/mL PE-conjugated anti-mouse IgG for 30 min at room temperature in the dark. The 
stained platelets were then washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and then 
centrifuged at 640 ×g for 10 minutes without brake. Finally, the platelets were diluted in 
300 μL of RCD buffer and a total of 10,000 platelet events were counted for each sample 
using FACS Canto II flow cytometry and Weasel software Version 3.0.2. 
2.2.5.4 Determination of platelet-leukocyte aggregates 
Whole blood was withdrawn from healthy human donors as described in section in 2.1.4 to 
be directly processed within 20 minutes of blood collection. In order to assess the effect of 
dose-dependent range of TKIs on the interaction of platelets with leukocytes, the optimal 
protocol and the consistency of experiments was performed prior to running real 
experiments in this assay based on Michelson group’s methods [407]. In brief, 10 μL 
leukocyte-specific antibody FITC mouse anti-human CD14 (to identify leukocyte 
specifically monocytes) and 10 μL platelet-specific antibody PE mouse anti-human CD41a 
(to identify platelets) or PE labelled mouse IgG1 negative isotype control were added into 
individually labelled tubes containing platelets. The final concentration of all antibodies 
selectively used in this assay was 0.5 μg/mL. PAR-1 agonist was added to all labelled tube 
samples with final concentrations of 1.25 or 2.5 μM. After mixing, 20 μL of whole citrated 
blood was added into each of the tubes. The sample tubes were incubated for 15 minutes at 
room temperature in the dark. Subsequently, 500 μL of BD FACS lysing solution (1:10 
  
 85  
diluted in distilled water) was added to mixture sample and incubated at room temperature 
for 10 min in the dark. The prepared samples were immediately analysed after incubation 
on FACS Canto II flow cytometry. Platelet-leukocyte aggregates were selected based on 
linear forward versus side light-scatter plot (logarithmic scale). The percentage of platelet-
leukocyte aggregates was identified as a CD14+CD41 positive cells and 1000 events were 
acquired. 
2.2.5.5 Analysis of platelet glycoprotein surface expression 
To assess the influence of a dose concentration of nilotinib on surface expression of 
glycoproteins in resting platelets, washed platelets (100×10
9
/L, 50µL) derived from treated 
mice with PBS or nilotinib (25 mg/kg) as described in section 2.1.6 were incubated with 
different primary antibodies, including for 1 hour at room temperature 10 µg/mL anti-
mouse PECAM-1, 10 µg/mL anti-mouse GPVI, 10 µg/mL anti-mouse CD9 and 10 µg/mL 
anti-mouse-CD3e  for one hour at room temperature [408]. Platelet-labelled primary 
antibodies were then washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged 
at 640 ×g for 10 minutes without brake, followed by subsequent incubation with a 
secondary antibody FITC-conjugated anti-rat (1/200 dilution) or PE-conjugated anti-rat 
(1/100 dilution) antibody for 45 minutes at room temperature in the dark. For glycoprotein 
expression, washed platelets were pre-labelled with 15 µg/mL anti-mouse integrin α2β1 
(CD49b), 10 µg/mL anti-mouse GPIbα-IX-V (CD42b), 10 µg/mL anti-mouse integrin β3 
(CD61) for 45 minutes at room temperature. Following, labelling platelets were then 
washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged at 640 ×g for 10 
minutes without brake. Lastly, platelets were diluted in 300 μL of RCD buffer, pH 7.4 and 
a total of 10,000 individual events based on forward and side light scatter characterisations 
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was acquired and quantified for each sample using FACS Canto II flow cytometry and 
Weasel software Version 3.0.2. 
2.2.5.6 Analysis of JON/A-PE mAb binding 
The ability of JON/A monoclonal antibody binding to the active conformation of integrin 
αIIbβ3 (GPIIb/IIIa) on platelets was tested as previously described [403]. In brief, 50 µL of 
washed platelets (100×10
9
/L) derived from mice untreated or treated with 25 mg/kg 
nilotinib were incubated with PE-conjugated JON/A mAb (1:50 dilution) for 1 hour at 
room temperature in the dark. Platelets were then terminated with 0.2% (w/v) BSA-RCD 
buffer pH 6.5, and then centrifuged at 640 × g for 10 minutes without brake. Labelled-
platelets were then stimulated with certain agonists such as thrombin (0.5 and 1 U/mL), 
PAR-4 peptide agonist (150 and 300 µM) and CRP (1 and 2 µg/mL) for 60 minutes at 
room temperature. Platelets were then washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and 
then centrifuged at 640 ×g for 10 minutes without brake. The activation of platelets was 
terminated by the addition of 1% (w/v) paraformaldehyde for 10 min at room temperature. 
Finally, platelets were diluted in 300 μL of RCD buffer, and a total of 10,000 events were 
quantified using FACS Canto II flow cytometry and Weasel software Version 3.0.2. 
2.2.6 In vitro and ex vivo flow arterial thrombosis onto immobilised type I collagen 
Blood was obtained from humans or wild-type mice as previously described in section 
2.2.1 and 2.2.2 respectively. Briefly, glass μ-slide III0.1 with specific dimensions 
(0.1×1.0×45 mm, H×W×L) (Ibidi Company, Martinsried, Germany) was coated with 500 
μg/mL type I equine ligament collagen (Nycomed, Linz, Austria) for one hour at 37oC 
followed by rinsing with PBS pH 7.4 to remove non-adherent collagen. For in vitro arterial 
thrombus growth studies, anticoagulant whole blood from human or mice were normalised 
with PBS pH 7.4 to 200×10
9
/L and 300×10
9
/L respectively. Blood was then pre-incubated 
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with different concentration of drugs 5 and 10 µM imatinib, 5 and 10 µM nilotinib, or 5 
and 10 µM dasatinib for 10 minutes at 37
o
C. For ex vivo arterial thrombus growth studies, 
mice were treated with imatinib (25 and 50 mg/kg), nilotinib (12.5, 25 and 50 mg/kg) or 
dasatinib (2.5 and 5 mg/kg) or PBS for 4 hours before blood collection as described in 
section 2.1.6. 
Whole blood from both human and mice in vitro or ex vivo arterial thrombus studies were 
fluorescently labelled with 0.05% (w/v) rhodamine 6G dye at 37
o
C for 30 minutes to allow 
visualisation of platelets. Labelled platelets in whole blood were then perfused over a 
matrix of type I collagen-coated μ-slide III0.1 microcapillaries during 6 minutes at shear 
stress rate of 1800 seconds
-1
 using a infuse/withdrew PHD 22/2200 syringe pump (Model 
999; Harvard Apparatus, Holliston, MA). The flow system was rinsed with PBS pH 7.4 
subsequently each perfusion at the same shear rate for 6 minutes. The intact thrombus 
formation derived from initial platelet adhesion with type I fibrillar collagen and 
accumulation of platelet aggregation on coated surface was directly visualised in real time 
using a Zeiss Axiovert 135 M1 microscope (Carl Zeiss, Gottingen, Germany) (objective 
LD 20×/0.4 NA) equipped with HAL 100-W bright light and HBO 100-W fluorescent 
light lamp sources. Image series of the time-lapse recording and examination of the extent 
of platelet thrombi production on the surface were carried out off-line from digital photos 
of the microchannel surface using Axiovision Rel version 4.6 software (Carl Zeiss Imaging 
Solution GmbH, Munich, Germany). The fluorescent thrombus formation of platelets in 
each image was determined and expressed as an arbitrary ‘pixel unit’ which is the total 
extent of thrombus growth production on the surface in a presenting 3D deconvolved 
thrombus area in each photograph. The determination of fluorescent platelet thrombus 
generation on a recognised surface coverage area is basically utilised for comparing 
thrombus formation between different TKIs phenotypes on human and mouse samples.  
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Z-stack slices of fluorescent images of aggregated platelets were captured and recorded by 
an AxioCam MRm camera (Carl Zeiss, Gottingen, Germany). Deconvolution process was 
carried out from the three dimension (3D) reconstructed rendered Z-stack images using the 
AxioVision Rel4.6 software (Carl Zeiss). Following deconvolution, the threshold was 
adjusted to be lower intensity for distinguishing platelets from the background and the 
same threshold characteristic was applied for all Z-stack images to keep analysis 
consistent. The thrombus volume (µm
3
) was determined from the surface coverage area 
(µm
2
) multiplied by the height (µm) of the platelet thrombi. 
2.2.7 In vivo thrombosis model experiments 
The ferric chloride (FeCl3) induced vascular injury is well-defined and extensively 
performed to examine arterial thrombosis and thrombogenesis in experimental mouse 
models in vivo [409, 410]. The FeCl3 mechanically induces arterial thrombosis through 
intensive injury to vasculature without complete damage to the inner layers of vessel wall, 
leading to endothelial cell denudation and exposure of the basement of membrane 
elements including collagen and tissue factor, resulting in platelet and leukocyte adhesion 
as well as progress of occlusive thrombus formation. Characteristically, FeCl3 contains 
pro-oxidative properties (redox-active iron) which trigger endothelial denudation. The 
moving of ferric ion (Fe
3+
) to the lumen initiates lipid peroxidation of erythrocyte 
membrane leading to direct red blood cell (RBC) haemolysis. The haemolytic cells secrete 
haemoglobin that is oxidised by iron generating reactive oxygen species. RBC haemolysis 
and oxidative haemoglobin generation are required for endothelial cell denudation 
exposing their molecules e.g. type I collagen [411]. 
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2.2.7.1 Ferric chloride-induced vascular injury model of mesenteric arterioles 
Male and female C57BL/6 mice (4-6 weeks old) were orally administrated with the TKIs, 
25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or PBS pH 7.4 (sham control 
mice) using an oral gavage procedures as described previously section 2.1.6. Treated mice 
were left for 4 hours (peak drug concentration) or 48 hours (trough drug concentration) 
before surgical procedures were performed. Mice were anaesthetised with a 
ketamine/xylazine (100:10 mg/kg) mixture intraperitoneally (IP). Mice were tested to 
ensure for receiving sufficient anaesthesia by using the pedal reflex test by pinching the 
front/hind paw of the mice with a pair of forceps to confirm the mouse is suitably 
anaesthetised. The mice were under anaesthesia, FeCl3 induced injury and Intravital 
microscopy (IVM) were performed. The mouse was taped to the board of dissection and its 
teeth, tail and the front paws were secured. An incision was made on the right side of 
mouse neck using surgical scissors and forceps used for blunt dissection to remove 
connective tissue to expose the jugular vein. After the jugular vein is completely exposed, 
the catheter tubing (cannulation) was inserted into the jugular vein to deliver the 
rhodamine 6G dye and to pump anaesthesia. To expose the intestines and mesenteric 
arterioles, an incision was made via a midline abdominal procedure. The intestines were 
kept moist throughout the experiment/imaging process by applying gauze soaked with 0.01 
M PBS pH 7.4. 
The animal was transferred to a viewing board which was placed over the microscope 
stage. Mesenteric arterioles of the ideal diameter (80-100 μm) were selected and visualised 
with a Zeiss Axiovert 135 microscope (Carl Zeiss, Gottingen, Germany) and Z-stack slices 
of the artery were captured with AxioCam MRm camera (Carl Zeiss, Gottingen, Germany) 
and projected onto the computer screen. The selected vessels were visualised under long-
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distance lens 20 ×/0.4 NA. A strip of Whitman filter paper (4 mm x 1 mm) was soaked in 
freshly prepared (7.5% w/v) FeCI3 solution for around 3 seconds, applied to a 2-to-5-mm 
length of mesenteric arterioles for 4 minutes and then removed. A volume of 75 μL of 
0.05% w/v rhodamine 6G dye was injected through the catheter for platelet labelling. The 
monitoring of blood flow and thrombus development within vessel was recorded in real 
time over 10 minutes. 
Z-stack images of the artery were progressively captured over 5 minutes in 2 cycles 
(defined as the artery vessel starts to occlude). The rendered Z-stack images were 
deconvolved with Zeiss Axiovert Rel 4.6 software to generate 3D reconstructions (Carl 
Zeiss Imaging Solution GmbH, Munich, Germany). Analysis of thrombus growth 
parameters including thrombus area (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
) was carried out, excluding any thrombi less than 50 µm
2
. The threshold was 
adjusted to be lower consistently for distinguishing platelets from the background and the 
same threshold typical was applied for all Z-stack images to analyse in the similar 
conditions. The calculations of thrombus volume and the percentage of vessel occlusion 
and stability scores were performed using Zeiss Axiovert Rel 4.6 software. Thrombus area 
was determined by measuring the selected thrombus by scaling outline in µm
2
. Thrombus 
volume (µm
3
) was calculated as thrombus area (µm
2
) multiplied thrombus height (µm) of 
the platelet thrombi. The vessel volume calculated based on this formula (The vessel 
volume= π × (vessel diameter ÷ 2)2 × vessel length). The percentage of vessel occlusion 
was derived based on this formula (% vessel occlusion = thrombus volume ÷ vessel 
volume × 100). To determine the average of vessel occlusion, the formula % vessel 
occlusion = (% vessel occlusion at 6-8 min + % vessel occlusion at 8-10 minutes) ÷ 2 was 
applied. Stability scores of thrombus formation were defined by calculating the percentage 
of the vessel that was occupied by forming thrombi in real time over 2 minutes. The 
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percentage of occlusion was scored from 1 to 10, 10 representing 91-100% occlusion of 
thrombi (vessel completely occluded). The stability score of the thrombi formed was 
calculated as the average of the % vessel occlusion as follows:  0-10 % = 1, 11-20 % = 2, 
21-30 % = 3, 31-40 % = 4, 41-50 % = 5, 51-60 % = 6, 61-70 % = 7, 71-80 % = 8, 81-90 % 
= 9, 91-100 % = 10. 
2.2.7.2 Ferric chloride-induced vascular injury model of carotid arteries 
C57BL/6 mice (sex and age-matched (6-8 weeks); weight 20±2 g) were orally 
administrated with TKIs, 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or PBS 
pH 7.4 (sham control) using an oral gavage as described in section 2.1.6. Treated mice 
were left for 4 hours (peak drug concentration) prior to the surgical procedure. The animals 
were anaesthetised by IP injection of ketamine and xylazine (100:10 mg/kg). The right 
common carotid artery was completely exposed utilising surgical scalpel and blunt 
dissection. A Doppler flow probe was placed proximal to surface of the carotid artery 
allowing to Doppler monitoring and baseline blood flow was recorded on a laser Doppler 
perfusion monitor using Moor Instruments Ltd (Millwey, Axminster, Devon, UK). 
Following surgical incision and the blood flow baseline adjusted, a piece of filter paper 
(0.5 × 1.0 mm) was saturated in 20% (w/v) FeCl3  for 3 seconds and placed on the 
adventitial surface of carotid artery for 4 minutes (to initiate sufficient injury mediated 
thrombus formation). The filter paper was carefully removed after 4 minutes and blood 
flow of carotid artery was recorded. The blood flow reading persisted till flow recording 
dropped to 50 AU (corresponding to 95% vessel occlusion). The initial time of artery 
injury to 95% vessel thrombotic occlusion was calculated [409, 412]. 
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2.2.8 Thrombin generation measurement 
Blood from C57BL/6 mice treated with PBS or nilotinib was collected by cardiac puncture 
as detailed in section 2.1.6 and plasma was isolated as described in section 2.2.2. To 
perform thrombin generation measurement of frozen-thawed plasma samples were 
processed at room temperature. Thrombin measurement was performed using The 
Calibrated Automated Thrombin Generation Method in a Fluoroscan Ascent®fluorometer 
(Thermolab systems OY, Helsinki, Finland) [413, 414]. In brief, PPP low affinity-reagent 
(Stago, Asnières, France), and thrombin Calibrator (Stago, Asnières, France) were 
reconstituted in 1 mL distilled water then gently mixed, and incubated  for 10 minutes at 
room temperature. A volume of  20 µL of PPP reagent was added per thrombin generation 
well of round-bottom 96 well-microtitre plates (Immunolon microtiter 96 Well Solid 
Plates, Fischer Scientific, Illkirch, France) and 20 µL of thrombin calibrator was added to 
each calibrator well, followed by aliquots of 80 µL of plasma sample/well. The automated 
fluorometer dispensed (20 μL per well) a starting reagent Fluca Kit (Stago, Asnières, 
France) composed of Fluorogenic synthetic substrate and CaCl2 which trigger thrombin 
generation. Latest version (SW5.0.0.742) of thrombinoscope dedicated software 
(ThrombinoscopeTM, Thrombinoscope BV, Maastricht, The Netherlands) was used to 
document and calculate the thrombin formation in test samples versus the calibrator and 
exhibit thrombin reactivity curves [thrombin generation (nM) vs. time (min)] were 
generated. Several parameters have been calculated including log lapse (the period 
required for triggering thrombin generation), thrombin generation peak (nM thrombin), 
time-to-peak (min) and the region underneath the curve was defined as endogenous 
thrombin potential (ETP) in nM (nM-min). 
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2.2.9 Mouse tail bleeding assay of haemostasis 
A 6-8 week old C57BL/6 male and female-age matched mouse were orally administered 
with 25 mg/kg imatinib, nilotinib or PBS as sham control and left for 4 hours from 
treatment as described in section 2.1.6. Mice underwent deep inhalation anaesthesia with 
2% isoflurane vapor from an Isotec3 vaporiser linked with 2 litres/min oxygen. A 
transection of 2 mm-diameter of the distal tip of the tail was performed using a sharp 
scalpel blade. A stopwatch was started immediately upon cut off of tail-tip and the blood 
volume lost was determined by collecting blood drops into an eppendorf tube containing 
100 μL of 3.2 % (w/v) trisodium citrate. The bleeding time and the volume of blood lost 
were documented over 15 minutes for all C57BL/6 mouse cohorts tested. 100 μL of 3.2 % 
(w/v) trisodium citrate was subtracted from obtained blood to measure the final volume of 
tail bleeding [415]. 
2.2.10 Enzyme linked immunosorbent assay 
Levels of soluble P-selectin (sP-selectin) and soluble CD40 Ligand (sCD40L) were 
measured by solid phase sandwich enzyme linked immunosorbent (ELISA) assay 
according to manufacturer’s instructions. Plasma was isolated from whole blood of human 
patient or mice treated PBS or 25 mg/kg imatinib or 25 mg/kg nilotinib as described in 
section 2.2.1 and 2.2.2 prospectively. 
2.2.10.1 Soluble P-selectin measurement 
Mouse sP-selectin/CD62P Quantikine ELISA kit and human sP-Selectin/CD62P ELISA 
kit were purchased from (R&D Systems, Minneapolis, MN, USA) and performed 
accordingly to the manufacturer’s instructions. Briefly, for measuring sP-selectin in mouse 
plasma, wells of 96 well polystyrene microplates have been pre-coated with monoclonal 
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anti-mouse P-selectin antibodies. Plasma samples were diluted in 1:50 in ‘calibrator 
diluent’ and 100 µL of diluent was added to wells in duplicates. A standard curve ranging 
from 0 to 10 ng/mL (mouse sP-selectin standard) was generated and a lyophilised control 
was used. The plate was incubated at room temperature for 2 hours. After five washes with 
400 µL ‘wash buffer’ containing PBS, 100 µL of a polyclonal antibody against mouse P-
selectin (conjugated) was then added and incubated at room temperature for 2 hours. The 
plate was then washed five times and colour was developed by adding 100 µL of substrate 
solution (tetramethyl-benzidine). After 30 minutes, 100 µL of stop solution (NaOH) was 
applied for terminating the reaction.  
For measuring sP-Selectin levels in patient plasma, ELISA plate was pre-incubated with 
anti-human sP-selectin monoclonal antibody. Plasma diluted in 1:20 in ‘sample diluent’ 
human sP-selectin standard and a lyophilised control was added. Subsequently, the ‘sP-
Selectin conjugate’ containing a polyclonal anti-human sP-Selectin antibody cross-linking 
with human P-selectin was then applied to each well and incubated for 1 hour at room 
temperature. The plate was washed three times with 400 μL ‘wash buffer’ and incubated 
with 100 μL of substrate in the dark. After 15 minutes, the reaction was stopped by adding 
100 μL of stop solution (NaOH). Optical density (OD) 450 nm was determined with 
wavelength correction set to 650 nm using A PerkinElmer’s Victor™ X3 Multilabel Plate 
Reader (Waltham, Boston, MA). 
2.2.10.2 Soluble CD40 ligand measurement 
For quantitative measurement of the soluble levels of sCD40L in mouse plasma using 
mouse sCD40L platinum ELISA kit from (sBioscience, San Diego, CA, USA) or in human 
plasma, using human CD40 Ligand Quantikine ELISA Kit from (R&D Systems, 
Minneapolis, MN, USA) were performed accordingly to the manufacturer’s instructions. 
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In brief, for measuring sCD40L levels in mouse plasma, microwell plates were pre-coated 
with anti-mouse sCD40L monoclonal antibody. The plate was washed twice with wash 
buffer (containing 0.01 M PBS pH 7.4) and then 50 µL of sample diluent in duplicate to 
the sample wells. A standard curve ranging from 0-40 ng/mL (mouse sCD40L Standard) 
was generated. 50 µl of plasma sample was added to the sample wells. Subsequently, 100 
µL of a biotinylated-conjugated secondary anti-mouse sCD40L antibody (1:100 dilution) 
was added and incubated at room temperature. After 2 hours, the plate was washed four 
times, and 100 µl of diluted streptavidin-HRP (1:100 dilution) was then added and 
incubated for 1 hour at room temperature. After four washes with wash buffer, 100 µL of 
substrate solution (tetramethyl-benzidine) was added to each well and incubated for 10 
minutes in the dark. The enzyme reaction was terminated by adding 100 µL of stop 
solution (phosphoric acid) to each well. 
For measuring sCD40L levels in patient plasma, ELISA plate was pre-incubated with anti-
human sCD40L monoclonal antibody. 100 μL of assay diluent RD1-65 was added to each 
well. A standard curve ranging from 0-4 ng/mL (human sCD40L Standard) was produced. 
Plasma diluted 1:5 in ‘calibrator diluent RD5P’ was added and incubated at room 
temperature for 2 hours. Plate was washed four times with 400 µL ‘wash buffer’ and 
incubated with 200 μL of human CD40L conjugate (containing a polyclonal anti-human 
CD40L antibody cross-reacting with human CD40L) at room temperature. After 2 hours, 
wells were washed four times and colour was developed using 200 μL/well of substrate 
solution (tetramethyl-benzidine). The reaction was stopped after 30 minutes by the 
addition of 50 μL of stop solution (sulphuric acid). A PerkinElmer’s Victor™ X3 
Multilabel Plate Reader (Waltham, Boston, MA), and OD 450 nm was determined with 
wavelength correction set to 650 nm. 
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2.2.11 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism software program version 6.03 
(GraphPad, San Diego, CA). All results are expressed as a mean ± standard error of mean 
(SEM). The statistical significance of differences was determined using Student’s t test, 
one-way and two-way analysis of variance (ANOVA). Two tailed unpaired Student’s t test 
was used to define if significant differences existed between one drug and normal control. 
The one-way ANOVA statistics test was performed to determine the effect of different 
drugs at one concentration in comparison with the sham control. Comparison between 
different drugs over a dose-dependent range was performed using two-way ANOVA test 
to determine any significant differences present between those drugs. A statistically 
significant difference was indicated by P values less than 0.05. Bonferroni post test for 
post hoc type I error was conducted for multiple comparisons. 
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3 CHAPTER THREE: INVESTIGATING THE EFFECT OF 
TKIs ON HUMAN PLATELET FUNCTION IN VITRO 
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3.1 INTRODUCTION 
Imatinib, nilotinib and dasatinib are orally bioavailable and potent ATP-competitive 
inhibitors developed and approved as a front-line treatment choice for the therapeutic 
management of patients with Bcr-Abl-positive CML. These TKIs achieve greater 
haematological remission rates and more extensively suppress the risk of progression to 
advanced stage disease when compared to traditional anti-leukaemic therapies [339, 398, 
416, 417].  
Imatinib, a phenylamino-pyrimidine derivative that was granted approval as a standard 
therapeutic regimen for CML, functions by inhibiting Bcr-Abl tyrosine kinase [346, 418] 
and the autophosphorylation of other dominant oncogenes such as PDGFR and c-Kit that 
are frequently constitutively phosphorylated in different categories of leukaemic lesions 
[274]. However, imatinib resistance due to Bcr-Abl kinase mutations, and/or intolerance to 
an imatinib regimen, has been recurrently observed in CML patients treated with imatinib, 
despite the capacity for imatinib to induce durable and complete cytogenetic and 
haematological remissions in CP-CML [353, 354, 356]. Dasatinib and nilotinib are 2G 
TKIs that have been formulated to overcome imatinib resistance complications [339, 341]. 
New clinical trials have revealed faster and stronger rates of molecular remission 
responses in patients administered these 2G TKI treatments; hence, these have now been 
approved as first-line therapies for CML [331, 339]. Nilotinib is a structural analogue of 
imatinib, with a distinct chemical structure imparted by addition of an aminobenzene 
group carrying trifluoromethyl and methyl imidazole substitutions [341, 362, 378]. 
Nilotinib is a highly effective TKI with 30-50 fold higher activity than imatinib in terms of 
inhibition of Bcr-Abl, PDGFR and c-Kit kinases. It overcomes the resistance and/or 
intolerance of imatinib seen in the chronic phase of CML disease [341, 362]. On the other 
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hand, dasatinib, a 2-amino-thiazole-5-carboxamide, is dissimilar to imatinib in its 
structure; it was designed as a multitarget tyrosine kinase inhibitor against Bcr-Abl, c-Kit, 
PDGFR and SFKs [370, 372].  
The 2G TKI therapies have substantial effectiveness on leukaemic cells, with achievable 
and durable CMR and CHR. However, subsequent clinical studies using these drugs have 
reported serious adverse events in vivo [334]. Haemorrhage incidents including epistaxis 
and gastrointestinal complications are frequently reported in patients treated with dasatinib 
[419]. A lower risk of bleeding was reported in patients treated with imatinib and this was 
a rare occurrence following nilotinib treatment [344, 388]. Recent data demonstrated that 
dasatinib doses significantly inhibited platelet aggregation and impaired haemostasis in 
vitro, ex vivo and in vivo for studies in both humans and mice, through inhibition of SFK-
signalling pathways [399]. Mazharian et al. showed that dasatinib administration to wild-
type mice induced a rapid reduction in platelet counts, disrupted platelet formation and 
impaired megakaryocyte biology, also via inhibition of SFKs [390]. 
Likewise, follow-up studies using nilotinib therapy reported more serious adverse events 
that had not been observed with over 10 years experience with imatinib; these adverse 
reactions could compromise its safe use for long-term consumption. Of particular 
consequence with nilotinib is the occurrence of vascular complications including PAOD 
and sudden death [392, 394, 400]. A primary study reported severe PAOD in 11/179 
(6.1%) CML patients receiving nilotinib treatment for a mean of 26 months [420]. More 
recent studies from a prospective clinical trial comparing the safety and efficacy of 
nilotinib versus imatinib equally demonstrated a cumulative 12.5% prevalence of clinically 
significant arterial thrombotic events over 3-4 years with nilotinib on standard dose, 
compared with <2% with imatinib [392, 394]. Determination of whether the action of 
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nilotinib treatment or leukaemic progression accounts for the increased occurrence of 
vascular thrombotic progression is incredibly complex, as this event may involve 
inappropriate vascular and platelet response/activity. Platelet function dysregulation is 
predominantly implicated in the development of CVD including atherosclerosis, 
myocardial infarction, PAOD and arterial thrombosis [9, 163, 194]. To date, the biological 
influence of nilotinib on platelet function has not yet been ascertained.  
The main function of platelets is to form haemostatic thrombi that terminate bleeding at 
sites of vascular injury and to sustain vascular integrity [194, 421]. A defect in platelet 
function and/or platelet numbers characteristically disrupts haemostasis and leads to 
promote bleeding episodes [194]. The accumulation of platelets and fibrin that takes place 
on the ruptured atherosclerotic plaque results in the progression of arterial thrombosis 
[162, 422]. The interactions of exposed ECM components such as vWF and collagen via 
binding to their receptors, particularly the GPIb-IX-V complex, GPVI and integrin α2β1 on 
the surface of platelets triggers platelet activation, granule secretion and platelet 
aggregation.  
Platelet activation in response to agonists derived from platelets is a tightly regulated 
process that involves several signal transduction proteins such as non-receptor tyrosine 
kinases and GPCRs that lead to platelet shape change and the release of platelet granules 
[159, 163, 170]. The platelet adhesion and activation process initiate platelet aggregation 
through cross-linking of fibrinogen to the active conformation of integrin αIIbβ3. The 
binding of integrin αIIbβ3 to vWF ultimately leads to thrombus formation [170]. 
One study has demonstrated that dasatinib treatment inhibited platelet activation, 
aggregation and impaired thrombus growth [399]. Emerging clinical trials propose that the 
TKI, nilotinib, but not imatinib or dasatinib, potentiates arterial events [392, 394, 400]. 
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However, no study has yet clearly demonstrated the effect of nilotinib on platelet 
activation, secretion of platelet granules or platelet aggregation. The aim of this chapter 
was therefore to compare platelet reactivity profiles over a dose-dependent range of 
imatinib, nilotinib and dasatinib, with a range of soluble agonists, using normal human 
platelets. The overall goal was to identify any differences in direct effects of these 
therapies on platelet aggregation, alpha and dense granule exocytosis and platelet-
leukocyte aggregates. Applying these approaches will provide an insight into the impact of 
TKI therapies on modulating human platelet function in vitro. 
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3.2 RESULTS 
3.2.1 Impact of TKIs on platelet aggregation profiles 
In order to examine the effect of TKIs on platelet function, platelets were preincubated 
with imatinib, nilotinib and dasatinib prior to agonist-induced platelet aggregation. 
Initially, optimal concentrations of respective agonists were determined to define the 
minimal concentrations of agonists that would sufficiently enhance the aggregation 
response. A 250 µL sample of PRP (platelet count was normalised to 100×10
9
/L) from 
healthy human donors was treated with a wide concentration range (0.05, 0.1, 1, 2.5, 5, 10, 
20, 40, 80 and 160 µM) of nilotinib, imatinib or dasatinib and pre-incubated at 37
o
C for 10 
minutes in the presence of 1 mM CaCl2. PRPs were stimulated with different agonists: 5 
µM ADP (nilotinib; Figure 3.1Aa-d), (imatinib; Figure 3.1Ae-h) and (dasatinib; Figure 3.1 
Ai-l); 1 µg/mL acid-soluble type I collagen  (nilotinib; Figure 3.2Aa-d), (imatinib; Figure 
3.2Ae-h) and (dasatinib; Figure 3.2Ai-l); and the GPVI-selective agonist, 0.5 µg/mL CRP 
(nilotinib; Figure 3.3Aa-d), (imatinib; Figure 3.3Ae-h) and (dasatinib; Figure 3.3Ai-l). 
 As shown in Figure 3.1Aa-d and 3.1B, Figure 3.2Aa-d and 2.3B, Figure 3.3Aa-d and 
3.3B, similar platelet aggregation profiles were observed in PRPs treated with nilotinib and 
the untreated control. While the higher concentrations (10-160 µM) of imatinib 
significantly inhibited platelet aggregation induced by collagen (Figure 3.2Ae-h and 3.2B; 
*P<0.05; n=3) and CRP (Figure 3.3Ae-h and 3.3B; *P<0.05; n=3) when compared to the 
normal control. However, ADP induced-platelet aggregation was not significantly different 
following imatinib treatment (Figure 3.1Ae-h and 3.1B; P>0.05; n=3).  
Dasatinib treatment of PRPs also showed a significant difference (*P<0.05; n=3) in 
inhibition of the platelet aggregation response to ADP (Figure 3.1Ai-l, 3.1B), soluble type 
I collagen (Figure 3.2Ai-l, 3.2B) and CRP (Figure 3.3Ai-l, 3.3B) versus the normal 
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control. As expected, CRP and collagen-induced platelet aggregations were significantly 
more inhibited than was ADP-induced platelet aggregation at the lowest doses of dasatinib. 
Interestingly, nilotinib is a known analogue of imatinib and both compounds acting on 
Abl, c-Kit, and PDGFR but not on SFKs. No noticeable effects of nilotinib (dose 
dependency) on normal platelet aggregation were observed in response to certain doses of 
agonist stimulation, while only high concentrations of imatinib acted as an inhibitory 
mediator of platelet aggregation responses. These results indicate that TKIs have different 
in vitro effects on platelet aggregation in response to soluble agonists. 
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Figure ‎3.1. The effect of TKIs on ADP-induced platelet aggregation. (A-B) Citrated PRP from normal 
human blood was normalised to 100×10
9
/L (platelet count). (a-d) nilotinib-treated PRP, (e-h) imatinib-
treated PRP and (i-l) dasatinib-treated PRP (dose-dependently) for 10 minutes at 37
o
C. Aggregation 
responses of PRP were determined following agonist stimulation by ADP (5 µM). Note that drug-treated 
PRP are comparable to untreated PRP. These results represent the mean±SEM from three independent 
experiments (* P<0.05; ** P<0.01 and *** P<0.001; n=3). 
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Figure ‎3.2. The effect of TKIs on collagen-induced platelet aggregation. (A-B) PRP from normal human 
blood was normalised to 100×10
9
/L (platelet count). (a-d) nilotinib-treated PRP, (e-h) imatinib-treated PRP 
and (i-l) dasatinib-treated PRP (dose-dependently) for 10 minutes at 37
o
C. Aggregation responses of PRP 
were determined following agonist stimulation by collagen (1 µg/mL). Note that drug-treated PRP are 
comparable to untreated PRP. Data is expressed as the mean±SEM and representative of at least three 
independent experiments (* P<0.05; ** P<0.01 and *** P<0.001; n=3). 
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Figure ‎3.3. The effect of TKIs on CRP-induced platelet aggregation. (A-B) PRP from normal human 
blood was normalised to 100×10
9
/L (platelet count). (a-d) nilotinib-treated PRP, (e-h) imatinib-treated PRP 
and (i-l) dasatinib-treated PRP (dose-dependently) for 10 minutes at 37
o
C. Aggregation responses of PRP 
were determined following agonist stimulation by CRP (0.5 µg/mL). Note that drug-treated PRP are 
comparable to untreated PRP. The platelet aggregation profiles displayed are representative of three 
independent experiments. Error bars represents mean±SEM (* P<0.05; ** P<0.01 and *** P<0.001; n=3). 
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3.2.2 Impact of TKIs on platelet dense granule exocytosis   
Platelet dense granules make an essential contribution during the amplification of the 
platelet initiation and thrombus development through secretion of their contents, such as 
ADP, ATP, calcium and serotonin [49]. Flow cytometry analysis was used to evaluate 
agonist-induced dense granule release with and without TKI treatment [406, 423]. As TKI-
treated platelets showed different agonist-mediated platelet aggregation responses, the 
concentration dependency of imatinib, nilotinib or dasatinib on agonist-induced dense 
granule exocytosis (quinacrine) in human platelets were examined. 
Analysis of dense granule secretion revealed that imatinib, nilotinib or dasatinib had no 
effect in the absence of platelet agonist when compared with the positive control (thrombin 
0.5 U/mL) (Figure 3.4). Upon agonist stimulation, analysis of dense granule secretion 
revealed that both dose dependency of imatinib and nilotinib had no detectable effect on 
dense granule exocytosis over a range of platelet agonists including thrombin (0.25-1.0 
U/mL) (Figure 3.5) and PAR-1 (5.0-1.25 µM) (Figure 3.6) and PAR-4 agonist peptide (50 
µM) (Figure 3.7A) and CRP (0.5 µg/mL) (Figure 3.7B). In contrast, the secretion of 
platelet dense granules was significantly inhibited (*P<0.05; n=3) at different 
concentrations of dasatinib in response to thrombin (0.25-1.0 U/mL) (Figure 3.5) and 
PAR-1 (5.0-1.25 µM) (Figure 3.6) and CRP (0.5 µg/mL) (Figure 3.7B) when compared to 
untreated platelets. In addition, dasatinib significantly reduced dense granule release in 
response to PAR-4 agonist peptide (50 µM) (Figure 3.7A) at higher, but not lower, 
concentrations. These data indicate that imatinib and nilotinib treatment results in normal 
dense granule release in human platelets in the presence of soluble agonists, while 
dasatinib has an inhibitory effect on agonist-induced dense granule release. 
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Figure ‎3.4. The effect of TKIs on spontaneous platelet dense granule exocytosis monitored by flow 
cytometry. Washed platelets from healthy human blood was normalised for platelets to 100×10
9
/L. 
Quinacrine labelled platelets were either untreated or with a dose-dependent range (0.05-160 µM) of 
nilotinib, imatinib or dasatinib for 10 minutes at 37
o
C in the absence of agonist except the positive control 
was stimulated with thrombin 0.5 U/mL. The results of dose response-drug were compared with thrombin 
0.5 U/mL. Results are representative of three independent experiments and are shown as the mean±SEM. 
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Figure ‎3.5. The effect of TKIs on thrombin-mediated dense granule release as determined using flow 
cytometry. Washed human platelets (platelet count normalised to 100×10
9
/L) were labelled with 100 µM 
quinacrine. Labelled platelets were either untreated or pre-incubated with increasing concentrations of 
imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C and stimulated by varying concentrations of 1U/mL 
thrombin (A), 0.5 U/mL thrombin (B), 0.25 U/mL thrombin (C). The results of dose response-drug were 
compared with baseline. Results are representative of three independent experiments and are shown as the 
mean±SEM (*P<0.05; ** P<0.01 and *** P<0.001; n=3). 
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Figure ‎3.6. The effect of TKIs on PAR-1-mediated dense granule release was assessed using flow 
cytometry. Quinacrine-labelled platelets (platelet count normalised to 100×10
9
/L) were either untreated or 
treated with imatinib, nilotinib or dasatinib in a dose-dependent manner for 10 minutes at 37
o
C and 
stimulated with 5 µM PAR-1 (A), 2.5 µM PAR-1 (B), 1.25 µM PAR-1 (C). Data is expressed as the 
mean±SEM from three independent experiments (*P<0.05; ** P<0.01 and *** P<0.001; n=3). 
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Figure ‎3.7. The effect of TKIs on PAR-4 or CRP-agonist peptide-mediated dense granule exocytosis 
was determined by flow cytometry. Washed platelets from normal human donors (platelet count 
normalised to 100×10
9
/L) were stained with quinacrine (100 µM). Quinacrine-labelled platelets were either 
untreated or treated with imatinib, nilotinib or dasatinib in a dose-dependent range and activated with 50 µM 
PAR-4 agonist peptide (A) or 0.5 CRP µg/mL (B). Results are expressed as the mean±SEM from three 
independent experiments (*P<0.01, **P<0.01 and ***P<0.001; n=3). 
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3.2.3 Impact of TKIs on platelet alpha granule exocytosis  
3.2.3.1 Platelet P-selectin expression  
P-selectin (CD62P) is an adhesion molecule that normally exists within alpha granules in 
resting platelets and endothelial cells, and upon stimulation it is quickly translocated from 
intracellular pools to the surface membrane to play a critical role in both haemostasis and 
thrombosis [424, 425]. Flow cytometry detection of an FITC-labelled monoclonal 
antibody (mAb) against P-selectin is one of most frequently used examinations for 
assessing the platelet alpha granule expression following agonist stimulation [406, 423]. In 
order to investigate the effect of TKI’s on alpha granule release, P-selectin expression was 
monitored by flow cytometry to determine whether imatinib, nilotinib or dasatinib can 
modulate the exocytosis of platelet alpha granules.  
As shown in Figure 3.8, these TKIs had no effect on resting platelet alpha granule release 
compared to the positive control [thrombin (0.5 U/mL)]. The ability of washed human 
platelets to release alpha (P-selectin) granules in response to soluble agonists was 
determined. A trend towards a greater increase in alpha granule release was observed in 
response to thrombin (0.5 and 0.25 U/mL), PAR-1 (2.5 µM) and CRP (0.5 and 0.25 
µg/mL), but not PAR-4 (50 µM) in nilotinib-treated platelets (Figure 3.9, Figure 3.10, 
Figure 3.11 and Figure 3.12). Interestingly, P-selectin expression induced by 1.25 µM 
PAR-1 (Figure 3.10C; *P<0.05; n=3) was significantly potentiated by 10-160 µM nilotinib 
when compared to the normal control. Treatment with 0.5 or 0.25 µM thrombin (Figure 
3.9A,B), 5.0-1.25 µM PAR-1 (Figure 3.10A,B and C), 50 µM PAR-4 agonist peptide 
(Figure 3.11) and 0.5 or 0.25 µg/mL CRP (Figure 3.12A and B) significantly inhibited 
alpha granule secretion induced by agonists in a dose-dependent manner following 
treatment with dasatinib. In addition, inhibition of alpha granule release was also observed 
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with imatinib-treated platelets but failed to achieve statistical significance, except at the 
higher doses (>20 µM), where significantly reduced P-selectin surface expression was 
observed compared to the normal control.  
The present study revealed differential effects of these TKIs on agonist-induced P-selectin 
exposure in human platelets. Imatinib and nilotinib exhibit opposing actions in modulating 
platelet alpha granule secretion, where imatinib appears to inhibit PAR-1-mediated alpha 
granule release (P-selectin exposure) whilst nilotinib induces PAR-1-mediated alpha 
granule release. Our data also are consistent with the view that dasatinib has potent 
inhibitory effect on agonist-mediated alpha granule exocytosis. 
3.2.3.2 Effect of TKIs on alpha granule release over time course 
Platelets treated with imatinib, nilotinib or dasatinib exhibited differential responses in 
terms of alpha granule secretion (P-selectin expression). Therefore, we examined whether 
a specific concentration (5 µM) of these drugs would affect the thrombin and PAR-1-
mediated alpha granule release over time, specifically at 0, 7.5, 15, 30 and 60 minutes after 
administration. As shown in Figure 3.13 A and B, alpha granule exocytosis was not altered 
in the presence of 5 µM imatinib or nilotinib in response to thrombin (0.25 U/mL) and 
PAR-1 (1.25 µM) at any time point. In contrast, 5 µM dasatinib significantly inhibited 
thrombin (0.25 U/mL) (Figure 3.13A) and PAR-1-(1.25 µM) (Figure 3.13B) induced P-
selectin expression at 15, 30 and 60 minute time points versus the control. Furthermore, 5 
µM dasatinib appeared to partially inhibited thrombin and PAR-1-induced P-selectin 
expression at 7.5 minutes, although it failed to achieve statistically significant differences 
(P>0.05; n=3). 
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Figure ‎3.8. Assessment of TKIs on spontaneous platelet alpha granule (CD62P) exposure in the 
absence of soluble agonist. Washed platelets derived from healthy human donors was treated with dose 
concentrations of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C. Resting platelets were not exposed 
to agonist stimulation except the control that activated by 0.5 U/mL thrombin. Platelet P-selectin CD62P 
expression was defined by mean fluorescent intensity. Results are represented as MFI±SEM from three 
independent experiments. 
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Figure ‎3.9. The effect of TKIs on thrombin-mediated platelet alpha granule exposure. Washed platelets 
incubated with dose responses of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C following agonist 
activation of thrombin (0.5 U/mL) (A), thrombin (0.25 U/mL) (B) or unstimulated (resting). The platelets 
were then labelled with FITC-P-selectin monoclonal antibody. Flow cytometric analysis was used for 
determining platelet P-selectin expression. Results are represented as MFI±SEM from three independent 
experiments (*P<0.05 and **P<0.01; n=3). 
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Figure ‎3.10. The effect of TKIs on PAR-1-mediated platelet alpha granule exocytosis. P-selectin surface 
expression for washed human platelets was measured by flow cytometry. Platelets were either untreated or 
treated with various concentrations of imatinib, nilotinib or dasatinib and stimulated by a dose-dependent 
range of 5 µM PAR-1 (A), 2.5 µM PAR-1 (B) and 1.25 µM PAR-1 (C) concentrations. Platelets were then 
stained with FITC-P-selectin monoclonal antibody. Data are expressed as MFI±SEM from three independent 
experiments (*P<0.05; **P<0.01 and ***P<0.001; n=3). 
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Figure ‎3.11. The effect of TKIs on PAR-4 agonist peptide-mediated platelet alpha granule exposure. 
Washed platelets pre-incubated with dose responses of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C 
following agonist activation of 50 µM PAR-4 agonist peptide. The platelets were then labelled with FITC-P-
selectin monoclonal antibody. Flow cytometric analysis was used for determining platelet P-selectin 
expression (alpha granule exposure) by measuring the MFI. Results are represented as MFI±SEM from three 
independent experiments (*P<0.05, **P<0.01 and***P<0.001; n=3). 
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Figure ‎3.12. The effect of TKIs on CRP-mediated alpha granule exocytosis was assessed by flow 
cytometry. Washed human platelets were either untreated or treated with a dose-dependent concentrations of 
imatinib, nilotinib or dasatinib for 10 minutes and stimulated with two different concentrations of GPVI 
selective agonist CRP (0.5 µg/mL) (A) and CRP (0.25 µg/mL) (B). Platelets were stained with FITC-P-
selectin monoclonal antibody for 30 minutes at room temperature. Platelet P-selectin CD62P expression was 
determined by flow cytometry. Results are cumulative data from three independent experiments and 
presented as mean±SEM (*P<0.05; **P<0.01 and ***P<0.001; n=3). 
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Figure ‎3.13. The effect of TKIs on thrombin or PAR-1-induced platelet alpha granule expression over 
time. Washed platelets were either  untreated or treated with 5 µM  imatinib, 5 µM nilotinib or 5 µM  
dasatinib for different time points including 0, 7.5, 15, 30 or 60 minutes at 37
o
C and platelet activation was 
induced by 0.25 U/mL thrombin (A) or 1.25 µM PAR-1 (B). Platelets were stained with FITC-P-selectin 
monoclonal antibody. Data are expressed as MFI±SEM from three independent experiments (*P<0.05 and 
***P<0.001; n=3). 
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3.2.4 Impact of TKIs on platelet lysosome (CD63) expression 
Lysosomes are a third category of platelet granules that contain a number of degradation 
enzymes that perform acidic hydrolysis [52, 53]. The lysosomes can participate in calcium 
ion regulation and serve as supportive factors for platelet activation and stable haemostasis 
upon blood vessel damage [426]. The present studies demonstrated that TKIs have 
differential influences on the secretion of dense and alpha granules in response to various 
agonists, so we assessed the potential impact and dose dependency of imatinib, nilotinib or 
dasatinib on agonist-mediated lysosomal exocytosis. As shown in Figure 3.14A and B, 
analysis of lysosomal surface expression revealed that imatinib, nilotinib and dasatinib did 
not alter platelet lysosomal granule exocytosis at any dose in response to PAR-1 (2.5 µM) 
and PAR-4 agonist peptide (100 µM) when compared against the normal control. These 
results suggest that imatinib, nilotinib and dasatinib have differential effects on the 
secretion of selected pool of platelet granules. 
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Figure ‎3.14. The effect of imatinib, nilotinib and dasatinib on PAR-1 or PAR-4-induced platelet 
lysosomal surface expression. Washed platelets were either untreated or treated with a dose-dependent 
manner of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C followed with agonist stimulation (A) 2.5 
µM PAR-1 and (B) 100 µM PAR-4 agonist peptide. Platelets were then labelled with anti-human-CD63 
unconjugated antibody. Subsequently, PE-conjugated-anti-mouse as secondary antibody was used for flow 
cytometric detection of platelet CD63 expression. Data are expressed as MFI±SEM from three independent 
experiments. 
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3.2.5 The effect of TKIs on platelet-leukocyte interaction 
3.2.5.1 Platelet-leukocyte aggregate formation 
Increased circulating platelet-leukocyte interactions specifically involving monocytes, is 
substantially participated in the progression of atherosclerosis and arterial thrombosis [427, 
428]. The raised occurrence of platelet-leukocyte aggregation (PLAs) is identified as a 
precise marker for arterial thrombosis development [428, 429]. This study was conducted 
to test the effect of imatinib, nilotinib and dasatinib on induced PLAs in response to 
agonists using whole human blood. Platelet-monocyte aggregates were analysed by dual 
CD14 and CD42a positivity for platelet and monocyte recognition. Likewise, analysis of 
platelet-neutrophil aggregation formation was measured by CD14 negativity and CD42a 
positivity for platelet and neutrophil recognition utilising flow cytometric analysis. The 
results showed platelet-monocyte aggregate formation was apparently not affected by 
imatinib, nilotinib or dasatinib (dose dependency) followed 5 µM PAR-1 (Figure 3.15A) 
or 50 µM PAR-4 (Figure 3.16A). TKI-treated whole blood was shown not to be altered 
with 5 µM PAR-1- and 50 µM PAR-4-induced platelet-neutrophil aggregate compared to 
controls at all doses tested (Figure 3.15B) and (Figure 3.16B) respectively. 
3.2.5.2 Platelet-leukocyte aggregate formation in the presence of protease inhibitors 
The apparent lack of inhibition by nilotinib may reflect some loss of P-selectin from 
normal donor platelet surface via cleavage in whole blood. In CML patients on nilotinib 
therapy PLAs are likely to be increased to promote vascular occlusion. Thus, two protease 
inhibitors, including trifluoperazine dihydrochloride (TFP) and metalloproteinase inhibitor 
(GM6001) used to see if cleavage of P-selectin could be blocked prior to formation of 
PLAs in whole blood.As shown in Figure 3.17, blood sample treated with nilotinib did not 
exhibit effect on PLAs in the presence of GM6001 or TFP compared to nilotinib alone. 
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Figure ‎3.15. The effect of TKIs on PAR-1-induced platelet-monocyte and platelet-neutrophil aggregate 
formation using flow cytometric analysis. Citrated whole blood from healthy human donors were either 
untreated or treated with increasing doses of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C and 
leukocytes were labelled with anti-CD14-FITC and platelets labelled with their specific marker CD42a-PE in 
the presence of platelet agonist (5 µM PAR-1). (A) Platelet-monocyte aggregate formation determined by 
dual CD14 and CD42a positively for both monocytes and platelets. (B) Platelet-neutrophil aggregate 
formation determined by CD14 negative and CD42a positive for neutrophil and platelets. The samples were 
done in parallel with unlabelled cells to evaluate auto-fluorescence and with isotype-matched IgG negative 
controls. These results represent the mean±SEM of three independent experiments. 
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Figure ‎3.16. The effect of TKIs on PAR-4-induced platelet-monocyte and platelet-neutrophil aggregate 
formation using flow cytometric analysis. Anticoagulated whole blood from healthy human donors were 
untreated or treated with various concentrations of imatinib, nilotinib or dasatinib for 10 minutes at 37
o
C. 
Leukocytes were labelled with anti-CD14-FITC and platelets were activated by 50 µM PAR-4 agonist 
peptide. (A) PAR-4-induced platelet-monocyte aggregate formation. (B) PAR-4-induced platelet-neutrophil 
aggregate formation. All samples were performed equivalently with unlabelled cells to evaluate auto-
fluorescence and with isotype-matched IgG negative control. Results are expressed as mean±SEM of three 
independent experiments. 
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Figure ‎3.17. The effect of nilotinib on PAR-1-induced platelet-monocyte and platelet-neutrophil 
aggregate formation in the presence of protease inhibitors. Anticoagulated whole blood from healthy 
human donors were untreated or treated with different doses of nilotinib by incubation of blood samples with 
or without protease inhibitors including trifluoperazine dihydrochloride (TFP) and metalloproteinase 
inhibitor (GM6001). Leukocytes were labeled with anti-CD14-FITC and platelets labelled with CD42a-PE in 
the presence of platelet agonist. (A) 5 µM PAR-1-induced platelet-monocyte aggregate formation. (B) 5 µM 
PAR-1-induced platelet-neutrophil aggregate formation. All samples were performed equivalently with 
unlabelled cells to evaluate auto-fluorescence and with isotype-matched IgG negative control. Results 
expressed as mean±SEM of three independent experiments. 
 
  
 126  
3.3 DISCUSSION 
In this Chapter, some important insights are provided by investigating the effects of TKIs 
on platelet function profiles using different in vitro approaches. The definitive observation 
of platelet aggregation goes along with the physiological alterations in platelets such as 
platelet activation, cytoskeletal reorganisation, granule exocytosis and activation of 
integrin αIIbβ3. The potential dose-dependent effects of TKIs on platelet aggregation 
responses to certain agonists were determined. Human PRP were pre-incubated with a 
range of TKIs (0.05-160 µM) (imatinib, nilotinib or dasatinib) that reflected the common 
therapeutic doses of these TKIs delivered to patients with CML and achieved steady-state 
levels in plasma [342, 396, 430]. Additionally, specific responses of platelets were 
evaluated following selective activation of various platelet receptor-signalling pathways 
such as GPCRs, using ADP, collagen and CRP. Dasatinib is well-identified as a potent 
inhibitor of platelet aggregation and thrombus formation in vitro and in vivo [388, 399]. 
Therefore, dasatinib was used in this research project as a positive control.  
In this Chapter, representative images of platelet aggregation in response to different 
agonists in the presence of different concentrations of drugs are shown in Figures 3.1, 3.2 
and 3.3. Overall, a dose-dependent response of dasatinib significantly reduced platelet 
aggregation upon agonist stimulation with ADP, collagen and CRP. Imatinib-treated PRP 
showed agonist induced aggregation responses that were not altered in response to ADP (5 
µM) at all doses tested, but compared to the normal control, a significant inhibition was 
seen in aggregation responses to collagen (1 µg/mL) and CRP (0.5 µg/mL) at high 
concentrations (10-160 µM) of imatinib. In contrast to dasatinib and imatinib, nilotinib had 
no apparent effect at any dose on platelet aggregation in response to agonists ADP, 
collagen or CRP. Previous clinical data reported that 59-80% of patients undergoing 
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dasatinib treatment show extensive inhibition of platelet aggregation responses, while 33% 
and 100% patients on imatinib or nilotinib, respectively, showed no detectable effects on 
platelet aggregation following stimulation with different agonists [388]. Taken together, 
these findings are in agreement with similar clinical results that provided evidence that 
these TKIs have different effects on platelet aggregation responses over a range of soluble 
agonists, which reflects the direct influence of TKI drugs on platelet aggregation. 
No further experimental evidence in the literature shows an association between TKIs and 
platelet granule secretion, such as dense, alpha and lysosome granules that have essential 
roles involving platelet function. This study assessed the effect of these drugs on platelet 
granule secretions over concentration range of agonists. The present data showed that 
secretion of dense granules by human platelets was markedly reduced in a dose-dependent 
manner by dasatinib across a range of soluble agonists. By contrast, no effect was 
observed on the release of platelet dense granules in the presence of corresponding doses 
of imatinib or nilotinib upon agonist stimulation with thrombin, PAR-1, PAR-4 agonist 
peptide and CRP.  
The current study also provides evidence for a differential influence of these TKIs on 
alpha granule secretion (P-selectin expression) in response to a range of agonists. Our 
results clearly demonstrated that dasatinib, in a dose-dependent manner, strongly 
diminished P-selectin exposure induced by a range of agonists including thrombin, PAR-1, 
PAR-4 agonist peptide and CRP. These results are consistent with previous observations 
showing that alpha granule release (P-selectin exposure) induced by collagen was 
significantly inhibited at 50 nM dasatinib. Therefore thrombin-induced P-selectin 
expression was partially inhibited by dasatinib [399].  
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Consistent with inhibition of platelet aggregation as shown in this chapter, the results 
showed that P-selectin exposure was significantly inhibited by imatinib (10-160 µM) upon 
agonist stimulation. In contrast, our study showed that 10-160 µM nilotinib significantly 
potentiated PAR-1 but not PAR-4 peptide agonist-mediated alpha granule release (P-
selectin expression) in platelets. High doses of nilotinib appear to elicit a partial 
potentiation of P-selectin expression induced by thrombin or CRP but the difference failed 
to reach statistical significance. Indeed, PAR-1 and PAR-4 are both expressed on platelets 
as protease activated receptors for thrombin that is a potent activator of platelets. PAR-1 
acts as the predominant thrombin receptor in humans but to a lesser extent in mouse 
platelets, which could be due to its higher affinity and sensitivity in response to thrombin 
in humans than in mice, while PAR-4 has a low affinity and sensitivity in response to 
thrombin in human but higher affinity in mouse platelets [97, 98]. In vitro studies showed 
that PAR-1 was blocked by antibodies or specific antagonists and the activation of human 
platelets was blocked at low concentrations of thrombin. In contrast, PAR-4 agonist 
peptide in a similar blockade study had no effect on human platelet activation [97]. Based 
on this evidence, the existence of PAR-1 on human platelets, and to a lesser extent on 
mouse platelets, could be postulated and may suggest that P-selectin exposure in human 
platelets is induced predominantly by PAR-1 but to a lesser extent by PAR-4. 
This study also demonstrated that these TKIs have no effect on either spontaneous platelet 
dense or alpha granule release in the absence of agonist stimulation, while the differential 
effects of TKIs on exocytosis of dense and alpha granules are observed in response to 
soluble agonist. The results presented here demonstrated that imatinib, nilotinib or 
dasatinib treated platelets did not demonstrate any effect on lysosomal granule exocytosis 
(CD63 expression) following agonist stimulation with PAR-1 or PAR-4 agonist peptide. 
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As described in the first Chapter, abundant numbers of dense and alpha granules are 
localised within platelets and are secreted upon platelet activation to promote platelet 
aggregation and thrombus growth [40, 183]. Dense granules contain signalling molecules 
such as ATP, ADP, calcium and serotonin [29], which have important roles in the 
amplification of platelet activation and thrombosis growth. The alpha granules consist of 
adhesive molecules (P-selectin, vWF), coagulation factors, platelet ligands (fibrinogen) 
and cytokines [40, 42] which are exclusively involved in platelet adhesion and platelet 
aggregation during haemostatic and thrombotic processes. Under pathophysiological 
conditions, the increased expression of alpha granule constituents, particularly adhesive 
and pro-inflammatory molecules and especially P-selectin from platelets promotes the 
development of arterial thrombosis and atherosclerotic lesions [40, 431]. Clinical data 
showed that patients with cerebrovascular ischaemia or acute stroke had elevated 
expression of P-selectin derived from circulating activated platelets [211, 432-434]. 
Furthermore, a small number of lysosomal glycoproteins at localised sites of platelets 
contain hydrolytic enzymes [52, 53]. Indeed, in vitro studies reported that lysosomal 
release requires a potential stimulation agonist (e.g., thrombin) at high concentrations to 
give 60% secretion of granules, whereas exocytosis of dense and alpha granule 
constituents occurs in a few minutes after induction with several agonists at the smallest 
effective doses to give nearly 100% secretion [435].  
Apart from SFK-mediated platelet activation through phosphorylation of FcγR-chain upon 
GPVI-collagen interaction [436], Gratacap et al. [399] have proposed that dasatinib 
strongly inhibits SFKs and FcγRIIa-mediated platelet activation. This concept is consistent 
with the crucial function of SFKs in regulation of platelet activation and aggregation. 
Upon FcRγ-chain phosphorylation, the Syk becomes autophosphorylated via binding to 
ITAM, leading to activation and recruitment of several downstream effector proteins, 
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including LAT, SLP-76, and adaptor proteins indispensable for PLCγ2 and PI3-kinase 
activation and the main effector of GPVI signalling cascade, which promotes Ca
2+
 
mobilisation and protein kinase phosphorylation [399, 437]. The SFK inhibitor dasatinib 
was developed to inhibit the phosphorylation of SFK and improve the molecular responses 
of therapy in CML patients [438]. Therefore, the inhibitory effect of dasatinib on platelet 
function and induction of platelet dysfunction are not surprising. Here, our results clearly 
demonstrated that dasatinib strongly inhibited platelet dense and alpha granule release 
induced by agonists. These findings are consistent with those of other studies, and also in 
agreement with clinical haemorrhagic observations in CML patients [419].  
As shown in this Chapter, high concentrations of imatinib (10-160 µM) significantly 
inhibited alpha but not dense granule secretion. The mechanisms triggering platelet dense 
and alpha granule secretion are believed to be quite similar. However, the secretion of 
platelet alpha granules occurs instantly upon agonist activation when compared with dense 
granule secretion [439]. The findings showed varied effectiveness of inhibition of imatinib 
on platelet granules. Imatinib may inhibit alpha agonist-induced alpha granule but not 
dense granule release. This suggests the possibility of selective inhibition of certain 
granules by drugs. For example, ADP-induced dense granule release was completely 
inhibited by increasing doses of acetylsalicylic acid (aspirin), while alpha granule release 
was not impacted [440]. No further studies have been conducted that explores the possible 
impacts of imatinib on platelet physiological aspects. The one exception is an individual 
clinical study that performed a platelet aggregation test using samples of CML patients 
under imatinib therapy. The results revealed that approximately 33% of patients had 
normal platelet aggregation [388]. Based on these findings, the present data could support 
the possibility that imatinib selectively inhibited alpha granule but not dense granule 
secretion in response to a soluble agonist. 
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This study revealed nilotinib (10-160 µM) significantly induced P-selectin exposure 
through potentiation of PAR-1 (SFFLRN) but not PAR-4 agonist peptide (AYPGFK)-
mediated alpha granule release in human platelets. In addition, alpha granule release was 
increased in the presence of 10-160 µM nilotinib in response to thrombin or CRP but 
failed to reach statistical significance.  This result may indicate a potentiation of secretion 
of the pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) and 
fibrinogen. Previous studies have shown that human platelets contain various alpha 
granule pools: 1) PAR-1-mediated alpha granule secretion of VEGF and fibrinogen-
containing pro-angiogenic proteins but not endostatin; and 2) PAR-4 agonist peptide-
mediated alpha granule secretion of endostatin and vWF-containing anti-angiogenic 
proteins but not VEGF [207, 441]. Upon activation of platelets and/or endothelial cells, P-
selectin is expressed on the membrane surfaces of platelets and endothelial cells to play an 
essential role in mediating the rolling of leukocytes, mainly monocytes or neutrophils, on 
activated endothelial cells through association with its ligand, PSGL-1. Therefore, the 
existence of P-selectin on stimulated endothelial cells is assumed to support the rolling of 
platelets [442-444]. Since platelet alpha granules secrete P-selectin onto their surfaces 
upon activation with greater intensity than on endothelial cells, monocytes and neutrophils 
directly adhere into the stimulated platelets following interaction with endothelium or in 
postponement, leading to the progression of pathogenic states [445, 446]. Thus, the 
expression of P-selectin-mediated platelets appears to consequently promote the 
development of arterial thrombosis and atherosclerosis via enhancement of the stability of 
thrombus formation [424, 447]. A more recent study proposed that pro-atherogenic factor 
adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1), intracellular 
cell adhesion molecule-1 and E-selectin (activation marker of endothelial cells) are 
potentially expressed or upregulated in response to nilotinib (1-10 µM) but not imatinib (1-
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10 µM) based on in vitro experiments using human umbilical vein endothelial cells 
(HUVECs) [448].  
Our findings seem to correlate with these earlier findings and highlight that nilotinib can 
potentiate selective alpha granule release (P-selectin expression) in platelets and/or 
endothelial cells, thereby elevating the in vivo levels of soluble P-selectin that specifically 
binds and induces signalling via PSGL-1 on leukocyte surfaces. Following vascular injury, 
platelets are stabilised at the blood vessel wall lined with endothelial cells to produce 
further P-selectin expression that can promote the recruitment of leukocytes under arterial 
states and accelerate the thrombus formation [163, 427]. Recent reports stated that the 
levels of circulating PLAs are potentially elevated in samples of patients with stable 
coronary artery syndrome [449] and acute myocardial infarction [428]. Therefore, 
assessment of the possible impact of TKI imatinib, nilotinib and dasatinib on platelets and 
PLAs was of interest. 
In this present study, the in vitro platelet-monocyte interactions determined by dual CD14 
and CD42a positivity for platelet and monocyte recognition was analysed by a flow 
cytometry method. All dasatinib, imatinib and nilotinib, had an undetectable effect on 
PAR-1-mediated platelet-monocyte or platelet-neutrophil aggregate formation in human 
donor platelets in a concentration dependent manner. Similarly, analysis of platelet-
neutrophil aggregate formation determined by CD14 negative and CD42a positive for 
platelet and neutrophil recognition by flow cytometry exhibited that a dose-dependent 
increase in imatinib, nilotinib and dasatinib concentrations did not affect PAR-4-mediated 
platelet-monocyte or platelet-neutrophil aggregate formation. The apparent absence of 
platelet-monocyte or platelet-neutrophil interactions by nilotinib may reflect some loss of 
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P-selectin from normal human platelet surface through proteolytic cleavage following 
platelet stimulation in whole blood samples.  
The investigation of PLAs in the presence of TKI concentrations in whole blood is 
challenging due to limitations. A stimulating agonist was added during the processing of 
samples, which might have initiated platelet aggregation to interfere with analysis. In 
addition, large platelet-platelet aggregates are able to display increasing laser light 
scattering characteristics which could interfere with the analysis [407]. Therefore, the 
effect of nilotinib on PAR-1 induced PLAs in the presence of protease inhibitors including 
trifluoperazine dihydrochloride (TFP) and a metalloproteinase inhibitor (GM6001) to 
minimise spontaneous platelet activation and formation of PLAs were tested. GM6001 is 
known to inhibit both the clearance of GPVI from the surface of platelets and the presence 
of the soluble cleavage product [450]. TFP, a calmodulin antagonist, was used to inhibit 
calmodulin as this plays an important role in platelet activation and aggregation through 
protein phosphorylation [451]. However, the use of protease inhibitors is still a limitation 
because of the alteration of agonist responses may interfere with the effect of TKIs on 
PLAs [450]. Taken together, the data here indicated no obvious dose-dependent effects of 
nilotinib or other TKIs on PLAs followed soluble agonist stimulation. 
Overall, several studies have reported a limitation in the measurement of cell surface or 
platelet P-selectin levels in whole blood samples because it can be cleaved within seconds 
to a few minutes [230, 452]. Accordingly, the assessment of soluble P-selectin level is a 
valuable method for measurement of P-selectin expression in vivo and usually used as an 
activation marker for platelets, particularly in vivo [223, 230]. 
In conclusion, the use of complementary approaches provided data in this Chapter revealed 
insights and differential effects in the behaviours of various TKIs on platelet function 
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profiles derived from healthy human donors. The laboratory experiments demonstrated 
that imatinib and dasatinib treatments have inhibitory effects on platelet aggregation, 
platelet granule exocytosis and platelet-leukocyte interaction. Up-to-date, the study in this 
Chapter revealed that nilotinib selectively potentiated platelet alpha granule release (P-
selectin exposure) in response to PAR-1 in human platelets which suggests an ability of 
nilotinib to induce platelet activation. 
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4.1 INTRODUCTION 
Increasing evidence points to a critical role for nilotinib treatment in adverse clinical 
outcomes of ischaemic vascular events including PAOD, heart attack, significant stenosis 
and sudden death [392, 453]. In Chapter three of this thesis, TKIs are shown to exert a 
variety of biological effects on platelet function phenotypes. Overall, nilotinib had a 
negligible effect on platelet aggregation responses. Instead, it selectively potentiated PAR-
1-mediated P-selectin exposure in human platelets in vitro particularly at subthreshold 
concentrations of PAR-1. By contrast, imatinib and dasatinib acted as inhibitors of platelet 
aggregation and platelet granule secretion in response to agonists in vitro. Previous study 
revealed that dasatinib significantly inhibited ex vivo thrombus formation on type I 
collagen under in vitro and ex vivo arterial flow conditions using both human and murine 
whole blood. These authors also demonstrated that patients treated with imatinib showed 
reduced thrombus formation under arterial flow conditions [399]. However, similar studies 
have not been conducted on nilotinib, an analogue of imatinib TKI, to determine whether it 
could affect thrombus formation in a mouse model. 
Platelet activation and aggregation can have a significant involvement in the development 
of arterial thrombotic occlusion and ultimately leading to heart attack and stroke [192]. 
Thrombosis related to cancerous lesions is the second major cause of death among 
leukaemic patients; therefore, platelets are an important blood component to target for 
treatment [192, 454]. Upon vascular injury, platelets adhere to exposed thrombogenic 
molecules of subendothelial matrix through binding vWF to GPIb-IX-V and collagen to 
GPVI leading to platelet adhesion, activation and spreading [10, 164]. Activated platelets 
secrete several soluble agonists, including ADP, TXA2 and thrombin, that can induce 
signalling pathways and promote platelet activation [9]. Furthermore, activated platelets 
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undergo a sequence of biochemical alterations that initiate intracellular signalling events to 
activate ‘inside-out’ signalling pathways via conversion of integrin αIIbβ3 from a low-
affinity inactive state to a high-affinity active state. The conversion to its active 
conformation of integrin αIIbβ3 enabling binding with fibrinogen, triggering ‘outside-in’ 
signalling pathway leading to irreversible stable platelet adhesion, cytoskeletal 
reorganisation, platelet aggregation and facilitation of thrombus growth [9, 158]. The 
stability of thrombus formation is regulated by different signalling pathways including 
protein tyrosine kinase receptors, particularly SFKs and GPCRs [170, 178]. 
Once platelets become activated and aggregated, they express and elevate the release of 
several potent proatherogenic molecules including cytokines (IL-6 and IL-8), chemokines 
PF4, RANTES, platelet surface expressed CD40L and P-selectin (CD62P); thereby 
modifying the integrity of the blood vessel wall and promoting the development of 
thrombotic events [45]. Platelet-derived adhesive proteins, specifically CD62P and 
CD40L, can be proteolytically cleaved from the surface of activated platelets into soluble 
forms [45].  In particular, P-selectin is also cleaved from endothelial cells upon activation 
[45, 455]. Increased soluble levels of these molecules have provided a significant 
enhancement of prothrombotic and pro-inflammatory phenotypes [45, 162]. Clinical data 
have provided evidence of elevated plasma levels of soluble P-selectin and/or CD40L in 
patients with artherothrombotic events such as PAOD, atherosclerosis, stroke and heart 
attack [45, 434]. Accordingly, these platelet-derived adhesive molecules are widely used 
as biomarkers of platelet and endothelial cell activation [45, 456, 457].  
In fact, type I fibrillar collagen is the chief adhesive mediator in the vascular 
subendothelium, acting as a soluble agonist with the ability to promote platelet adhesion, 
platelet signalling and aggregation [458, 459]. Most in vitro or ex vivo perfusion studies 
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therefore have used type I collagen-coated or vWF-coated flow champers microcapillary to 
study shear-induced platelet thrombus formation in the presence or absence of drugs to 
observe real time formation of arterial thrombi and to identify the multiple mechanisms of 
thrombus formation and stability [460].  
Accordingly, the aim of this Chapter is to test the ability of TKIs, specifically nilotinib, to 
modulate thrombus formation under physiological flow condition in vitro and ex vivo in a 
C57BL/6 model. Specifically, the effect of mice treated with different TKIs on platelet 
thrombus growth, platelet glycoprotein surface expression, conversion of integrin αIIbβ3 to 
its high-affinity state, P-selectin exposure, thrombin generation and plasma soluble levels 
of P-selectin and CD40L were investigated. The use of these approaches would provide an 
insight into the influence of TKIs including nilotinib platelet phenotype and thrombus 
formation in vitro and ex vivo under arterial flow in a C57BL/6 mouse model. 
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4.2 RESULTS 
4.2.1 Impact of TKIs on thrombus growth under conditions of mouse in vitro 
arterial flow on immobilised type I collagen 
In vitro arterial flow assays were performed to assess the effect of TKIs (imatinib, nilotinib 
and dasatinib) on platelet thrombus formation in wild-type C57BL/6 mouse samples. 
Rhodamine-labelled whole blood from C57BL/6 mice was pre-incubated for 10 minutes 
with two different doses of imatinib (5 µM and 10 µM), nilotinib (5 µM and 10 µM) or 
dasatinib (0.1 µM and 1 µM) and subsequently perfused over immobilised glass capillaries 
coated with fibrillar collagen type I at an arterial shear rate of 1800 seconds
-1
 for 6 
minutes. Whole blood obtained from untreated mice was utilised as a control in this assay. 
Thrombus images for imatinib, nilotinib and dasatinib-treated whole blood of C57BL/6 
mice were documented in real time (Figure 4.1A, 4.2A and 4.3A, respectively). Z-stack 
images were deconvolved and thrombus parameters including thrombus area, thrombus 
height and thrombus volume were determined. As shown in Figure 4.1B and C, analysis of 
imatinib-treated mouse blood in vitro with imatinib showed no significant differences in 
terms of thrombus surface area and thrombus volume versus untreated blood. Similarly, as 
shown in Figure 4.2B and C, thrombus area and thrombus volume were not altered at 
different nilotinib concentrations. By comparison, dasatinib-treated mouse blood in vitro 
exhibited much smaller thrombi with significant inhibition in thrombus area and thrombus 
volume compared to the untreated mouse blood. Taken together, these data confirmed that 
nilotinib and imatinib treatment had no effect on platelet thrombus formation in vitro under 
physiological arterial flow in whole blood of wild-type mice, whereas dasatinib 
progressively reduced platelet adhesion and thrombus formation in vitro on immobilised 
type I collagen at all doses tested.  
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Figure ‎4.1. The effect of imatinib on in vitro murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice in the presence of 5 µM or 10 µM imatinib was 
perfused over 500 µg/mL type I collagen under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-
stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl Zeiss)  and 
analysed with Zeiss Axiovision Rel4.6 software. 3D deconvolved reconstructions of thrombi formed were 
analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice whole blood treated with imatinib 5 µM or 10 µM versus sham control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised type I 
collagen perfused with whole blood from mice treated with imatinib or PBS. (C) Thrombus volume (µm)  
over time was calculated from thrombus area (µm
2
)×thrombus height (µm) for mice treated with imatinib or 
PBS. Results are cumulative data from three independent experiments and presented as mean±SEM (P> 
0.05, n=3). 
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Figure ‎4.2. The effect of nilotinib on in vitro murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice in the presence of 5 µM or 10 µM nilotinib was 
perfused over 500 µg/mL type I collagen under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-
stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl Zeiss)  and 
analysed with Zeiss Axiovision Rel4.6 software. 3D deconvolved reconstructions of thrombi formed were 
analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice whole blood treated with nilotinib 5 µM or 10 µM versus sham control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised type I 
collagen perfused with whole blood from mice treated with imatinib or PBS. (C) Thrombus volume over 
time was calculated from thrombus area (µm
2
)×thrombus height (µm) for mice treated with nilotinib or PBS. 
Results are cumulative data from three independent experiments and presented as mean±SEM (P> 0.05, 
n=3). 
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Figure ‎4.3. The effect of dasatinib on in vitro murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice in the presence of 5 µM or 10 µM dasatinib was 
perfused over 500 µg/mL type I collagen under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-
stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl Zeiss)  and 
analysed with Zeiss Axiovision Rel4.6 software. 3D deconvolved reconstructions of thrombi formed were 
analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice whole blood treated with imatinib 5 µM or 10 µM versus sham control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised type I 
collagen perfused with whole blood from mice treated with dasatinib or PBS. (C) Thrombus volume over 
time was calculated from thrombus area (µm
2
)×thrombus height (µm) for mice treated with dasatinib or PBS. 
Results are cumulative data from three independent experiments and presented as mean±SEM (*P<0.05, 
**P<0.01, and ***P<0.001, n=3). 
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4.2.2 Impact of TKIs on thrombus growth under conditions of mouse ex vivo 
arterial flow on immobilised type I collagen 
The influence of TKIs on platelet function was further examined by comparing thrombus 
formation ex vivo by pre-treating C57BL/6 mice with TKI for four hours followed by 
examination of thrombus growth characteristics under physiological flow conditions of 
mouse whole blood. The procedure is as described in section 2.3.6. Briefly, blood was 
collected from C57BL/6 mice which were treated with either 25 mg/kg or 50 mg/kg of 
imatinib or 12.5 mg/kg, 25 mg/kg or 50 mg/kg of nilotinib, 2.5 mg/kg, 5 mg/kg dasatinib 
or PBS (control) by oral gavage and left for four hours from the initial dose (peak drug 
concentration). Whole blood with fluorescently labelled platelets was perfused onto 
immobilised type I collagen at an arterial shear rate of 1800 seconds
-1
 for six minutes. The 
blood from imatinib-, nilotinib- and dasatinib-treated mice were compared to the sham 
control and the images of thrombi formed were recorded in real time (Figure 4.4A, Figure 
4.5A and Figure 4.6A, respectively). Analysis of 3D deconvolved images revealed that 
surface coverage of platelet adhesion, thrombus height and the thrombus volume were 
significantly enhanced with nilotinib doses versus control. As shown in Figure 4.5B and C, 
both doses of 25 and 50 mg/kg but not 12.5 mg/kg nilotinib caused a significant potent 
action of thrombus area and thrombus volume over time versus control. In contrast, as 
shown in Figure 4.4B and C, both the surface coverage of platelet aggregates and the 
thrombus volume were significantly diminished with 25 mg/kg or 50 mg/kg imatinib 
treatment over time at all doses tested compared to control. Similarly, mice treated with 
2.5 mg/kg or 5 mg/kg dasatinib displayed a significant inhibition in thrombus area and 
thrombus volume versus control (Figure 4.6B and C). Based upon these results, whole 
blood of mice treated with nilotinib doses shows strong potentiation of platelet adhesion 
and thrombus growth in real time, while imatinib or dasatinib treatment had an inhibitory 
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effect on platelet thrombus formation on immobilised type I collagen matrix under ex vivo 
physiologic arterial flow shear. These results indicate that the prothrombotic effect of 
nilotinib treatment of wild-type mice required the presence of the endothelium to prime the 
platelets in vivo to potentiate ex vivo thrombus growth under arterial flow conditions. 
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Figure ‎4.4. The effect of imatinib on ex vivo murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice untreated or treated with 25 or 50 mg/kg imatinib was 
perfused over 500 µg/mL type I collagen under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-
stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl Zeiss)  and 
analysed with Zeiss Axiovision Rel4.6 software. 3D devolved reconstructions of thrombi formed were 
analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice treated with 25 or 50 mg/kg imatinib versus wild-type treated PBS over 6 minutes. (B) 
Thrombus area (µm
2
) of thrombi formed on immobilised type I collagen perfused with whole blood from  
mice treated with imatinib or PBS was determined in real time. (C) Thrombus volume (µm) over time was 
calculated from thrombus area (µm
2
)×thrombus height (µm) for both mice treated with imatinib or PBS. 
Results are cumulative data from three independent experiments and presented as mean±SEM (*P<0.05 and 
**P<0.01, n=3). 
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Figure ‎4.5. The effect of nilotinib on ex vivo murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice untreated or treated with 12.5, 25 or 50 mg/kg nilotinib 
was perfused over 500 µg/mL type I collagen matrix under arterial flow conditions at shear rate of 1800 
seconds
-1
. Z-stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl 
Zeiss)  and analysed with Zeiss Axiovision Rel4.6 software. 3D devolved reconstructions of thrombi formed 
were analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice treated with 12.5, 25 or 50 mg/kg nilotinib versus wild-type treated PBS over 6 minutes. 
(B) Thrombus area (µm
2
) of thrombi formed on immobilised type I collagen perfused with whole blood from  
mice treated with nilotinib or PBS was determined in real time. (C) Thrombus volume (µm)  over time was 
calculated from thrombus area (µm
2
)×thrombus height (µm) for both mice treated with nilotinib or PBS. 
Results are cumulative data from three independent experiments and presented as mean±SEM (*P<0.05, 
**P<0.01, and ***P<0.001, n=3). 
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Figure ‎4.6. The effect of dasatinib on ex vivo murine thrombus formation and growth. (A-C) 
Fluorescently-labelled whole blood of C57BL/6 mice untreated or treated with 2.5 or 5 mg/kg dasatinib was 
perfused over 500 µg/mL type I collagen under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-
stack images were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl Zeiss)  and 
analysed with Zeiss Axiovision Rel4.6 software. 3D devolved reconstructions of thrombi formed were 
analysed for surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume 
(µm
3
). (A) Representative images of thrombus formation over type I collagen under arterial flow conditions 
for wild type mice treated with 2.5 or 5 mg/kg dasatinib versus wild-type treated PBS over 6 minutes. (B) 
Thrombus area (µm
2
) of thrombi formed on immobilised type I collagen perfused with whole blood from  
mice treated with dasatinib or PBS was determined in real time. (C) Thrombus volume (µm)  over time was 
calculated from thrombus area (µm
2
)×thrombus height (µm) for both mice treated with dasatinib or PBS. 
Results are cumulative data from three independent experiments and presented as mean±SEM (*P<0.05, 
**P<0.01, and ***P<0.001, n=3). 
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4.2.3 Effect of a single dose of nilotinib TKI treatment on haematological 
parameters 
The effect of acute TKI (nilotinib) treatment on haematological parameters in the C57BL/6 
mouse model was tested by oral administration of 25 mg/kg nilotinib or PBS (sham 
control) to 6–8 week old and sex-matched wild-type mice. All peripheral blood 
haematological parameters derived from treated or untreated mice were determined at 
baseline (time=0) and at peak concentration (time=4 hours). As shown in Table 4.1, mice 
treated with nilotinib exhibited normal haematological parameters [white blood cell 
(WBC) counts, red blood cell (RBC) counts, haemoglobin (Hgb), packed cell volume 
(PCV), mean cell volume (MCV), mean cell haemoglobin (MCH), mean cell haemoglobin 
concentration (MCHC), mean platelet volume (MPV), neutrophil (Neut), lymphocyte 
(Lymph), monocytes (Mono) and platelet (PLT)] when compared with sham control mice 
(*P> 0.05, n=6 for each group) following a single acute dose of nilotinib at peak Cmax 
concentration. Results are represented as mean±SEM for 6 independent experiments, and 
all experiments were performed in triplicate. 
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Table 4.1: Peripheral blood haematological parameters for wild-type C57BL/6 mice treated 
with nilotinib versus untreated wild-type C57BL/6 mice. 
 
WBC; white blood cell, RBC; red blood cell, Hgb; haemoglobin, PCV; packed cell volume, MCV; mean cell 
volume, MCH; mean cell haemoglobin, MCHC; mean cell haemoglobin concentration, PLT; platelet, MPV; 
mean platelet volume, Neut; neutrophil, Lymph; lymphocyte, Mono; monocyte, WCC; white cell count. 
Results are represented as mean±SEM, and the P value for all haematological parameters is greater than 
0.05.   
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4.2.4 Flow cytometry analysis of the effect of nilotinib on murine platelet profiles 
The in vitro human studies performed in Chapter three and the ex vivo arterial thrombus 
formation studies in this Chapter provided novel insights into the prothrombotic effect of 
nilotinib to increase thrombus formation by activation of platelets and endothelial cells in 
vivo. Therefore, in order to characterise how nilotinib induced a prothrombotic state, we 
examined the influence of nilotinib on the surface expression of platelet glycoproteins, the 
conformation of the major platelet integrin αIIbβ3, surface expression and soluble levels of 
plasma P-selectin and sCD40L in the murine model using flow cytometry and ELISA-
based assays. 
4.2.4.1 The effect of nilotinib on platelet glycoprotein surface expression 
Platelet glycoprotein receptors are known to play an important role in the regulation of 
platelet function and haemostatic mechanisms. In the present study, this assay was 
conducted to examine whether nilotinib treatment would alter the expression of 
glycoproteins on the surface of resting platelets in wild-type C57BL/6 mice. Several 
glycoproteins, including GPVI, GPIb-IX-V complex, integrin α2β1, integrin αIIbβ3, 
PECAM-1 and CD9, were detected on resting platelets using well-characterised specific 
monoclonal antibodies. Wild-type C57BL/6 mice were orally administered with 25 mg/kg 
nilotinib and blood samples were collected by cardiac puncture four hours later. Washed 
platelets in the resting state derived from untreated or nilotinib treated mice were incubated 
with anti-mouse GPVI (JAQ1) or anti-mouse-conjugated GPIbα-IX-V complex (CD42b) 
or anti-mouse integrin α2β1 (CD49b) or anti-mouse integrin β3 (CD61) or anti-mouse, 390 
mAb (PECAM-1 monoclonal antibody) or anti-mouse CD9 or isotype control anti-mouse 
CD3e. As shown in Figure 4.7, the surface expressions of all glycoproteins GPVI, GPIb-
IX-V complex, integrin α2β1, integrin αIIbβ3, PECAM-1 and CD9 on platelets derived from 
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nilotinib-treated mice were normal when compared to untreated mice. Results were 
derived from three independent experiments and are represented as mean fluorescence 
intensity MFI±SEM. Therefore, a single acute dose of nilotinib TKI did not appear to 
affect platelet glycoprotein expression despite inducing an ex vivo prothrombotic state 
under arterial flow conditions. 
 
 
Figure ‎4.7. The effect of 25 mg/kg nilotinib on surface expression of platelet glycoproteins. Flow 
cytometric analysis on a FACS Canto II analyser of GPVI, Integrin α2β1, Integrin αIIbβ3, GPIb-IX-V, 
PECAM-1 and CD9 expression on resting platelets of C57BL/6 mice treated with 25 mg/kg nilotinib versus 
sham control (PBS) using specific fluorescently labelled monoclonal antibodies for wild-type mouse 
platelets. The assay samples were performed in triplicate, and the results shown are representative of three 
independent experiments and presented as MFI±SEM (P>0.05; n=3). 
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4.2.4.2 The effect of nilotinib on the conversion of integrin αIIbβ3 to its active 
conformation on platelets  
Integrin αIIbβ3 has the ability to transfer bidirectional signalling pathways through “inside-
out” (agonist-induced activation of integrin αIIbβ3) signalling events. Postligand binding 
active conformation of integrin αIIbβ3 lead to irreversible stable platelet adhesion, 
cytoskeletal reorganization required for platelet spreading, microvesicle formation, platelet 
aggregation, and following thrombus formation. JON/A has ability to bind the high affinity 
of integrin αIIbβ3 on mouse platelets in the presence of soluble agonist. Thus, we used the 
PE-labeled JON/A mAb to study the agonist-induced activation of integrin αIIbβ3 in wild-
type mice treated or untreated with 25 mg/kg nilotinib. Samples were analysed with a 
FACScan flow cytometer. In this Chapter, we showed that mice treated with nilotinib 
showed increased ex vivo thrombus formation. We studied the effect of nilotinib on the 
conversion of integrin αIIbβ3 to its active conformation in wild-type platelets detected using 
JON/A mAb-PE binding. Washed platelets derived from nilotinib-treated (25 mg/kg) or 
untreated C57BL/6 mice showed minimal binding of  JON/A-PE under resting condition, 
compared with agonist-induced activation with thrombin (0.5 and 1 U/mL), PAR-4 agonist 
peptide (150 and 300 µM) or CRP (1 and 2 µg/mL). As shown in Figure 4.8, CRP, 
thrombin and PAR-4-induced activation of platelets derived from nilotinib-treated or 
untreated mice displayed a similar ability to bind with the fibrinogen mimetic JON/A mAb 
that recognises the active conformation of integrin αIIbβ3 on platelets. These results 
indicated that platelets from nilotinib-treated mice had normal conversion from a resting 
state of integrin αIIbβ3 to an activate conformation in platelets. 
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Figure ‎4.8. The effect of 25 mg/kg nilotinib on JON/A mAb binding. Flow cytometric analysis on a 
FACS Canto II analysis resting versus agonist induced active conformation of integrin αIIbβ3 on platelet from 
wild-type mice treated with 25 mg/kg nilotinib or PBS using JON/A-PE mAb binding to platelets stimulated 
with CRP (1, 2 µg/mL), PAR-4 agonist peptide (150, 300 µM), thrombin (0.5, 1 U/mL), or unstimulated 
(sham control). The assay samples were performed in triplicate, and the results shown are representative of 
three independent experiments and presented as MFI±SEM (P>0.05; n=3). 
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4.2.4.3 The effect of nilotinib on platelet P-selectin expression 
In Chapter 3, platelet alpha granules but not dense or lysosomal granules in a human 
platelet model treated with a range of nilotinib doses potentiated P-selectin exposure in 
response to agonist stimulation, specifically PAR-1. Therefore, the kinetics of alpha 
granule secretion in C57BL/6 mice treated with nilotinib was investigated. As shown in 
Figure 4.9, platelets obtained from mice treated with 25 mg/kg nilotinib demonstrated a 2-
fold reduction in the surface expression of P-selectin upon activation by thrombin (0.5 and 
1 U/mL), PAR-4 agonist peptide (150 and 300 µM) and CRP (1 and 2 µg/mL) when 
compared with platelets from untreated mice. These findings highly support the hypothesis 
that nilotinib selectively activates platelets to induce P-selectin release in vivo. 
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Figure ‎4.9. The effect of 25 mg/kg nilotinib on surface expression of P-selectin. Surface expression of P-
selectin was assessed for washed platelets stimulated by CRP (1, 2 µg/mL), PAR-4 agonist peptide (150, 300 
µM) or thrombin (0.5, 1 U/mL), and then incubated with either a buffer control and FITC-P-selectin Ab for 
platelets derived from C57BL/6 mice treated with nilotinib (25 mg/kg) or PBS (sham control). FITC-labelled 
samples were analysed on a FACS Canto II analyser. The assay samples were performed in triplicate, and the 
data shown are representative of three independent experiments and presented as MFI±SEM (*P<0.05, 
**P<0.01; n=3). 
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4.2.5 Thrombin generation assay 
Increased concentrations of procoagulants lead to plasma hypercoagulability; thereby 
resulting in development of atherothrombotic events among patients, particularly who have 
cardiovascular risk factors such as arterial thrombosis [461, 462]. It was determined 
whether nilotinib treatment altered platelet procoagulant activity under static conditions by 
measuring thrombin generation using plasma derived from nilotinib-treated (25 mg/kg) or 
untreated mice. Thrombin activity was measured in the presence of tissue factor and 
phospholipids by a calibrated automated thrombogram. All parameters of thrombin 
generation including lag time, thrombin peak concentration, time to peak, endogenous 
thrombin potential (ETP) and α2-macroglobulin measured in plasma from nilotinib-treated 
mice showed no significant differences when compared with values from sham control 
mice. As shown in Figure 4.10, similar thrombin peak and ETP levels were observed in 
nilotinib-treated and control. These data suggest that nilotinib did not affect the pro-
coagulant clotting factors assessed by the thrombin generation test.  
 
Figure ‎4.10. Assessment of  thrombin generation in plasma derived from C57BL/6 mice treated with 
nilotinib or PBS (control) after four hours of ingestion. (A) Levels of peak thrombin (B) endogenous 
thrombin potential (ETP) were determined for mice treated with 25 mg/kg nilotinib versus PBS on the 
Calibrated Automated Thrombin Generation using a Fluoroscan Ascent®fluorometer. The assay samples 
were performed in triplicate, and results are represenative of eight independent experiments and presented as 
mean±SEM (P>0.05; n=8). 
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4.2.6 Circulating soluble P-selectin levels in murine plasma of nilotinib-treated mice 
P-selectin can be cleaved from the platelet surface to circulate in vivo as a soluble 
molecule in the plasma. Soluble P-selectin plays an important role in the promotion of 
thrombotic events by exerting procoagulant reactivity. Consequently, sP-selectin is 
commonly used as a marker of platelet and endothelial cell activation. Sandwich ELISA 
was used to measure the levels of sP-selectin in mouse plasma. As shown in Table 4.2 and 
Figure 4.11, nilotinib (25 mg/kg) treatment significantly increased plasma levels of sP-
selectin (209.51±21.52 ng/mL) by 2-fold compared to sham controls (139.26±11.50 
ng/mL; **P<0.05; n=8), which may reflect proteolytic shedding of P-selectin from 
activated platelets and endothelial cells in vivo in response to nilotinib treatment. By 
contrast, imatinib (25 mg/kg) treatment did not affect sP-selectin levels compared with 
sham control (144.00±13.12 vs. 139.26±11.50 ng/mL; *P>0.05; n=8; Figure 4.11). Thus, 
these results strongly support the hypothesis that nilotinib treatment positively induces 
platelet activation via potentiation of P-selectin exposure and cleavage from platelet-
endothelial cell surface in wild-type mice.  
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Figure ‎4.11. Measurement of sP-selectin levels in plasma derived from C57BL/6 mice treated with 
imatinib, nilotinib or PBS. Plasma obtained from C57BL/6 mice treated with 25 mg/kg imatinib, 25 mg/kg 
nilotinib or PBS (control) was collected after 4 hours of ingestion. Plasma sP-selectin (ng/mL) levels of 
C57BL/6 mice treated with imatinib, nilotinib and PBS was determined by ELISA. Each experiment were 
performed in duplicate and represented as mean±SEM of eight independent experiments (NS: Not 
statistically significant, **P<0.01; n=8). 
 
Table 4.2: Levels of sP-selectin (ng/mL) in plasma of C57BL/6 mice treated with nilotinib (25 
mg/kg) or imatinib (25 mg/kg) versus PBS were determined by ELISA. (**P<0.01; n=8). 
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4.2.7 Effect of nilotinib treatment on murine plasma soluble CD40L levels 
Increasing levels of sCD40L are significantly associated specifically with augmented 
platelet activation and aggregation [463]. The plasma levels of sCD40L from mice treated 
with nilotinib (25 mg/kg), imatinib (25 mg/kg) or PBS (control) was measured by 
sandwich ELISA. As shown in Table 4.3 and Figure 4.12, wild-type mice treated with a 
single dose of nilotinib did not affect the plasma levels of sCD40L compared to PBS-
treated mice (5.093±0.069 versus 4.818±0.068 ng/mL, P>0.05, n=11). Moreover, no 
statistically significant differences in sCD40L levels were found between mice treated with 
imatinib compared to mice treated with PBS (4.927±0.049 versus 4.818±0.068 ng/mL; 
P>0.05; n=11) (Figure 4.12). Overall, the results suggest that wild-type mice treated with 
either imatinib or nilotinib do not modulate plasma levels of sCD40L upon platelets at a 
single acute dose. 
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Figure ‎4.12. Measurement of sCD40L levels in plasma derived from C57BL/6 mice treated with 
imatinib, nilotinib or PBS. Plasma obtained from C57BL/6 mice treated with 25 mg/kg imatinib, 25 mg/kg 
nilotinib or PBS (control) was collected after four hours of ingestion. Plasma sCD40L (ng/mL) levels of 
C57BL/6 mice treated with imatinib, nilotinib and PBS was determined by ELISA. Each experiment were 
performed in duplicate and represented as mean±SEM of 11 independent experiments (P>0.05; n=11). 
 
Table 4.3: Levels of sCD40L  (ng/mL) in plasma of C57BL/6 mice treated with nilotinib (25 
mg/kg) or imatinib (25 mg/kg) versus PBS were determined by ELISA. (P>0.05; n=11). 
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4.3 DISCUSSION 
It is widely accepted that ruptured atherosclerotic lesions expose high concentrations of 
fibrillar type I collagen which initiates localised thrombosis through recruitment and 
adherence of platelets to exposed ECM constituents within the vascular wall followed by 
activation of coagulation that intensify thrombus formation [464, 465]. To examine the 
contribution of TKIs, specifically nilotinib in modulating platelet aggregation and arterial 
thrombus growth several complementary approaches were used. The findings achieved in 
this Chapter provided some novel observations into the effect of imatinib, nilotinib and 
dasatinib on platelet characterisations and thrombus formation in vitro and ex vivo in wild-
type mice. 
Unlike dasatinib and imatinib, the effect of nilotinib on platelet thrombus formation under 
in vitro or ex vivo flow conditions had not been examined. In this Chapter, it was of 
interest to test and compare the ability of nilotinib and other TKIs to modulate platelet 
thrombus growth under arterial in vitro and ex vivo flow conditions by intravital 
microscopy that allowed capturing of real time images from C57BL/6 mice. These 
experiments demonstrated that nilotinib and imatinib had no effects on thrombus growth 
under in vitro arterial flow conditions over immobilised type I collagen at all doses tested. 
By contrast, dasatinib inhibited platelet adhesion on type I collagen and the thrombus 
volume was significantly reduced at 4 and 6 minutes of perfusion when compared with 
untreated whole blood. Furthermore, the ex vivo studies used drug concentrations that were 
optimised based on dose response curves, and the drug concentrations were similar to 
those used previously (dasatinib concentrations) [399, 466] and (imatinib and nilotinib 
concentrations) [466, 467]. As demonstrated in this Chapter, 25 mg/kg, 50 mg/kg but not 
12.5 mg/kg nilotinib significantly increased ex vivo thrombus growth on immobilised type 
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I collagen over time when compared to sham control (Figure 4.5A and B) in real time. By 
contrast, thrombus growth on type I collagen under ex vivo flow shear conditions was 
inhibited by imatinib (Figure 4.4A and B) and dasatinib (Figure 4.6A and B).  
Previous study by Gratacap et al. [399] demonstrated that imatinib-treated patients 
significantly reduces thrombus formation on immobilised type I collagen under 
physiologic shear rate while dasatinib-treated patients formed smaller and less stable 
thrombi with much more pronounced than imatinib. The same research group also reported 
that blood derived from dasatinib-treated mice formed much smaller thrombi over type I 
collagen. Importantly, the dosing of mice with these drugs imatinib (25 mg/kg), nilotinib 
(25 mg/kg) and dasatinib (5 mg/kg) correlated with equivalent dosing used in human CML 
patients. An interesting feature of this study was that the requirements for increased ex vivo 
thrombus formation were the pre-treatment of mice until peak drug (Cmax-4 hours) was 
achieved and the priming of vessel wall and blood components. Without in vivo exposure 
to the intact blood vessel, the in vitro thrombus formation from whole blood treated with 
nilotinib did not display increased thrombus formation on type I collagen. 
We also examined whether a single dose of nilotinib treatment affected the production of 
haematopoietic cells, specifically platelets in C57BL/6 mice. Determination of 
haematological parameters from treated and untreated mice showed that 25 mg/kg nilotinib 
had no effect on any of the haematological parameters including platelet production after 
four hours of treatment when compared with sham control. This could reflect an 
insufficient time frame for treatment with nilotinib to show an involvement in 
haematopoiesis. In particular, the required period for completing and releasing mature 
platelets into bloodstream by processing of megakaryocytes in bone marrow is five days in 
adult human and two to three days in rodents [468, 469].  
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The existence of glycoprotein receptors on the platelet surface, such as GPIb-IX-V, GPVI, 
integrin α2β1, integrin αIIbβ3, PECAM-1 and CD9, are important participants in the 
regulation of platelet function in both in humans and in mice. The expression of these 
receptors contributes directly to haemostatic processes through involvement by either 
coordinating adhesive receptors with exposed subendothelial molecules at vascular trauma, 
platelet stimulation in response to soluble agonists or aggregating growth for associating 
with other platelets or with other blood components, including leukocytes, which leads to 
formation of the haemostatic plug. However, up-regulation of receptor expression on 
platelet surfaces has been shown to play a critical role in platelet arterial thrombosis in 
both humans and mice [5, 64]. Previous research showed that dasatinib impaired the 
collagen/GPVI association and created subsequent defects in the ITAM-mediated 
signalling pathways in platelets, particularly for FcRIIa and collagen GPVI/FcR gamma 
chain that involve tyrosine kinase phosphorylation, PI3-kinase activation and PLC/DAG 
kinase activation, with the end result of increased bleeding events and prevention of 
thrombus growth [399]. 
Following identification that nilotinib treatment of C57BL/6 mice resulted in a 
prothrombotic phenotype under ex vivo arterial flow conditions. The next step therefore 
was to investigate whether this could be attributed to increased platelet glycoprotein 
expression or induced activated conformation of integrin αIIbβ3 or enhanced adhesive 
mediator release (sP-selectin and sCD40L) in vivo. This Chapter’s results demonstrated 
that 25 mg/kg nilotinib did not show direct effects on the surface expression of 
glycoproteins on resting platelets in C57BL/6 mice. In addition, the results here 
demonstrated that nilotinib did not directly alter conversion of integrin αIIbβ3 to its active 
conformation in murine platelets without agonist stimulation. Platelets from nilotinib-
treated mice had a similar ability for binding with JON/A mAb as platelets from untreated 
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mice, resulting in normal conversion of integrin αIIbβ3 from resting to activated 
conformation to bind its fibrinogen mimetics JON/A mAb. Collectively, these findings of 
the initial characterisation of nilotinib treatment suggest that nilotinib had no effect on 
modulation of platelet glycoprotein expression or conformation of integrin αIIbβ3 at a 
single acute dose. However, further studies could be of interest to ascertain the possibility 
of potential effects of multiple treatments of nilotinib (chronic model) on regulation of 
platelet glycoprotein receptors. 
The pathogenesis of arterial thrombosis is considerably complicated and is distinguished as 
a multifactorial syndrome. Every risk factor of thrombosis may work individually. 
Hypercoagulability results in an imbalance of anti- versus pro-coagulation is associated 
with increased risk factors, including increased thrombin generation. The augmented 
thrombin generation would result in coagulation activation with thrombin generation 
leading to platelet activation potentiating the formation of blood clots [461, 470, 471]. A 
calibrated automated thrombogram was used to measure thrombin generation parameters 
in plasma from mice treated with nilotinib to ascertain elevated thrombin concentrations 
that reflect hypercoagulability, although no clinical studies have reported any abnormality 
in coagulation among CML patients undergoing nilotinib therapy. The measurement of 
thrombin generation-derived parameters is believed to indicate the balance of coagulation 
may provide better investigating [471, 472], specificity in CML patients on nilotinib 
treatment and if increased may justify the concurrent use of anticoagulants. The present 
data confirmed normal thrombin generation in plasma of mice treated with nilotinib (25 
mg/kg) as shown by no alteration in the pro-coagulant parameters, including ETP and 
thrombin peak. In general, it is possible that the acute model of nilotinib treatment may not 
interfere with coagulation factors that mediate an imbalance of anti- and pro-coagulation to 
initiate to a thrombogenic phenotype of hypercoagulopathy.   
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Increased platelet reactivity in peripheral blood circulation is a pivotal risk factor for 
atherothrombosis and vascular inflammation via secretion of several bioactive adhesive 
molecules [9, 45]. Adhesive molecules, including P-selectin and CD40L, are important 
mediating factors produced and constitutively expressed on the platelet surface membrane 
that impact on the integrity of the blood vessel wall [45]. The production of soluble forms 
of P-selectin and CD40L by proteolytic cleavage in vivo suggest a direct involvement in 
vascular events [45, 208, 219, 223]. Other adhesive molecules such as beta 
thromboglobulin and platelet factor 4 have been utilised as activator markers for platelets 
but their half-life is short and they rapidly disappear from the plasma [209]. By contrast, 
sP-selectin or sCD40L are distinguished by longer half-lives of approximately two hours. 
Thus, soluble P-selectin or CD40L are now widely used as markers for platelet activation 
[227, 255, 473]. 
P-selectin is essentially localised in both platelets and endothelial cells [212]. Upon 
activation and degranulation of platelets or endothelial cells, P-selectin is expressed and 
translocated onto the surface of platelets and exists on plasma membrane for at least one 
hour [474]. Research studies reported the greatest storage pool of P-selectin is in alpha 
granule of platelets and the smallest storage pool is in Weibel-Palade bodies of endothelial 
cells; therefore, P-selectin is clinically important as a biomarker of platelet activation [209, 
455, 475]. Platelet P-selectin can be proteolytically shed from the plasma membrane as a 
soluble form within a few seconds to minutes in vivo [43, 220]. Increased levels of P-
selectin were reported in widely different vascular diseases, including atherosclerosis [447, 
452] , PAOD [224], ischemic heart disease and stroke [222, 452]. 
As discussed in Chapter three, CML patients undergoing nilotinib regimens have been 
recurrently reported with vascular adverse events, in particular PAOD [392, 420]. P-
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selectin, either existing on the platelet and/or endothelial cell surfaces or as a soluble form 
in the plasma, potentially affects thrombus formation and atherosclerotic development via 
different mechanisms [232]. Woollard et al. demonstrated increased levels of sP-selectin in 
plasma of patients with PAOD that may potentially enhance pathological leukocyte 
recruitment and adhesion to platelets at sites of vascular injury through mediation of the 
interaction of exposed P-selectin (on activated platelets) with its ligand PSGL-1 (on 
leukocytes), thereby supporting disease progression [223]. Furthermore, GPIbα has been 
recognised as a platelet membrane counter-receptor for P-selectin on endothelial cells. 
Thus, GPIbα mediates the association of unstimulated platelets on activated endothelium; 
thereby promoting thrombosis [229]. In Chapter three, nilotinib was found to potentiate 
PAR-1-mediated P-selectin expression when compared with an untreated control. In 
addition, P-selectin exposure was assumed to be slightly initiated in response to different 
agonists including thrombin and CRP but not PAR-4 in healthy human platelets. Recent 
observations demonstrated that nilotinib significantly promoted the expression of the 
endothelial activation marker, E-selectin (CD62E) in HUVECs [448]. E-selectin is a class 
of selectin family adhesive molecules that are expressed on the surface of endothelial cells 
following activation; it is clinically used as an activation marker for endothelial cells 
[476]. On this basis, the effect of 25 mg/kg nilotinib on P-selectin expression was 
determined in wild-type mice. The present data in this Chapter demonstrated the first 
evidence that nilotinib significantly induced platelet and endothelial activation in vivo 
through cleavage of P-selectin from the platelet and endothelial cell surface in mice treated 
with nilotinib following agonist stimulation (Figure 4.11). This study showed that nilotinib 
is capable of activating platelets and endothelium shown by reduced P-selectin exposure 
indicating P-selectin cleavage in vivo.  
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Previous studies from Wagner’s group elucidated that the absence of P-selectin resulted in 
a minor prolongation of bleeding time in mice [211]. They also showed that P-selectin-
deficient mice had delayed and diminished arterial thrombotic formation, indicating that P-
selectin had an important function in haemostasis and also in atherothrombotic events 
[211, 477]. Further study from the same group showed that mice genetically engineered to 
generate abnormally increased levels of sP-selectin also displayed more infarcts in an 
cerebral artery occlusion, ischaemic stroke models and elevated susceptibility to 
atherosclerotic progression in apolipoprotein E (ApoE)-deficient mice [457].  
In this Chapter, mice treated with nilotinib showed markedly increased levels of sP-
selectin while imatinib doses had no effect on P-selectin cleavage from the platelet surface. 
On the other hand, the current findings support and provide strong evidence for the 
involvement of nilotinib dose in potentiation of platelet P-selectin expression and elevated 
sP-selectin in circulating plasma in vivo. The production of sP-selectin derived from 
activated platelets may mediate leukocyte recruitment and microparticle formation, 
resulting in arterial thrombus growth at the blood vessel wall [447]. P-selectin plays a 
central role in the adhesion of leukocytes to activated platelets with endothelium [478]. 
The interactions of P-selectin on activated platelets with PSGL-1 on the membrane surface 
of leukocytes triggers leukocyte recruitment and activation of leukocyte-derived 
microparticles; thereby promoting thrombus formation and fibrin deposition at sites of 
injured vascular endothelium leading to atherosclerotic development [442]. The presence 
of high levels of plasma sP-selectin induces the production of tissue factor induced by 
leukocyte-derived microparticles and also activates endothelial cells to enhance tissue 
factor exposure, which mediates thrombus formation [232]. Further studies are warranted 
to evaluate the impact of nilotinib on tissue factor bearing microparticle release and tissue 
factor expression to address this limitation in the present study. 
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To test the hypothesis that nilotinib may alter platelet reactivity by influencing platelet 
adhesive molecules, we determined the soluble levels of CD40L in mouse plasma 
following 25 mg/kg nilotinib or 25 mg/kg imatinib treatment by ELISA quantitation. The 
findings showed that nilotinib but not imatinib elevated the levels of sCD40L in murine 
plasma that indicating nilotinib treatment may activate platelets through inducing CD40L 
release in vivo. The transmembrane protein CD40L is a member of the TNF family. It was 
originally recognised on T-lymphocytes to play vital function in the humoral immune 
system [479]. Platelets have abundant copies of CD40L, and approximately >95% of 
circulating sCD40L of platelet origin [480]. It is produced by activated platelets and 
translocated to the membrane surface of platelets in vivo for release [241, 480]. Andre et al 
stated that CD40L-deficient mice altered the thrombus formation stabilisation and delayed 
vessel occlusion, suggesting that this molecule enhances platelet activation and the 
stability of thrombi formed [242]. The interaction of exposed CD40L with its receptor 
CD40, which is expressed on many cell types, including endothelial cells, leukocytes and 
platelets, has been implicated in pathophysiology of different diseases, including 
atherosclerosis and inflammatory disorders [208, 481].  
The present data showed that nilotinib treatment induced P-selectin and CD40L release in 
vivo and that strongly suggested that nilotinib but not imatinib modulated platelet and 
endothelial cell reactivity in the mouse model. P-selectin can be expressed on activated 
platelets and/or activated endothelium, the levels of circulating plasma soluble P-selectin 
can be derived from either platelet P-selectin or endothelial cells [447]. Hence, further 
work is required to distinguish the true cellular origin of the observed sP-selectin with 
current ELISA based sP-selectin systems cannot distinguish the cellular origin of sP-
selectin. Similarly, CD40L is expressed on various cells, so even though 95% of sCD40L 
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is released from platelets [480], further studies are also required to establish the origin of 
CD40L released following nilotinib treatment.  
In conclusion, clinical data have reported that treatment of CML patients with nilotinib is 
associated with increase rates of atherothrombotic events. This Chapter confirms a 
potential involvement of nilotinib treatment in the induction of thrombus formation, both 
ex vivo on collagen type I under arterial flow conditions and in vivo by initiation of platelet 
activation through cleavage of P-selectin from platelets or/and endothelium with a 
corresponding increase in soluble P-selectin in mouse plasma. The results in this Chapter 
also demonstrate a partial augmentation of soluble levels of CD40L in mouse plasma 
following treatment with nilotinib but not with imatinib. Here, an inhibition of thrombus 
growth over immobilised collagen fibres in ex vivo but not in vitro studies using imatinib 
was observed. The imatinib treatment had no detectable effect on sP-selectin or sCD40L 
levels in mouse plasma. These studies further showed that the growth of thrombi under 
physiological flow conditions in vitro and ex vivo was significantly inhibited when mice 
were treated with dasatinib. Taken together, the results presented in this Chapter provide 
considerable evidence that TKIs have differential effects on platelet aggregation and 
thrombus formation in the C57BL/6 mouse model. Specifically, the ex vivo data provide 
strong evidence that nilotinib induces increased arteriolar thrombus development 
associated with fibrillar collagen as a thrombogenic substance exposed from the 
endothelium, and it also enhances release of adhesive molecules from activated platelets 
and endothelium. These results indicate a potential mechanism for supporting an increased 
rate of thrombus formation in vascular disease and atherosclerosis. 
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5 CHAPTER FIVE: INVESTIGATING THE ACUTE 
EFFECT OF TKI TREATMENT ON ARTERIAL 
THROMBUS FORMATION IN AN IN VIVO MODEL 
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5.1 INTRODUCTION 
Atherosclerosis is known as a chronic inflammatory complication distinguished by the 
association of platelets with injured endothelium and additional interaction can occur 
between leukocytes and endothelial cells [482, 483]. The adhesive interaction is mainly 
mediated by binding P-selectin from platelet and endothelial cells to PSGL-1 on 
leukocytes, that consequently promotes thrombus stability in vivo upon vascular injury 
[209, 444, 447]. Accordingly, arterial thrombi that form at sites of ruptured atherosclerotic 
plaque are platelet rich and exposed to blood flow forces [484]. Our experiments 
demonstrated in Chapter four showed that nilotinib reduced P-selectin exposure on 
platelets after four hours of treatment in C57BL/6 mice with a two-fold increase in soluble 
plasma P-selectin levels compared to PBS-treated or imatinib-treated mice. The results 
suggested that nilotinib can induce endothelial and platelet activation in vivo in mice which 
lead to the development of thrombus formation in vivo. 
In vivo, platelets freely circulate within the blood stream and do not interact with 
nonactivated endothelium; however, they will immediately tether, adhere and aggregate in 
response to activated, damaged or diseased endothelial surfaces; thereby leading to the 
progression of arterial thrombosis [158, 485]. Exposed tissue factor will induce the 
activation of coagulation cascade resulting in the production of thrombin and fibrin 
deposition either promoting platelet activation and potentiating thrombus growth [9, 486]. 
Furthermore, disturbance in blood flow is recently identified to play a critical role in 
modulating platelet activation and enhancing thrombus formation in vivo [159, 160, 168]. 
However, striking results from intravital microscopy, which allows real time analysis of 
thrombi formed in vivo, have demonstrated platelet aggregation as a dynamic process with 
much complexity operating at sites of vascular injury [487, 488].  
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Several years ago, evidence was presented that treatment with TKI including nilotinib, but 
not imatinib or dasatinib, is associated with concomitant development of arterial 
cardiovascular events, including PAOD, ischaemic heart disease and sudden death among 
CML patients [392, 401, 489]. However, no further studies have evaluated the effect of 
nilotinib in modulating platelet thrombus formation in humans or animal models. In 
Chapter four, the ex vivo perfusion results reported for the first time that treatment of mice 
with 25 or 50 mg/kg nilotinib potentiated ex vivo thrombus growth over immobilised type I 
collagen under physiological flow conditions in real time. In contrast, C57BL/6 mice 
treated with either imatinib (25 and 50 mg/kg) or dasatinib (2.5 and 5 mg/kg) showed an 
inhibitory effect on thrombus formation on type collagen over time. Previous study 
demonstrated that blood from dasatinib-treated mice inhibited thrombus formation in vitro, 
ex vivo and in vivo [399]. Additionally, the same research team showed that that primary 
haemostasis in vivo was defective following dasatinib treatment four hours after ingestion. 
No similar studies have examined the contribution of TKI, nilotinib or imatinib in 
mediating in vivo thrombus growth. Furthermore, the presented observations in Chapter 
four indicate different behaviours of TKIs on in vitro and ex vivo thrombus formation 
studies in murine models. Thus, the aim of the present Chapter was to assess the effect of 
acute TKI therapy in modulating thrombus formation in vivo using a C57BL/6 mouse 
model.  
In this Chapter, cohorts of mice treated with nilotinib or imatinib underwent a tail bleeding 
time test carried out under controlled conditions to assess primary haemostasis in vivo. 
Next, cohorts of TKI-treated mice were subjected to FeCl3-mediated vascular induced 
injury of the mesenteric arterioles (80-100 µM) and in vivo microvascular thrombus 
growth was evaluated. Moreover, cohorts of TKI-treated mice were subjected to FeCl3-
mediated vascular induced injury of the carotid arteries as a mechanism for inducing 
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arteriolar thrombosis in vivo. Additionally, cohorts of C57BL/6 mice treated with anti-P-
selectin blocking antibody in the presence or absence of nilotinib were subjected to FeCl3-
mediated vascular injury of the mesenteric arterioles analysed by in vivo thrombus 
formation. These approaches were taken to determine the effect of TKIs on both primary 
haemostasis in vivo and thrombus formation in vivo.  
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5.2 RESULTS 
5.2.1 Investigating the effect of nilotinib and imatinib on in vivo primary 
haemostasis via performing tail bleeding time analysis 
The effect of TKI, nilotinib or imatinib on primary haemostasis was assessed by the tail 
bleeding assay. Wild-type mice were treated with an acute dose of nilotinib (25 mg/kg) or 
imatinib (25 mg/kg) or PBS for four hours prior to measuring bleeding time following the 
removal of tail tip. As shown in Figure 5.1, the tail bleeding time was equivalent between 
imatinib-treated mice and wild-type PBS control (7.30±0.53 min versus 6.10±0.43 min; 
n=10) (Figure 5.1A). Similarly, imatinib-treated mice showed equivalent volumes of blood 
loss compared to the control mice (65.50±5.08 µL versus 64.00±4.06 µL; n=10) (Figure 
5.1B). As shown in Figure 5.1A, nilotinib-treated mice displayed no change in mean tail 
bleeding time compared with the control mice (5.20±0.35 min versus 6.10±0.43 min; 
n=10). A similar pattern was noticed in the mean volume of blood loss, which was 
undetectable effect in mice treated with nilotinib when compared to the wild-type PBS 
control (57.70±4.74 µL versus 64.00±4.06 µL; n=10) (Figure 5.1B). However, no 
significant differences were documented in either the tail bleeding time or the blood loss in 
mice treated with nilotinib versus the control mice. This result may indicate that a single 
dose of nilotinib or imatinib has no significant effect on primary haemostasis in vivo in 
acute models, as measured by the tail bleeding time. 
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Figure ‎5.1. The effect of imatinib and nilotinib on in vivo primary haemostasis by the tail bleeding 
analysis. C57BL/6 mice ages 6-8 weeks old (sex-matched) were orally administrated with PBS as sham 
control or the TKI’s, imatinib 25 mg/kg or nilotinib 25 mg/kg and left for four hours. (A) Time taken for 
initial tail bleeding cessation for wild-type mice untreated or treated with imatinib or nilotinib. (B) The 
volume of blood lost (µL) through tail bleeding time was calculated in mice untreated or treated with 
imatinib or nilotinib. Cohorts of imatinib-treated mice group or nilotinib-treated mice group were compared 
to the wild-type PBS control group. Results presented as mean±SEM, P>0.05. (n=10). 
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5.2.2 Assessment of arterial thrombosis formation and stability in TKI-treated 
C57BL/6 mice subjected to FeCl3-induced vascular injury of the mesenteric 
arterioles 
The nilotinib TKI displayed a potentiating effect on ex vivo thrombus formation, whereas 
imatinib and dasatinib exhibited an inhibitory role on ex vivo thrombus growth under 
arterial flow conditions. Therefore, the effect of these drugs was examined on the 
formation of in vivo microvascular thrombi in mesenteric arterioles using FeCl3-induced 
vascular injury in a C57BL/6 mouse model. Thrombus formation and stability 
characteristics were analysed in real time by measuring the number of fluorescently-
labelled platelets bound to injured endothelium. In this model, wild-type mice were treated 
with 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or PBS by oral 
administration at four or 48 hours before surgery. The mice were then completely 
anaesthetised, the ideal diameter of the mesenteric arterioles (80-100 µm) was determined, 
and the animals were administered rhodamine 6G dye. Thrombus growth was observed 
and compared between TKI-treated mice and PBS-treated mice for 10 minutes in real time 
in vivo through intravital microscopy. The rendered Z-stack images were deconvolved 
with Axiovision Rel 4.6 software, to construct 3D-images, and the volume of the thrombi 
was calculated from the area multiplied by the height of each thrombus. The percentages 
of vessel occlusion and stability scores were also analysed for untreated wild-type mice or 
those treated with TKIs. Thrombi formed were analysed at all time points (0-2, 2-4, 4-6, 6-
8 and 8-10 min). As shown in the representative images in Figure 5.2A, enhanced 
thrombus growth was observed in FeCl3-injured mesenteric arterioles of 25 mg/kg 
nilotinib-treated mice four hours after ingestion when compared to mouse control at each 
time point beyond four minutes. In contrast to the effects seen with nilotinib, thrombus 
growth and stability was reduced in mice treated with imatinib (25 mg/kg) and 
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significantly diminished over a ten-minute period in 5 mg/kg dasatinib treated-mice 
following FeCl3-induced injury, when compared with the mouse control. 
The Z-stack analysis of thrombus growth over all time-points revealed that imatinib-
treated mouse arterioles displayed slightly decreased thrombus formation and stability. No 
statistically significant differences were observed for any thrombus formation parameters 
when compared with PBS-treated mouse arterioles (Figure 5.2B-F). At 6 minutes, the 
kinetics of surface coverage of platelets (kinetics of thrombus area) for imatinib-treated 
mice was 2493±256.7 versus 2648±85.2 µm
2 
(P>0.05; n=3) (Figure 5.2B). The kinetics of 
thrombus volume in imatinib-treated mice were 28608±5319 versus 37802±3973 µm
3
 
(P>0.05; n=3) (Figure 5.2D). However, the kinetics of thrombus area at 6 minute revealed 
a significant increase in nilotinib-treated mice arterioles compared those of the control 
(4033±32.8 versus 2648±85.2 µm
2
; *P<0.05; n=3) (Figure 5.2B). Similarly, mice treated 
with nilotinib exhibited a significant increase in the kinetics of thrombus volume at 6 
minutes when compared to the control (64600±3457 versus 37802±3973 µm
3
; *P<0.05; 
n=3) (Figure 5.2D). Nevertheless, significant inhibition was observed in the kinetics of 
thrombus area (1838±144.9 versus 2648±85.2 µm
2
; *P<0.05; n=3) (Figure 5.2B) and the 
thrombus volume (15495±3717 versus 37802±3973 µm
3
; *P<0.05; n=3) (Figure 5.2D) at 6 
minutes in mice treated with 5 mg/kg dasatinib compared to the wild-type control. 
Additionally, thrombus height was smaller in dasatinib-treated mice than in the control at 6 
minutes (8.94±1.05 versus 14.22±1.17 µm; *P<0.05; n=3) (Figure 5.2C). Overall, changes 
were observed in the kinetics of thrombus height for mice treated with either imatinib or 
nilotinib, but no significant differences were observed when compared to the PBS control 
(Figure 5.2C). 
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The percentage of vessel occlusion in nilotinib-treated mice arterioles was greater 
(55.00±2.30% versus 42.33±2.84%; *P<0.05; n=3) (Figure 5.3A) and the stability score of 
thrombi formed was higher (6.05±0.24 versus 4.66±0.33; *P<0.05; n=3) than the control 
(Figure 5.3B). The dasatinib-treated mice, when compared to the control, also had a 
significantly decreased percentage of vessel occlusion (19.16±3.94% versus 42.33±2.84%; 
*P<0.05; n=3) (Figure 5.3A) and thrombus stability score (2.94±0.24 versus 4.66±0.33; 
*P<0.05; n=3) (Figure 5.3B). Less stable thrombi were formed in imatinib-treated mice 
arterioles over 6 minutes (34.80±1.89 versus 42.33±2.84; P>0.05; n=3) (Figure 5.3A) 
which corresponded to less vessel occlusion when compared to control mice (3.86±0.13 
versus 4.66±0.33; P>0.05; n=3) (Figure 5.3B).  
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Figure ‎5.2. Assessment of in vivo thrombus growth in FeCl3 induced vascular injury of  mesenteric 
arterioles of TKI-treated mice following a single acute dose after four hours. (A) Representative images 
of thrombus formation in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% (w/v) 
FeCl3-induced vascular injury in imatinib (25 mg/kg), nilotinib (25 mg/kg), dasatinib (5 mg/kg) or PBS 
(control) treated mice at four hours. All microvessels are viewed at 200x magnification, and images acquired 
at a 1280x1024 pixel array using Axiovision Rel 4.6 version software attached to an Axiovert 135 M1 
microscope (Carl Zeiss). (B-D) Quantitative analysis of arterial thrombogenesis of TKI-treated mice. (B) The 
kinetics of thrombus area in (µm
2
), (C) the kinetics of thrombus height (µm) and (D) the kinetics of 
thrombus volume (µm
3
) were analysed in real time for thrombi formed in mesenteric arterioles of various 
TKI-treated mice after four hours. Compared to WT+PBS, nilotinib-treated arterioles exhibited significantly 
increased thrombus area and volume. In contrast, dasatinib-treated arterioles showed significantly reduced 
thrombus area and volume over time. Each data point demonstrated on the graph represents an average of 
three vessels examined per mouse. These results are expressed as mean±SEM from at least three independent 
experiments performed (*P<0.05 and **P<0.01; n=3 mice/group). 
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Figure ‎5.3. Assessment of in vivo thrombus stability in FeCl3 induced vascular injury of  mesenteric 
arterioles of TKI-treated mice following a single acute dose after four hours. Thrombus stability was 
monitored in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% (w/v) FeCl3-induced 
vascular injury in imatinib (25 mg/kg), nilotinib (25 mg/kg) dasatinib (5 mg/kg) or PBS (control) treated 
mice at four hours. All microvessels are viewed at 200x magnification, and images acquired at a 1280x1024 
pixel array using Axiovision Rel 4.6 version software attached to an Axiovert 135 M1 microscope (Carl 
Zeiss). (A) The percentage (%) of vessel occlusion and (B) and the initial stability of thrombi formed in TKI-
treated arterioles was scored from 1 to 10, with 1 being 0% to 10% occupancy and 10 being 91% occupancy 
(ie, complete occlusion of vessel) observed over time. Compared to WT+PBS, nilotinib-treated arterioles 
exhibited increased thrombus growth and % vessel occlusion with greater stability in thrombi formed over 
time. In contrast, dasatinib-treated arterioles showed significantly reduced thrombus area and volume and % 
vessel occlusion with lower stability in the thrombi formed. Each data point demonstrated on the graph 
represents an average of three vessels examined per mouse. These results are expressed as mean±SEM from 
at least three independent experiments performed (*P<0.05 and **P<0.01; n=3 mice/group). 
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As shown in the current study, a single dose of various TKIs had varied influences on 
thrombus growth and stability in vivo after four hours in wild type mice. Thrombus 
formation and stability characteristics of C57BL/6 mice arterioles were also examined 48 
hours after treatment with 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or 
PBS. Interestingly, representative real time images clearly demonstrated that mice treated 
with TKIs (imatinib, nilotinib or dasatinib) had no effect on in vivo thrombus formation at 
all time points after 48 hours of treatment (Figure 5.4A). Furthermore, thrombus growth 
parameters, such as the kinetics of thrombus area (Figure 5.4B), thrombus height (Figure 
5.4C), thrombus volume (Figure 5.4D), percentage of vessel occlusion (Figure 5.5A) and 
stability score (Figure 5.5B) were measured and demonstrated that the TKIs had no 
detectable effect after 48 hours following treatment. These results suggested that these 
drugs reversibly affect platelet function and thrombus formation. Taken together, these 
data indicate that a single dose of nilotinib after four hours of treatment has a potentiating 
effect on in vivo thrombus growth and stability in real time. In contrast, single doses of 
dasatinib have inhibitory roles on thrombus formation over time. Imatinib also showed 
partial activity as an inhibitory modulator on in vivo thrombus growth in C57BL/6 mouse 
mesenteric arterioles. 
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Figure ‎5.4. Assessment of in vivo thrombus growth in FeCl3 induced vascular injury of  mesenteric 
arterioles of TKI-treated mice following a single acute dose after 48 hours. (A) Representative images of 
thrombus formation in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% (w/v) FeCl3-
induced vascular injury in imatinib (25 mg/kg), nilotinib (25 mg/kg), dasatinib (5 mg/kg) or PBS (control) 
treated mice at 48 hours. All microvessels are viewed at 200x magnification, and images acquired at a 
1280x1024 pixel array using Axiovision Rel 4.6 version software attached to an Axiovert 135 M1 
microscope (Carl Zeiss). (B-D) Quantitative analysis of arterial thrombogenesis of TKI-treated mice. (B) The 
kinetics of thrombus area (µm
2
), (C) the kinetics of thrombus height (µm) and (D) the kinetics of thrombus 
volume (µm
3
) were analysed in real time as thrombi formed in mesenteric arterioles of various TKI-treated 
mice after 48 hours. Compared to WT+PBS, thrombus formation in TKI-treated arterioles was equivalent in 
real time after 48 hours of treatment. Each data point demonstrated on the graph represents an average of 
three vessels examined per mouse. These results are expressed as mean±SEM from at least three independent 
experiments performed. (n=3 mice/group). 
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Figure ‎5.5. Assessment of in vivo thrombus stability in FeCl3 induced vascular injury of  mesenteric 
arterioles of TKI-treated mice following a single acute dose after 48 hours. Thrombus stability was 
monitored in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% (w/v) FeCl3-induced 
vascular injury in imatinib (25 mg/kg), nilotinib (25 mg/kg), dasatinib (5 mg/kg) or PBS (control) treated 
mice at 48 hours. All microvessels are viewed at 200x magnification, and images acquired at a 1280x1024 
pixel array using Axiovision Rel 4.6 version software attached to an Axiovert 135 M1 microscope (Carl 
Zeiss). (A) The percentage (%) of vessel occlusion and (B) and the initial stability of thrombi formed in TKI-
treated arterioles was scored from 1 to 10, with 1 being 0% to 10% occupancy and 10 being 91% occupancy 
(ie, complete occlusion of vessel) observed over time. Compared to WT+PBS, thrombus formation in TKI-
treated arterioles was reversible after 48 hours of treatment. Each data point demonstrated on the graph 
represents an average of three vessels examined per mouse. These results are expressed as mean±SEM from 
at least three independent experiments performed. (n=3 mice/group). 
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5.2.3 Evaluation of arterial thrombosis formation and time to vessel occlusion in 
TKI-treated C57BL/6 mice through FeCl3-induced vascular injury of the 
carotid arteries 
Mice treated with a single dose of nilotinib exhibited larger and more stable thrombi in 
vivo following FeCl3-induced injury of the mesenteric arterioles, whilst those treated with 
imatinib and dasatinib displayed smaller and fewer thrombi compared to control mice. The 
possibilities that nilotinib has comparable prothrombotic phenotypes, and that imatinib and 
dasatinib can inhibit thrombus formation in vivo were determined by measuring the time to 
achieve 95% vessel occlusion in real time. In this model, platelet recruitment and adhesion 
to form thrombi at injured sites is initiated by FeCl3-induced vascular injury of the carotid 
artery and observed using a laser Doppler flow probe. As shown in Figures 6A-E, the 
mean time to reach >95% vessel occlusion four hours after  nilotinib-treatment (25 mg/kg) 
of C57BL/6 mice was 446.92±19.71 seconds, which was significantly shorter than the time 
observed for imatinib-treated (25 mg/kg) (649.36±26.37 seconds) or PBS-treated 
(587.54±27.32 seconds) C57BL/6 mice. In contrast, the time was significantly prolonged 
in dasatinib-treated (1272.56±59.89 seconds) versus PBS-treated (587.54±27.32 seconds) 
C57BL/6 mice. These results suggest that a single acute dose of nilotinib can potentiate 
carotid artery vessel occlusion, whereas imatinib and dasatinib reduced vessel occlusion in 
vivo. 
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Figure ‎5.6. Examination of thrombus formation in the injured carotid artery in TKI-treated C57BL/6 
mice. (A-D) Representative graphs of blood flow restriction in the carotid artery due to thrombus formation 
following 20% (w/v) FeCl3-induced injury. (A) PBS-treated mice, (B) imatinib-treated mice, (C) nilotinib-
treated mice and (D) dasatinib-treated mice. The vertical lines indicate the time when the carotid artery 
reached 95% occlusion, and the arrows indicate when FeCl3 injury was initiated. (E) Time to 95% carotid 
occlusion was determined from the initiation of FeCl3-induced injury in various TKI-treated mice. Each 
symbol represents one mouse, and all mice were sex-matched and weight-matched (20±2g). Data represent 
as mean±SEM and are representative of n=6 mice/group *P<0.05 and ***P<0.001. 
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5.2.4 Examination of thrombus formation in mice treated with P-selectin blocking 
antibody following FeCl3-induced injury of the mesenteric arterioles in 
nilotinib-treated mice 
As presented in this thesis, nilotinib activates platelets and endothelium in vivo, leading to 
P-selectin exocytosis from alpha granules in activated platelets and from Weibel-Palade 
bodies in endothelial cells, which contribute to the occurrence of prothrombotic events. 
The possibility that nilotinib contributes to P-selectin-dependent rolling was investigated 
by pretreatment of the C57BL/6 mice with anti-P-selectin blocking antibody (RP40.34; 
100 µg/mouse) or isotype control antibody (100 µg/mouse). After one hour of treatment, 
the mice were treated with 25 mg/kg nilotinib or PBS for four hours prior to surgery. In 
this model, the FeCl3-induced vascular injury of mesenteric arterioles was used for mice 
treated with blocking anti-P-selectin antibody and with isotype antibody to trigger 
thrombus formation in vivo. Thrombus growth and stability characteristics were examined 
in real time by measuring fluorescently labelled platelets bound to damaged endothelium. 
The Z-stack images were deconvolved and observed with a Zeiss Axiovert 135 M1 
microscope and Axiovision Rel4.6 version software. Thrombus characteristics, including 
thrombus area, thrombus height, thrombus volume, percentage of vessel occlusion and 
stability score, were assessed. As shown in Figure 5.7A, smaller thrombi formed in 
arterioles of mice treated with 25 mg/kg nilotinib and injected with P-selectin blocking 
antibody than in the controls (nilotinib-treated mice and mice treated with isotype control) 
after ten minutes. Nevertheless, the mice treated with nilotinib and P-selectin blocking 
antibody showed increased thrombus growth when compared with mice treated with P-
selectin blocking antibody alone. 
As shown in Figure 5.7A-D and Figure 5.8A-B, real time Z-stack analysis of in vivo 
thrombus formation showed an approximately three-fold smaller thrombus growth and 
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stability in mice treated with P-selectin blocking antibody without nilotinib compared to 
mice treated with the isotype control antibody without nilotinib at each time point over 4 
minutes. By contrast, arterioles of mice treated with nilotinib in the presence of anti-P-
selectin blocking antibody displayed a two-fold smaller thrombus formation and stability 
over 6 minute when compared to isotype control-treated mice treated with nilotinib. Figure 
5.7B shows that the kinetics of thrombus area were diminished in mouse arterioles treated 
with nilotinib and P-selectin blocking antibody when compared to isotype control-treated 
mice treated with nilotinib (4268±415.1 versus 2946±30.8 µm
2
; *P<0.05; n=3). Similarly, 
the kinetics of thrombus height in mouse arterioles treated with nilotinib and P-selectin 
blocking antibody was reduced over time when compared to isotype control-treated mice 
treated with nilotinib (14.66±0.38 versus 17.55±0.44 µm; *P<0.05; n=3) (Figure 5.7C). 
Figure 5.7D shows a significant inhibition of the kinetics of thrombus volume in arterioles 
of mice treated with nilotinib and P-selectin blocking antibody when compared to isotype 
control-treated mice treated with nilotinib (64770±8141 versus 43282±848 µm
3
; *P<0.05; 
n=3) and the vessels were also less occluded by thrombi (59.66±4.70 versus 35.23±2.28; 
*P<0.05; n=3) (Figure 5.8A). Mice treated with P-selectin blocking antibody and nilotinib 
also showed significantly decreased thrombus stability compared to the sham control 
(3.99±0.93 versus 6.33±0.33; *P<0.05; n=3) (Figure 5.8B).  
Figures 5.7A-D and Figures 5.8A-B show that larger and more stable thrombi were formed 
over ten minutes in arterioles of mice treated with nilotinib and P-selectin blocking 
antibody compared to mice treated with the antibody alone. At 6 minutes, the kinetics of 
the thrombus area, height and volume were apparently unaffected by the presence of 
nilotinib in mice treated with P-selectin blocking antibody and no statistically significant 
differences were noted. At 8 minutes, the kinetics of thrombus area showed greater 
thrombus production in arterioles of nilotinib-treated mice than in mice treated with P-
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selectin blocking antibody alone (2946±30.8 versus 2318±47.7 µm
2
; *P<0.05; n=3) 
(Figure 5.7B). Similarly, the kinetics of thrombus volume were also significantly faster in 
arterioles from mice treated with nilotinib and P-selectin blocking antibody compared to 
controls (43282±848 versus 26671±895 µm
3
; *P<0.05; n=3) (Figure 5.7D) and the 
percentage of vessel occlusion was also greater (35.23±2.28% versus 25.06±1.88%; 
*P<0.05; n=3) (Figure 5.8A). The stability score was also higher for thrombi in mice 
treated with nilotinib and P-selectin blocking antibody than in the control mice (3.99±0.93 
versus 3.22±0.11; *P<0.05; n=3) (Figure 5.8B). Overall, these findings indicate that 
nilotinib activates platelets and endothelium, leading to P-selectin exposure and 
participation in prothrombotic development. However, nilotinib treatment may promote 
platelet activation and thrombus formation through multiple pathways. 
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Figure ‎5.7. Examination of in vivo thrombus growth in FeCl3 induced vascular injury of  mesenteric 
arterioles of nilotinib-treated mice following a single injection of P-selectin blocking antibody. (A) 
Representative images of thrombus formation in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes 
after vascular injury was induced with 7.5% (w/v) FeCl3 for one hour in P-selectin blocking antibody-treated 
mice that were subsequently treated with nilotinib (25 mg/kg). Surgery was performed four hours post-
treatment to gain access to microvessels. All microvessels are viewed at 200x magnification, and images 
acquired at a 1280x1024 pixel array using Axiovision Rel 4.6 version software attached to an Axiovert 135 
M1 microscope (Carl Zeiss). (B-D) Quantitative analysis of arterial thrombogenesis of TKI-treated mice. (B) 
The kinetics of thrombus area (µm
2
), (C) the kinetics of thrombus height (µm) and (D) the kinetics of 
thrombus volume (µm
3
) were analysed in real time for thrombi formed in mesenteric arterioles of nilotinib-
treated mice. Each data point demonstrated on the graph represents an average of three vessels examined per 
mouse. These results are expressed as mean±SEM from at least three independent experiments performed 
(*P<0.05 and **P<0.01; n=3 mice/group). 
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Figure ‎5.8. Examination of thrombus stability in FeCl3 injured mesenteric arterioles of nilotinib-
treated mice following a single injection of anti-P-selectin mAb. Thrombus stability was monitored in 
mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after vascular injury was induced with 7.5% 
(w/v) FeCl3 for 1 hour in P-selectin blocking antibody-treated mice that were subsequently treated with 
nilotinib (25 mg/kg). Surgery was performed four hours post-treatment to gain access to microvessels. All 
microvessels are viewed at 200x magnification, and images acquired at a 1280x1024 pixel array using 
Axiovision Rel 4.6 version software attached to an an Axiovert 135 M1 microscope (Carl Zeiss). (A) The 
percentage (%) of vessel occlusion and (B) and the initial stability of thrombi formed in nilotinib-treated 
arterioles was scored from 1 to 10, with 1 being 0% to 10% occupancy and 10 being 91% occupancy (i.e, 
complete occlusion of vessel) observed over time. Each data point demonstrated on the graph represents an 
average of three vessels examined per mouse. These results are expressed as mean±SEM from at least three 
independent experiments performed (**P<0.01; n=3 mice/group). NS: Not statistically significant. 
 
 
 
 
 
 
 
  
 191  
5.3 DISCUSSION 
An emerging subject in recent TKI research is the observation that TKIs have differential 
impacts on platelet thrombus formation. Several clinical studies have indicated that 
nilotinib may have a direct effect on vasospasm of blood vessels and initiate PAOD events 
over time. However, no further direct evidence has demonstrated a role for nilotinib 
treatment in modulating pathological thrombus development [392-394, 420]. In this 
Chapter, a variety of methods were applied to investigate the formation and stability of 
platelet thrombi formed in C57BL/6 mice treated with a single acute dose of nilotinib (25 
mg/kg), imatinib (25 mg/kg), dasatinib (5 mg/kg) or PBS (sham control). This included 
examining platelet thrombus formation following FeCl3-induced vascular injury in either 
mesenteric arterioles (80-100 µm in diameter) or in the carotid artery. Using intravital 
microscopy to FeCl3-induced injury of mesenteric arterioles or carotid artery, we have 
demonstrated for the first time that thrombi in mice treated with nilotinib are greater and 
more stable in vivo over time. We and others [399] have demonstrated that dasatinib-
treated mice produced smaller and less stable thrombi providing evidence that dasatinib 
has potent inhibitory effect on platelet thrombus growth in vivo. In this study, smaller and 
less stable thrombi generated were observed in mouse arterioles treated with imatinib. 
Furthermore, this single acute dose effect of TKIs was reversible after 48 hours following 
treatment. Importantly, the dosing of mice with nilotinib (25 mg/kg), imatinib (25 mg/kg) 
or dasatinib (5 mg/kg) correlated with equivalent dosing used to treat human CML 
patients. 
In this Chapter, the influence of TKI treatments on modulating in endothelial or platelet-
mediated haemostasis in vivo was examined by conducting tail bleeding assays. Compared 
with control mice, C57BL/6 mice treated with either nilotinib or imatinib showed 
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unaffected in tail bleeding times and volume of blood loss and no statistically significant 
differences were observed (Figure 5.1A and B). However, a previous study emphasised 
that dasatinib-treated wild-type mice showed dose-dependent increases in bleeding times 
over four hours, which corresponds to increased volumes of blood lost. This effect was 
reversed 48 hours after ingestion, suggesting that dasatinib has a reversible effect on 
platelet function in vivo and its effect rapidly dissipates after discontinuation of the drug 
[399]. These findings suggest the possibility that a single acute dose of a TKI (imatinib or 
nilotinib) had no effect on primary haemostasis due to underlying platelet or vascular 
endothelium. Nevertheless, a potential effect of nilotinib is still expected on in vivo 
platelet-platelet interactions and/or platelet-endothelium interactions.  
As described in Chapter four, TKIs have direct effect on platelet thrombus growth under 
arterial shear rate, where nilotinib-treated mice induced ex vivo larger and more stable 
thrombi on type I collagen, while imatinib and dasatinib acted as inhibitors of thrombus 
formation. Nevertheless, the physiological characteristics of these TKI phenotypes on the 
in vivo platelet aggregation and thrombus formation in response to vascular injury have not 
been ascertained. In in vivo models, FeCl3 was added to ablate the endothelium and induces 
extensive injury to blood vessels (e.g. the mesenteric arterioles and carotid artery), leading 
to exposure to thrombogenic ECM substances, including type I collagen. In addition, 
FeCl3 oxidises haemoglobin, resulting in erythrocyte haemolysis which further required for 
endothelium denudation and leads to exposure of ECM molecules such as collagen [411]. 
At sites of vascular injury, platelets in blood circulation will tether and adhere to 
subendothelial collagen by binding with their receptors (the GPVI and GPIb-IX-V 
complexes) expressed on the platelet surface membrane, thereby recruiting platelet 
adhesion, activation followed promotion of platelet aggregation and thrombus growth 
[409]. In fact, dysfunction of endothelial cells is well known to play a significant role in 
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the development of arterial thrombosis and is distinguished by disturbed platelet function, 
recruited leukocyte adhesion and promotion of the initiation of proinflammatory mediators 
[490]. Upon platelet stimulation, several adhesive proteins, such as P-selectin [224, 425] 
and CD40L [208, 242] are produced which amplify platelet activation and contribute to 
arterial thrombus formation in vivo.  
Using intravital microscopy in this study, the extent of FeCl3-induced injury of mesenteric 
arterioles in terms of thrombus formation and stability was enhanced in nilotinib treated 
mice compared to sham control (Figure 5.2A-D and Figure 5.3A-B) providing evidence 
that nilotinib may upregulate platelet-endothelium interaction and thrombus formation in 
vivo. However, FeCl3-induced vascular injury led to reduced thrombus growth and less 
stability among mice treated with imatinib than in sham control, although the differences 
were not statistically significant (Figure 5.2A-D and Figure 5.3A-B). As expected, the 
thrombi in dasatinib-treated mice were smaller and less stable than in the sham control 
group following FeCl3-induced injury of mesenteric arterioles (Figure 5.2A-D and Figure 
5.3A-B). This result is consistent with previous observation where showed that dasatinib 
inhibited platelet thrombus growth ex vivo and in vivo through inhibition of SFKs and 
impaired ITAM-mediated platelet signalling pathways [399]. Based on the presented data, 
it could be highlighted that nilotinib but not imatinib or dasatinib may initiate endothelial 
dysfunction which plays a key role in arterial thrombus growth, dysregulated platelet 
adhesion, enhanced rolling of circulating monocytes and neutrophils and generation of 
inflammatory protein mediators [490].  
In vivo, 48 hours after ingestion, the effect of a single dose of nilotinib, imatinib or 
dasatinib on thrombus formation was reversed in FeCl3-induced vascular injury of 
mesenteric arterioles when compared to sham control over time (Figure 5.4A-D). 
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Additionally, Figure 5.5A-B shows that the stable phenotypes of thrombi formed in vivo 
were equivalent between mice treated with imatinib, nilotinib or dasatinib and the sham 
control. Gratacap et al. [399] stated that the tail bleeding times of mice treated with a range 
(1.25-5 mg/kg) of dasatinib TKI was dose-dependently diminished after 24 hours 
compared to 4 hours after ingestion, while the effect of dasatinib on in vivo primary 
haemostasis was no longer noticed 48 hours following treatment. Moreover, the same 
group showed that the effect of a single dose of dasatinib (5 mg/kg) resulted in 
undetectable ex vivo thrombus formation over immobilised type I collagen under arterial 
shear conditions 48 hours after ingestion. Taken together, these findings are consistent 
with the current results that showed rapid reversibility of the effects of imatinib, nilotinib 
and dasatinib on in vivo platelet thrombus growth, suggesting that the pharmacokinetics of 
imatinib [350, 351], nilotinib [365, 491] and dasatinib  are in agreement with the observed 
quick reversibility of their influence. Imatinib and nilotinib reach in peak plasma 
concentrations within approximately 3-5 hours after oral administration, with a half-life of 
approximately 15-20 hours [352, 364, 491, 492]. In contrast, the plasma half-life of 
dasatinib is shorter than TKIs with approximately 3-5 hours [371]. Future studies should 
be performed to test the chronic effect of TKIs on in vivo thrombus formation, to compare 
the effectiveness of these drugs on platelet aggregation and thrombus growth at different 
time points, including 24 hours following treatment using C57BL/6 mouse model. 
Nilotinib-mediated prothrombotic phenotype was confirmed by using an alternative in vivo 
experimental model involving a different vascular bed with a higher shear rate. The time 
taken to achieve >95% vessel occlusion in C57BL/6 mouse arterioles treated with a single 
dose of nilotinib, imatinib, dasatinib or PBS (control) was measured. This was followed by 
inducing FeCl3-induced injury of the carotid arteries that were monitored with a laser 
Doppler flow probe. As described in Figure 5.6C-E, the time taken to reach >95% vessel 
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occlusion was significantly shorter in nilotinib-treated mice four hours after treatment than 
observed in imatinib-treated mice or sham control. Whilst a trend towards prolongation of 
the mean time to 95% occlusion was reported in imatinib-treated mice, with no significant 
differences compared to the sham control. As predicted, treatment of mice with dasatinib 
caused a significant lengthening of the mean time to 95% vessel occlusion following 
FeCl3-induced injury of the carotid artery when compared with the sham control. The 
FeCl3-induced thrombosis initially occurs due to platelet recruitment at the site of vascular 
injury via interaction of circulating platelets with exposed subendothelial adhesive 
proteins, such as type I collagen and vWF, which bind to their receptors (the GPVI and 
GPIb-IX-V complexes, respectively) [161, 170]. These data are consistent with the above 
observations derived from the first experimental model representing that a single dose of 
nilotinib, but not imatinib or dasatinib, potentiated in vivo thrombus growth following 
FeCl3-induced injury of mesenteric arterioles. Taken together, the results suggest that 
nilotinib therapy contributes to the increase in platelet recruitment at sites of FeCl3-
induced vascular injury to promote progressive prothrombotic growth over time. In 
contrast, the treatment of mice with either imatinib or dasatinib would delay platelet 
aggregation at FeCl3-induced injury sites in vivo.  
The murine model used here is a well-established method for platelet-mediated thrombus 
formation. Once again, this study showed for the first time that nilotinib selectively 
enhanced in vivo prothrombotic phenotype in the context of blood vessels with diverse 
shear flow rates and vascular beds to examine both microvascular and arterial thrombosis. 
As shown in Chapter four, in the absence of exposed endothelial molecules, the in vitro 
thrombus growth with whole blood incubated with nilotinib did not demonstrate elevated 
thrombus growth over type I collagen (Figure 4.2A-C). Thus, the results suggest that the 
nilotinib mediated thrombus formation in vivo requires an intact vessel with presence of 
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endothelial cells to prime platelets over time. An interesting aspect of this study was that 
the induced prothrombotic state required pre-treatment of C57BL/6 mice until peak drug 
concentration (Cmax) was accomplished and the vessel wall and blood components primed. 
We would favour the potential mechanism of increased prothrombotic state during 
nilotinib therapy may be triggered through upregulated platelet-endothelial reactivity in 
vivo which leads to induced bioactive adhesive molecules and consequently promoted 
pathologic thrombosis. Future studies are required to examine the effects of either imatinib 
or nilotinib on primary haemostasis and vascular thrombus formation in chronic models at 
dose-dependent manner to identify their capacity to influence platelet function and 
endothelial cells in modulating prothrombotic states in vivo. 
As described in section 1.5.5.1, numerous studies have shown that increased surface 
expression of adhesive molecule (P-selectin) significantly promotes cardiovascular 
disorders including atherosclerosis, myocardial infarction and peripheral artery occlusive 
disease [211, 224, 447, 452]. P-selectin is now known to mediate arterial thrombus via 
recruiting and tethering both platelets and leukocytes onto activated endothelial cells 
through associations with its ligand on leukocytes (PSGL-1) [230, 478]. Furthermore, P-
selectin may also be implicated in the platelet-platelet interactions, which significantly 
promotes platelet aggregation and is a chief factor in arterial thrombosis [184, 224, 425]. 
Gross et al. [493] used FeCl3-induced vascular injury and intravital microscopy methods to 
show that P-selectin was initially expressed on the platelet surface at sites of vessel wall 
injury after FeCl3-induced arteriolar thrombus development in vivo. The wave of P-selectin 
expression was also documented after 3 minutes by the development of thrombi at sites of 
vascular injury, which suggested that the rolling leukocytes required a high density of P-
selectin expression to promote arterial thrombosis. This phenomenon may explain the 
current findings, which showed thrombi were significantly formed in nilotinib-treated mice 
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after 4 minutes following FeCl3-induced injury of mesenteric arterioles. Studies from other 
research groups demonstrated extensive expression of P-selectin on activated platelets in 
the injured endothelium, resulting in association with leukocytes in FeCl3-induced injury 
of the carotid artery and subsequent thrombus development [210]. Different research 
groups showed a reduction in atherosclerotic plaque development and inhibition in 
neointimal formation among P-selectin-deficient mice [211, 443, 494] or within mice 
injected with P-selectin blocking antibody (RB40.34) [495] due to lower platelet 
aggregation and less leukocyte recruitment to the denuded endothelial vascular wall. 
Further studies are required to elucidate the potential impact of nilotinib on the 
mechanisms of platelet and/or endothelial P-selectin with PSGL-1 on leukocytes.  
As described in Chapter three, nilotinib selectively potentiated platelet activation, as 
shown by increased PAR-1-mediated P-selectin expression in human platelets, and in 
Chapter four a single dose of nilotinib induced platelet activation in vivo through cleavage 
of P-selectin from platelets, with a corresponding increase in soluble P-selectin in mouse 
plasma. Drawing upon the basis of this thesis, it was of interest to characterise the role of a 
nilotinib regimen on thrombus formation in vivo in presence or absence of anti-P-selectin 
blocking antibody. The present study defined the association between nilotinib treatment 
and P-selectin expression in prothrombotic states. Figure 5.7A-D and Figure 5.8A-B 
showed that C57BL/6 mice treated with 25 mg/kg nilotinib and 100 µg of P-selectin 
blocking antibody followed by FeCl3-induced injury of mesenteric arterioles, had 
significantly attenuated thrombus formation and stability, approximately two-fold smaller 
when compared to nilotinib-treated and isotype-control treated mice arterioles at time 
points over 6 minutes. However, the thrombi formed were approximately two-fold larger 
and more stable in arterioles of mice treated with nilotinib and P-selectin blocking 
antibody compared to that treated with P-selectin blocking antibody alone. Compared to 
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mice treated with isotype control alone, thrombus growth and stability were significantly 
reduced in the P-selectin antibody-treated mice over time, by approximately three fold. P-
selectin is an important mediating factor that is intensively expressed and translocated on 
the activated platelet surface and activated endothelium to affect the integrity of the blood 
vessel wall and contribute to arterial thrombus formation in vivo [227, 425, 447].  
The observation of attenuating thrombus growth in nilotinib-treated mice that received P-
selectin blocking antibody suggested that nilotinib has a potential role in the development 
of prothrombotic states in vivo through the induction of P-selectin expression in platelets 
and/or endothelium. However, potentiating thrombi were formed in nilotinib-treated mice 
over time despite the antibody blockade of P-selectin which may indicate that nilotinib 
treatment induced atherogenesis by off targeting effects on multiple adhesive molecules 
apart from P-selectin. Thus, further studies are warranted to test the operative mechanisms 
of nilotinib in modulating thrombus formation through other important adhesive proteins. 
In conclusion, this Chapter has provided novel insights into the influence of TKIs on 
arteriolar thrombus formation in vivo using different models. Nilotinib selectively induced 
a prothrombotic state in vivo four hours after a single dose (Cmax) of the drug in the context 
of blood vessels with vascular beds. This included examining platelet thrombus formation 
following FeCl3-induced vascular injury in either mesenteric arterioles (80-100 µm in 
diameter) or in the carotid artery. This single dose effect was reversible after 48 hours 
following treatment. The defect in thrombus growth obviously occurs with imatinib but is 
significantly observed with dasatinib treatment following FeCl3-induced injury of either 
mesenteric arterioles or carotid artery in real time. Ultimately, prothrombotic states could 
be triggered by multiple mechanisms in response to nilotinib doses rather than by the P-
selectin molecule expressed on platelets and/or endothelium in vivo.   
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6 CHAPTER SIX: THE EFFECT OF TKIs ON PLATELET 
ACTIVATION AND THROMBUS FORMATION IN 
EITHER HEALTHY HUMAN OR CML PATIENTS 
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6.1 INTRODUCTION 
The triggering of arterial thrombotic events by the TKIs used for the treatment of CML 
patients is an emerging phenomenon in cardiovascular disease [496]. In recent years, both 
PAOD and myocardial infarction have been recurrently reported among CML patients 
treated with nilotinib, but not in those patients treated with imatinib or dasatinib [392, 394, 
420, 453]. A preliminary study by Aichberger et al. [392] reported that 12.5% of CP-CML 
patients developed PAOD during their nilotinib treatment. Different groups found that 
CML patients treated with nilotinib (400 mg BID) had an increased incidence of vascular 
adverse events and myocardial infarction when compared with a lower dose (300 mg BID) 
[400, 401]. Several prospective studies reported that patients with CML frequently 
experienced cardiovascular events, particularly PAOD, with a frequency of 6.1% (300 
BID) and 12.5% (400 BID) when on nilotinib therapy [392, 397]. Most subjects receiving 
nilotinib therapy were affected in their lower limbs and required angioplasty, stent 
implantation and/or even amputation [394]. In contrast, a frequency of lower to rare 
occurrence of prothrombotic events was reported for imatinib or dasatinib-treated patients 
when compared with a healthy population [394, 497]. Bleeding disorders are reported in 
around 40% of the patients treated with dasatinib but are less commonly seen during 
imatinib treatment [344, 388].  
During nilotinib-treatment, patients were frequently reported to have increased fasting 
glucose levels and had disturbed lipid profiles. The presence of concomitant conventional 
cardiovascular risk factors (including smoking, arterial hypertension, diabetes mellitus, 
dyslipidaemia, obesity and/or males aged >60 years) is, as expected, associated with 
metabolic disturbances, including altered lipid profiles and glucose parameters [392, 420]. 
In a clinical trial, designed to switch CP-CML patients from imatinib to nilotinib, those 
  
 201  
patients exhibited a pro-atherogenic phenotype with hypercholesterolemia and augmented 
LDL, as well as an elevated risk in vascular events [498].  
Arterial thrombosis is one of the most common causes of health issues and even death 
worldwide [9]. It arises as a consequence of ruptured atherosclerotic lesions, resulting in 
recruitment of plaque development and platelet aggregation due to exposed thrombogenic 
proteins in the presence of oxidised lipid deposits at sites of atherosclerotic lesions [9, 
158]. Platelet activation plays an essential role in thrombus growth. This is mainly due to 
the ability of platelets to adhere to and aggregate with injured endothelium under arterial 
shear conditions [10, 160]. In the early stages of atherosclerotic plaque formation, the 
platelets initiate and adhere to exposed ECM constituents (e.g. collagen, vWF and soluble 
agonists); thereby progressively inducing local thrombus growth within the vascular walls, 
followed by activation of the coagulation cascade that results in amplification of arterial 
thrombosis [484, 499]. Several studies have shown that treatment of leukaemia patients 
with anti-cancer therapies is associated with altered platelet function including increased 
platelet aggregation and formation of pathologic thrombi [464, 465].  
The data from clinical trials thus far proposes that nilotinib may have specific additional 
prothrombotic/atherogenic effects that are not observed with other TKIs. However, data 
suggest that the increased risk is not entirely explained by an adverse vascular risk profile 
as events also occur unexpectedly in patients with low-risk profiles [394, 400, 420]. To our 
knowledge, the findings in this thesis provide the first demonstration of the potential effect 
of nilotinib on platelet activation and thrombus formation in both ex vivo and in vivo 
thrombus formation in the presence of endothelium in whole blood components of a 
murine C57BL/6 model. Other studies [388, 399] in addition to ours have shown an 
inhibitory influence of either imatinib or dasatinib on platelet activation, aggregation and 
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thrombus growth in both human and mouse models. This study focuses on the assessment 
of nilotinib and other TKIs on platelet and endothelial activation, thrombus formation, 
PLAs and coagulation activity in both healthy humans and CML patients in order to 
determine the ability of TKIs to induce or inhibit the prothrombotic state. 
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6.2 RESULTS 
6.2.1 Assessment of platelet thrombus growth in TKI-treated normal human whole 
blood over type I collagen under in vitro arterial flow conditions 
In order we examined the dose-dependent of TKIs on in vitro platelet thrombus formation 
in whole blood samples of healthy humans, as described in section 2.2.6. Citrated whole 
blood was treated with imatinib (1, 5 and 10 µM), nilotinib (1, 5 and 10 µM) or dasatinib 
(0.05, 0.1 and 1 µM) for 10 minutes at 37
o
C. Whole blood containing rhodamine 6G 
fluorescently labelled platelets [untreated whole blood or whole blood treated with 
imatinib (1, 5 and 10 µM), nilotinib (1, 5 and 10 µM) or dasatinib (0.05, 0.1 and 1 µM)] 
was perfused through a collagen-coated microcapillary tube flow chamber at an arterial 
shear rate of 1800
-1
 seconds. After six minutes of sample perfusion, thrombus images for 
imatinib, nilotinib and dasatinib-treated whole blood were recorded and determined in real 
time (Figure 6.1A, Figure 6.2A and Figure 6.3A, respectively). Deconvolved Z-stack 
images of thrombi recorded in real time were analysed for thrombus parameters including 
thrombus area, thrombus height and thrombus volume in the TKI-treated whole blood 
samples. As shown in Figure 6.1A-C, imatinib-treated whole blood displayed no 
significant differences in terms of thrombus surface area, thrombus height and thrombus 
volume when compared to untreated whole blood at any imatinib concentration. Similarly, 
whole blood treated with nilotinib showed a negligible difference in in vitro thrombus 
growth over type I collagen and the area covered by platelet thrombi and the thrombus 
volume were similar to those observed for untreated control blood (Figure 6.2A-C). As 
shown in Figure 6.3A-C, dasatinib significantly diminished the development of thrombus 
growth over type I collagen under arterial conditions and the thrombus area and thrombus 
volume were notably smaller when compared to thrombi formed by untreated control 
blood. These results are consistent with our observations reported in Chapter four, where 
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whole blood from C57BL/6 mice treated with either imatinib or nilotinib showed 
negligible differences in in vitro thrombus formation on immobilised type I collagen under 
physiological flow at all doses tested while dasatinib-treated wild-type mouse blood 
formed much smaller thrombi when compared to control blood. 
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Figure ‎6.1. The effect of imatinib on in vitro human thrombus formation and growth. (A-C) 
Fluorescently-labelled platelets in whole blood (platelet count normalised to 250×10
9
/L) of normal human 
donors in the presence of 1 µM, 5 µM or 10 µM imatinib was perfused over 500 µg/mL type I collagen 
matrix under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-stack images were captured over 6 
minutes duration with a digital Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision 
Rel4.6 software. Three dimensional (3D) deconvolved reconstructions of thrombi formed were analysed for 
surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume (µm
3
). (A) 
Representative images of thrombus formation over type I collagen under arterial flow conditions for normal 
human whole blood treated with imatinib 1 µM, 5 µM or 10 µM versus normal control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised in type I 
collagen flow perfused with whole blood from normal human treated with imatinib. (C) Thrombus volume 
(µm
3
) over time was calculated from thrombus area (µm
2
)×thrombus height (µm) for whole blood treated 
with imatinib or PBS. Results shown are mean±SEM from 5 independent experiments (P>0.05; n=5). 
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Figure ‎6.2. The effect of nilotinib on in vitro human thrombus formation and growth. (A-C) 
Fluorescently-labelled platelets in whole blood (platelet count normalised to 250×10
9
/L) of normal human 
donors in the presence of 1 µM, 5 µM or 10 µM nilotinib was perfused over 500 µg/mL type I collagen 
matrix under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-stack images were captured over 6 
minutes duration with a digital Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision 
Rel4.6 software. Three dimensional (3D) deconvolved reconstructions of thrombi formed were analysed for 
surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume (µm
3
). (A) 
Representative images of thrombus formation over type I collagen under arterial flow conditions for normal 
human whole blood treated with nilotinib 1 µM, 5 µM or 10 µM versus normal control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised in type I 
collagen flow perfused with whole blood from normal human treated with nilotinib. (C) Thrombus volume 
(µm
3
) over time was calculated from thrombus area (µm
2
)×thrombus height (µm) for whole blood treated 
with imatinib or PBS. Results shown are mean±SEM from 5 independent experiments (P>0.05; n=5). 
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Figure ‎6.3. The effect of dasatinib on in vitro human thrombus formation and growth. (A-C) 
Fluorescently-labelled platelets in whole blood (platelet count normalised to 250×10
9
/L) of normal human 
donors in the presence of 0.05 µM, 0.1 µM or 1 µM dasatinib was perfused over 500 µg/mL type I collagen 
matrix under arterial flow conditions at shear rate of 1800 seconds
-1
. Z-stack images were captured over 6 
minutes duration with a digital Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision 
Rel4.6 software. Three dimensional (3D) deconvolved reconstructions of thrombi formed were analysed for 
surface coverage of platelet aggregates (µm
2
), thrombus height (µm) and thrombus volume (µm
3
). (A) 
Representative images of thrombus formation over type I collagen under arterial flow conditions for normal 
human whole blood treated with dasatinib 0.05 µM, 0.1 µM or 1 µM versus normal control (PBS) over 6 
minutes. (B) Thrombus area (µm
2
) in real time was determined for thrombi formed on immobilised in type I 
collagen flow perfused with whole blood from normal human treated with dasatinib. (C) Thrombus volume 
(µm
3
) over time was calculated from thrombus area (µm
2
)×thrombus height (µm) for whole blood treated 
with imatinib or PBS. Results shown are mean±SEM from five independent experiments (*P<0.05 and 
**P<0.01; n=5). 
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6.2.2 Assessment of TKIs on platelet activation, endothelial cell and coagulation 
reactivity in CML patient samples 
The clinical characteristics of the CML patient treated with different TKIs (imatinib, 
nilotinib and dasatinib) are shown in Table 2.1. The drugs were administrated four hours 
prior to the collection of blood. Normal healthy donors were used, as all available TKI-
treated patients were in complete haematological remission. The data in this research 
project elucidated the differential effects of TKIs on platelet reactivity and endothelial 
interactions in C57BL/6 mice, where nilotinib treatment had potential effects on platelet 
activation and thrombus formation, while imatinib and dasatinib platelet function and 
thrombus growth in vitro, ex vivo and in vivo. Therefore, in this Chapter, it was of interest 
to investigate whether TKIs showed similar phenotypic effects on platelet function and 
thrombus formation in blood samples from CML patients. This approach was taken by 
conducting several assays, such as evaluating platelet thrombus growth under 
physiological flow conditions, determining platelet-leukocyte interactions, measuring 
soluble levels of P-selectin and CD40L and measuring thrombin generation. 
6.2.2.1 Assessment of platelet thrombus growth in nilotinib-treated CML patients 
on aspirin over type I collagen under arterial flow conditions 
In order to assess the effect of nilotinib on thrombus formation under arterial flow 
conditions in whole blood from CML patients treated with nilotinib and aspirin (100 
mg/day) or in whole blood from healthy donors who only received aspirin (100 mg/day). 
Rhodamine fluorescently labelled platelets in whole blood were perfused over a type I 
collagen matrix at an arterial shear rate of 1800s
-1
 over a 6 minute time frame and real time 
imaging was recorded. As shown in Figure 6.4A-C, blood from nilotinib-treated patients 
(who were also on aspirin) formed larger thrombi over time compared to blood from 
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healthy donors on aspirin only. At the 4 minute time point, the surface coverage of 
platelets (503±56.9 versus 362±15.5 µm
2
; *P<0.05; n=5) (Figure 6.4B) and the thrombus 
volume (3220±567 versus 2100±114 µm
3
; *P<0.05; n=5) (Figure 6.4C) were significantly 
increased in the nilotinib-treated patients. Overall, platelet adhesion over immobilised type 
I fibrillar collagen under physiologic flow shear conditions revealed that nilotinib 
potentiated ex vivo platelet thrombus growth under arterial shear stress conditions.  
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Figure ‎6.4. The effect of nilotinib-treated patients received aspirin on ex vivo thrombus formation and 
growth. Venous blood obtained from normal human donors or patients treated with nilotinib and aspirin 
(ASP) for 4 hours prior blood collection. Platelet count was normalised to 200×10
9
/L, or run the blood 
sample when platelet count below 200×10
9
/L. (A-C) Fluorescently-labelled platelets in whole blood from 
normal human donors or patients treated with nilotinib+aspirin passed through a collagen-coated 
microcapillary (500 µg/mL) at a shear rate of 1800s
-1
 for 6 minutes. Z-stack images were captured in real 
time with a digital Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision Rel4.6 software. 
3D deconvolved reconstructions of thrombi formed were analysed for surface coverage of platelet aggregates 
(µm
2
), thrombus height (µm) and thrombus volume (µm
3
). (A) Representative images of platelet adhesion 
from control+aspirin and patient’s treated with nilotinib+ daily 100 mg aspirin. (B) Thrombus area (µm2) in 
real time was determined for thrombi formed on immobilised in type I collagen flow perfused with whole 
blood from normal control or patients treated with nilotinib+aspirin. (C) Thrombus volume (µm
3
) over time 
was calculated from thrombus area (µm
2
)×thrombus height (µm) and determined at 2,4,6 minute time points 
for control+aspirin and nilotinib-treated patients+aspirin. Results shown are mean±SEM from five 
independent experiments. (*P<0.05; n=5). 
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6.2.2.2 Assessment of platelet thrombus growth in TKI-treated CML patients 
without aspirin therapy over type I collagen under arterial flow conditions 
We conducted this assay to investigate the effects of TKIs on human platelets by 
comparing thrombus growth under arterial shear conditions by whole blood derived from 
CML patients treated with TKIs (with no aspirin treatment) (Table 6.1) with blood from 
normal age matched healthy human donors (not on any antiplatelet or anticoagulant 
therapy). Rhodamine fluorescently labelled platelets in whole blood were perfused over 
type I collagen at an arterial shear rate of 1800s
-1
 over a 6 minute time frame and real time 
imaging recorded. As shown in Figure 6.5A-C, blood from nilotinib-treated patients 
formed larger thrombi over time compared to blood from normal donors and from 
imatinib-treated patients. A Z-stack analysis undertaken at 4 minutes of thrombus growth 
showed that the thrombus area of blood from nilotinib-treated patients was significantly 
larger (535±43.7 versus 404±16.3 µm
2
; *P<0.05; n=3) (Figure 6.5B) and thrombus volume 
was increased when compared to blood from healthy donors (4032± 398 versus 2308±204 
µm
3
; *P<0.05; n=3) (Figure 6.5C). By contrast, blood from patients treated with imatinib 
displayed a reduction in thrombus area (266±53.5 versus 404±16.3 µm
2
; *P<0.05; n=3) 
(Figure 6.5B), and in thrombus volume (1229±725 versus 2308±204 µm
3
; *P<0.05; n=3) 
(Figure 6.5C) when compared to the thrombi formed by blood from normal donors. Blood 
from dasatinib-treated patients showed decreased thrombus area (157±67.2 versus 
404±16.3 µm
2
; P<0.05; n=3) (Figure 6.5B), and thrombus volume (643±116 versus 
2308±204 µm
3
; *P<0.05; n=3) (Figure 6.5C) when compared to normal human donors, 
consistent with previous observations [399].  
Collectively, whole blood derived from nilotinib-treated patients showed a significant 
increase in thrombus growth under flow conditions, which provided strong evidence that 
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nilotinib treatment leads to an increased thrombus growth phenotype. By contrast, imatinib 
or dasatinib inhibited thrombus formation over immobilised type I collagen under ex vivo 
arterial flow shear. Taken together, these results indicate that the prothrombotic 
consequence of nilotinib treatment of patients requires the presence of the endothelium and 
priming of the platelets in vivo. 
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Figure ‎6.5. The effect of TKI-treated patients without aspirin therapy on ex vivo thrombus formation 
and growth. Venous blood obtained from normal human donors or patients treated with nilotinib, imatinib 
or dasatinib for 4 hours prior to blood collection. Platelet count was normalised to 200×10
9
/L, or run the 
blood sample when platelet count below 200×10
9
/L. (A-C) Fluorescently-labelled platelets in whole blood 
from normal human donors or patients treated with nilotinib, imatinib or dasatinib were through a collagen-
coated microcapillary (500 µg/mL) at a shear rate of 1800s
-1
 for 6 minutes. Z-stack images were captured in 
real time with a digital Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision Rel4.6 
software. 3D deconvolved reconstructions of thrombi formed were analysed for surface coverage of platelet 
aggregates (µm
2
), thrombus height (µm) and thrombus volume (µm
3
). (A) Representative images of platelet 
adhesion from control, nilotinib, imagine or dasatinib. (B) Thrombus area (µm
2
) in real time was determined 
for thrombi formed on immobilised in type I collagen flow perfused with whole blood from normal control, 
nilotinib, imatinib or dasatinib. (C) Thrombus volume (µm
3
) over time was calculated from thrombus area 
(µm
2
)×thrombus height (µm) and determined at 2, 4, 6 minute time points for control, nilotinib, imatinib or 
dasatinib. Results shown are mean±SEM from three independent experiments. (*P<0.05, , **P<0.01 and 
***P>0.001; n=3). 
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6.2.3 Analysis of platelet-leukocyte aggregate formation 
This assay was conducted to assess the impact of these TKIs on platelet-leukocyte 
interactions in whole blood sample of TKI, nilotinib-, imatinib- or dasatinib-treated 
patients using flow cytometry. As described in section 2.2.5.4, platelet-monocyte 
aggregates were determined by dual CD14 and CD42a positivity for platelet and monocyte 
recognition. Similarly, platelet-neutrophil aggregation formation was analysed by CD14 
negativity and CD42a positivity for platelet and neutrophil recognition. The percentage of 
either platelet-monocyte aggregates or platelet-neutrophil aggregates was determined by 
flow cytometry in response to a range of platelet agonists: PAR-1 (5 and 10 µM), PAR-4 
agonist peptide (50 and 100 µM) or CRP (0.5 and 1 µg/mL). 
As shown in Figure 6.6A and B, clinical subgroup analysis demonstrated an unchanged 
circulation of platelet-monocyte aggregates and platelet-neutrophil aggregates following 
agonist stimulation with PAR-1 or CRP or PAR-4 in patients treated with nilotinib (also 
receiving aspirin) compared to normal controls on aspirin (P>0.05, n=5). Figures 6.6 C and 
D show positive trends for both circulating platelet-monocyte aggregates and platelet-
neutrophil aggregates in the presence of a soluble agonist in a subgroup of nilotinib-treated 
patients who did not receive aspirin but no statistically significant differences were 
detected when compared to healthy donors (P>0.05, n=3). As shown in Figure 6.6 C and 
D, imatinib-treated patients showed no detectable effects on the interaction of either 
platelet-monocyte aggregates or platelet-neutrophil aggregates following agonist 
stimulation (P>0.05, n=3). Correspondingly, both circulating platelet-monocyte aggregates 
and platelet-neutrophil aggregates were partially reduced in response to PAR-1, CRP and 
PAR-4 agonist peptides among dasatinib-treated patients but no statistically significant 
differences were noted (Figure 6.6C and D) (P>0.05, n=3). These results indicate that 
nilotinib treatment may support in vivo platelet-monocyte and platelet-neutrophil 
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interactions in the absence of aspirin but this trend needs to be confirmed by increasing the 
patient cohort size with more patients on nilotinib therapy. Attenuation of platelet-
monocyte aggregates and platelet-neutrophil aggregates following treatment with platelet 
agonists was observed in patients treated with dasatinib but not with imatinib. 
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Figure ‎6.6. The effect of TKIs on agonist-induced platelet-leukocyte aggregate formation using flow 
cytometric analysis. Whole blood obtained from normal human donors or patients treated TKI. Leukocytes 
were labelled with anti-CD14-FITC and platelets labelled with their specific marker CD42a-PE in the 
presence of platelet agonist CRP (0.5 and 1 µg/mL), PAR-1 (5 and 10 µM) or PAR-4 (50 and 100 µM). 
Platelet-monocyte aggregate formation determined by dual CD14 and CD42a positively for both monocytes 
and platelets. Platelet-neutrophil aggregate formation determined by CD14 negative and CD42a positive for 
neutrophil and platelets. The percentage of (A) platelet-monocyte aggregate and (B) platelet-neutrophil 
aggregate were determined in patients on nilotinib+aspirin therapy. The percentage of (C) platelet-monocyte 
aggregate and (D) platelet-neutrophil aggregate were determined in patients with nilotinib, imatinib or 
dasatinib in the absence of aspirin treatment. The results in A and B are representative of at least 5 patients 
with nilotinib+aspirin therapy while the results in C and D are representative 3 patients/drug without aspirin 
independent experiments performed in triplicate and presented as mean±SEM (P>0.05; n=5/patients-treated 
with nilotinib and aspirin or n=3/ patients-treated with nilotinib, imatinib or dasatinib without aspirin). 
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6.2.4 Measurement of soluble P-selectin 
To examine whether nilotinib and other TKIs treatment altered plasma levels of sP-selectin 
in CML patients, the levels of sP-selectin were measured in patient plasma using sandwich 
ELISA, as described in section 2.2.10.1. As shown in Figure 6.7A, patients with CML 
treated with nilotinib and aspirin demonstrated a significant increase in plasma levels of 
sP-selectin, with a mean±SEM of 32.57±3.16 (ng/mL) compared to 21.71±2.19 (ng/mL) in 
normal controls on aspirin (*P<0.05, n=5). Similarly, nilotinib-treated patients without 
aspirin treatment also had elevated sP-selectin plasma levels, with a mean±SEM of 
42.39±6.56 (ng/mL) compared to 24.94±2.52 (ng/mL) in matched normal controls (Figure 
6.7B). Figure 6.7B showed unchanged levels of sP-selectin in plasma derived from 
patients treated with either imatinib (22.43±3.66 ng/mL) or dasatinib (21.82±1.99  ng/mL) 
without aspirin when compared to normal human controls 24.94±2.52 (ng/mL) (P>0.05, 
n=3). Notably, the spread of plasma levels of sP-selectin reported in the present study is 
consistent with studies of random normal human donors (R&D system) [500]. Based on 
these results, elevated plasma levels of sP-selectin in nilotinib-treated patients in the 
presence or absence of aspirin may indicate that nilotinib induces the exposure of P-
selectin in vivo, resulting in cleavage of P-selectin from activated platelets and/or 
endothelial cells and leading to accumulation of circulating sP-selectin in patient plasma. 
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Figure ‎6.7. sP-selectin levels were determined in TKI-treated patients. (A) Nilotinib-treated patients 
received aspirin therapy versus normal human controls on aspirin. (B) Nilotinib-, imatinib- or dasatinib-
treated patients in the absence of aspirin versus normal human controls. Venous blood was collected from 
patients after 4 hours of TKI treatment. Plasma sP-selectin (ng/mL) levels of patients treated with nilotinib, 
imatinib or dasatinib was determined using commercial ELISA. The results in Figure 6.7A are representative 
of at least 5 patients with nilotinib+aspirin therapy while the results in Figure 6.7B are representative 3 
patients/drug without aspirin independent experiments performed in triplicate and presented as mean±SEM 
(*P<0.05; n=5/patients-treated with nilotinib and aspirin or n=3/ patients-treated with nilotinib, imatinib or 
dasatinib without aspirin). 
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6.2.5 Measurement of soluble CD40L 
Measurement of soluble CD40L was needed to determine whether nilotinib and other TKIs 
treatment alter plasma levels of sCD40L in CML patients. The levels of sCD40L from 
patients treated with nilotinib, imatinib or dasatinib were measured by sandwich ELISA, as 
described in section 2.2.10.2. Clinical group analysis showed significantly elevated 
circulating sCD40L plasma levels in patients receiving nilotinib and aspirin treatment, 
with a mean±SEM of 1.58±0.27 (ng/mL) compared to 1.07±0.06 (ng/mL) (*P<0.05; n=5) 
for the matched controls (Figure 6.8A). Correspondingly, a trend towards increased plasma 
sCD40L levels was observed in patients treated with nilotinib without aspirin when 
compared to normal healthy controls (1.66±0.30 versus 1.10±0.05 ng/mL; P>0.05; n=3) 
(Figure 6.8B). As expected, imatinib treatment had a negligible effect on plasma levels of 
sCD40L when compared to sham control patients (1.22±0.039 versus 1.10±0.05 ng/mL; 
P>0.05; n=3) (Figure 6.8B). Figure 6.8B shows that plasma sCD40L was not affected in 
patients treated with dasatinib when compared with normal controls (1.18±0.01 versus 
1.10±0.05 ng/mL; P>0.05; n=3). Taken together, the results confirm that treatment of 
patients with nilotinib, but not imatinib or dasatinib, may induce in vivo platelet activation, 
as measured by sCD40L [44, 501].  
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Figure ‎6.8. Levels of sCD40L were determined in TKI-treated patients. (A) Nilotinib-treated patients 
received aspirin therapy versus normal human controls on aspirin. (B) Nilotinib-, imatinib- or dasatinib-
treated patients in the absence of aspirin versus normal human controls. Venous blood was collected from 
patients after 4 hours of TKI treatment. Plasma sCD40L (ng/mL) levels of patients treated with nilotinib, 
imatinib or dasatinib was determined using commercial ELISA. The results in Figure 6.8A are representative 
of at least 5 patients with nilotinib+aspirin therapy while the results in Figure 6.8B are representative 3 
patients/drug without aspirin independent experiments performed in triplicate and presented as mean±SEM 
(*P<0.05; n=5/patients-treated with nilotinib and aspirin or n=3/ patients-treated with nilotinib, imatinib or 
dasatinib without aspirin). 
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6.2.6 Measurement of thrombin generation  
In order to determine whether TKIs modulate the activity of pro-coagulant factors in 
plasma derived from CML patients, thrombin generation assay was conducted. These 
patients were treated with nilotinib, imatinib or dasatinib with or without aspirin. 
Thrombin activity was measured in the presence of tissue factor and phospholipids by a 
calibrated automated thrombogram. As shown in Figure 6.9A, thrombin peak 
concentrations were significantly increased in nilotinib-treated patients who received 
aspirin (*P<0.05, n=5), with a mean±SEM of 414.08±37.38 nM, compared to 
258.39±27.71 nM for the matched controls. The ETP levels were also raised in plasma 
derived from patients treated with nilotinib and aspirin, when compared to healthy donors 
on aspirin alone (2434.46±145.47 versus 1990.73±81.70 nM.min; *P<0.05, n=5) (Figure 
6.9B). Likewise, thrombin peak was significantly higher in nilotinib-treated patients 
without aspirin (399.21±44.04 versus 274.25±30.23 nM; *P<0.05, n=3) (Figure 6.9C). The 
levels of ETP appeared to be greater in nilotinib-treated patients without aspirin when 
compared to normal controls (2141.04±231.02 versus 1734.01±22.49 nM.min; *P<0.05, 
n=3) (Figure 6.9D). As shown in Figures 6.9C and D, the thrombin peaks (270.40±63.31 
versus 274.25±30.23 nM; *P<0.05, n=3) and ETP (1767.20±261.82 versus 1734.01±22.49 
nM.min; *P<0.05, n=3) are equivalent between normal controls and patients treated with 
imatinib. The dasatinib-treated patients also had equivalent thrombin peaks (229.72±16.48 
versus 274.25±30.23 nM; *P<0.05, n=3) (Figure 6.9C) and ETP concentrations 
(1675.63±274.97 versus 1734.01±22.49 nM.min; *P<0.05, n=3) (Figure 6.9D) compared 
to normal controls. Overall, these data indicate that nilotinib treatment enhances thrombin 
generation in these patients, whereas imatinib and dasatinib had no effect. 
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Figure ‎6.9. Levels of  thrombin generation in plasma derived from TKI-treated patients. (A) Levels of 
peak thrombin and (B) ETP were measured in plasma from control+aspirin and patients treated with 
nilotinib+aspirin. Levels of thrombin peak (C) and (D) endogenous thrombin potential (ETP) were measured 
in patients with nilotinib, imatinib or dasatinib in the absence of aspirin treatment. Calibrated Automated 
Thrombin Generation using a Fluoroscan Ascent®fluorometer for measuring thrombin generation. The 
results in Figure 6.9A and B are representative of at least 5 patients with nilotinib+aspirin therapy while the 
results in Figure 6.9C and D are representative 3 patients/drug without aspirin independent experiments 
performed in triplicate and presented as mean±SEM (*P<0.05; n=5/patients-treated with nilotinib and aspirin 
or n=3/ patients-treated with nilotinib, imatinib or dasatinib without aspirin). 
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6.3 DISCUSSION 
Several studies have indicated that nilotinib may have a direct effect on vasospasm of the 
blood vessels and initiation of PAOD events over time. However, neither imatinib nor 
dasatinib has this effect [392, 394, 401]. This may be reason why younger patients without 
cardiovascular risk factors can also develop a rapidly progressive form of PAOD over time 
[401]. The intent of this Chapter was to reveal novel insights into the ability of nilotinib 
treatment to modulate dysregulation of platelets and endothelial cells among CML patients 
in the presence or absence of aspirin treatment. First, the results reported here show that 
treatment of patients with nilotinib, but not with imatinib or dasatinib, significantly 
potentiated ex vivo thrombus formation on type I collagen, as analysed by intravital 
microscopy real-time imaging. Secondly, the results from this Chapter demonstrated that 
patients treated with nilotinib but not with the other two TKIs. The potential impact of 
nilotinib treatment on upregulation of pro-coagulation activity in patients was further 
emphasised by confirming increases in the thrombin peak and ETP. Here, the cohorts of 
CML patient treated with various TKIs showed no incidence of cardiovascular disease 
according to the patient database. However, patients with risk factors for vasculature 
events were not excluded. Therefore, some subjects were receiving aspirin (low dose 100 
mg/daily) two weeks after the commencement of nilotinib treatment to prevent unexpected 
vascular events.    
The risk of vascular events increases with known cardiovascular risk factors such as 
diabetes mellitus, arterial hypertension, dyslipidaemia, obesity and advancing age.  
However, arterial vascular events can also be observed in patients with no or minimal risk 
factors and they can be rapidly progressive leading to treatment resistance [502]. Some of 
these patients display vascular events that seem to be vasospastic in nature [503, 504]. 
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Nilotinib may also induce vascular mediated events as a result of metabolic effects of 
increased glucose and lipid levels, or as a direct or indirect effect on vascular endothelium 
and platelets or by stimulating the coagulation cascade in vivo. 
 In this Chapter, in vitro and ex vivo thrombus formation was studied using whole blood 
derived from either healthy donors or CML patients treated with nilotinib, imatinib or 
dasatinib. This approach was used to answer the question of whether nilotinib and other 
TKIs treatment of humans showed correlations with wild-type mice regarding the 
modulation of arterial thrombus formation upon type I collagen in real time. Analysis of 
the captured images over a six minute period revealed that platelet adhesion and the 
thrombi formed on fibrillar collagen under ex vivo flow conditions showed two-fold 
increases in surface coverage of platelets and the thrombus volume in nilotinib-treated 
patients in the absence or presence of aspirin treatment (Figure 6.4A-D and Figure 6.5A-
D). In contrast, ex vivo platelet adhesion and thrombus formation were significantly 
inhibited in patients treated with either imatinib or dasatinib over time when compared to 
healthy human controls (Figure 6.5A-D). Under in vitro conditions of arterial shear flow, 
nilotinib and imatinib had no effect on platelet thrombus growth on immobilised type I 
collagen at all doses tested (Figure 6.1A-D and Figure 6.2A-D respectively), while 
thrombus formation from healthy human whole blood was significantly inhibited by 0.1 
and 1 µM dasatinib (Figure 6.3A-D). These observations are consistent with the findings 
reported in Chapter four where nilotinib treatment of C57BL/6 mice significantly 
potentiated ex vivo thrombus formation (Figure 4.5A-C) whereas imatinib- and dasatinib-
treated mice acted as inhibitory modulators of thrombus formation (Figure 4.4A-C and 
Figure 4.6A-C respectively). In addition, treatment of whole blood from wild-type mice 
with various concentrations of nilotinib or imatinib had no effect on in vitro thrombus 
formation under physiologic shear conditions, whilst dasatinib (0.1 µM and 1 µM) 
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treatment reduced platelet thrombus growth. These observations correlated with previous 
studies indicating that treatment of patients with dasinatib significantly reduced ex vivo 
thrombus growth on type I collagen under arterial shear flow, while treatment with 
imatinib clearly diminished thrombus formation, although the effect was less pronounced 
than with dasatinib [399]. Taken together, these results confirmed strong correlations 
between the results from wild-type mice and normal humans regarding the influence of 
TKIs on platelet adhesion and thrombus formation under in vitro or ex vivo arterial flow 
conditions in real time.  
Aspirin is widely used as a commonly anti-platelet agent and to inhibit platelet activation 
and prevent thrombotic events by 25% through inhibition of TXA2 synthesis, which 
suppresses the COX-1 signalling pathway [125, 505]. This study showed that nilotinib 
treatment, even with aspirin treatment, resulted in the formation of larger thrombi over 
time under shear flow conditions (Figure 6.4A-D). Several studies have shown that aspirin 
treatment does not affect platelet adherence onto collagen in flowing blood perfusion 
[506]. Further studies have verified that inhibition of TXA2 production is not affected by 
aspirin during shear-mediated platelet thrombus growth, suggesting that aspirin has no 
inhibitory influence on arterial thrombus formation at arterial flow conditions at high or 
low shear rates [507-509]. These results may demonstrate an ineffectiveness of aspirin in 
terms of reducing vascular thrombotic occlusion, particularly in patients with high levels 
of arterial stenosis [510]. Consequently, the findings in this Chapter demonstrated that 
patients treated with nilotinib and aspirin will still have larger thrombi formed over time 
compared to matched controls which strongly indicates that nilotinib plays a critical role in 
the development of prothrombotic events in patients despite the anti-platelet effects of 
aspirin therapy. 
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The flow perfusion experiment allowed us to study platelet adherence onto immobilised 
type I fibrillar collagen and platelet-platelet interactions under arterial shear flow [205, 
488]. Under flow conditions, platelets are recruited and tethered to produce a haemostatic 
plug through binding GPIb-IX-V to vWF bound to a thrombogenic surface (collagen). 
Further attachment between the collagen receptor GPVI and integrin α2β1 is then initiated 
to mediate stable adhesion, followed by the release of alpha and dense granule contents to 
amplify platelet activation. Following the platelet aggregation that is mediated via binding 
of the active conformation of αIIbβ3 to fibrinogen, the coagulation cascade is activated and 
ultimately leads to thrombus formation [168, 488, 511]. Taken together, our flow perfusion 
findings in the murine models in Chapter four and the results reported here for human 
patients provide strong evidence for an involvement of nilotinib treatment in triggering 
prothrombotic events and confirm a requirement for the presence of the endothelium to 
prime the platelets in vivo to potentiate ex vivo thrombus formation under arterial flow. 
Exaggerated accumulation of activated platelets at a damaged endothelial site or in 
vascular disease conditions such as ruptured atherosclerotic lesions enrich the levels of 
type I collagen and trigger pathologic thrombosis and responses such as myocardial 
infarction, PAOD and stroke. Increased platelet adhesion to the vascular injury may 
initiate PLAs. This occurs via adhesion of leukocytes to the endothelium or platelets linked 
to the endothelium and P-selectin-mediated rolling that consequently enhances 
atherothrombosis and pro-inflammation [10, 162]. Circulating platelet-leukocyte 
conjugates, mainly monocytes and neutrophils is relatively increased with risk factors for 
cardiovascular disease [428, 449, 512]. PLAs as a sensitive marker used for assessing 
platelet activation in vivo in patients with vascular events [457, 513]. 
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In the study reported in this Chapter, the analysis of platelet-monocyte and platelet-
neutrophil interactions by whole blood flow cytometry demonstrated that nilotinib-treated 
patients who also received aspirin had no detectable responses to CRP, PAR-1 and PAR-4 
in terms of their platelet-monocyte or platelet-neutrophil aggregate formation (Figure 6.6A 
and B). However, a tendency towards an increase in circulating platelet-monocyte and 
platelet-neutrophil aggregates following CRP and PAR-1 and PAR-4 was noted in 
nilotinib-treated patients in the absence of aspirin (Figure 6.6C and D). Other studies have 
reported attenuation of platelet-monocyte and platelet-neutrophil conjugates in patients 
receiving anti-platelet therapy including aspirin, which suggests that anti-platelet therapy 
contributes to the prevention of the interactions of platelets with leukocytes; thereby 
leading to a decreased risk of pro-inflammatory and atherothrombosis [514-516]. 
However, a previous study by Klinkhardt et al. [517] demonstrated that aspirin had no 
effect on platelet-leukocyte aggregate formation, but a significant reduction was observed 
in patients with atherosclerotic vascular lesions who received Clopidogrel. This was due to 
reduced upregulation of the surface predominant integrin receptor-expressed on 
leukocytes, Mac-1 (CD11b/CD18). A reduction in PLAs in whole blood of patients treated 
with aspirin may explain why increased PLAs were observed in nilotinib-treated patients 
in the absence of aspirin. In this Chapter, the increased circulation of platelet-monocyte 
and circulating platelet-neutrophil aggregates in response to agonists was not affected by 
imatinib treatment (Figure 6.6C and D).  
In addition, CRP, PAR-1 and PAR-4-induced platelet-monocyte and platelet-neutrophil 
aggregates were partially inhibited in patients on dasatinib therapy (Figure 6.6C and D). 
As described previously, dasatinib altered platelet activation and aggregation via 
suppressing the SFK signalling pathways [399]. Blake et al. revealed that dasatinib 
inhibited normal human T-lymphocyte function by suppression T-cell receptor (TCR) 
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signal transduction through SFK (Lck) [518], as well as inhibition of the cytolytic activity 
of natural killer cells [519], suggesting that dasatinib acts as a global inhibitor of various 
cells in humans and mice. Futosi and colleagues [520] also stated that dasatinib 
significantly inhibited both integrin-dependent and Fc-receptor-dependent neutrophil 
activation. As previously stated in Chapter three, the TKIs had a negligible effect on PAR-
1 and PAR-4 agonist peptide-induced platelet-monocyte and platelet-neutrophil aggregate 
formation in whole blood derived from normal human donors. Consequently, future 
experiments should investigate the impact of TKI-treated patients on platelet-monocyte 
and platelet-neutrophil aggregate formation in the presence or absence of aspirin before 
any conclusions are drawn. 
Increased circulation of plasma soluble levels of P-selectin and CD40L have been 
described within various subclasses of cardiovascular disease such as atherosclerosis, 
myocardial infarction and arterial thrombosis [9, 45]. Soluble forms of P-selectin and 
CD40L are produced by proteolytic cleavage of surface-expressed P-selectin and CD40L, 
respectively [45, 208, 223, 501]. Today, sP-selectin and sCD40L are widely used as 
bioactive markers of in vivo platelet and endothelial cell activation [45, 208, 473, 501] . 
This Chapter focuses on the levels of sP-selectin and sCD40L that have been measured by 
ELISA in plasma derived from patients treated with nilotinib, imatinib and dasatinib. The 
data showed that plasma sP-selectin levels were significantly elevated in patients treated 
with nilotinib regardless of aspirin therapy (Figure 6.7A and B), whereas plasma levels of 
sP-selectin did not display any changes in patients treated with either imatinib or dasatinib 
(Figure 6.7B). The results in the present Chapter are similar, where significant increases 
were noted in plasma sCD40L in nilotinib-treated patients receiving aspirin therapy 
(Figure 6.8A) and a tendency towards increased plasma sCD40L levels was shown in 
nilotinib-treated patients not receiving aspirin therapy (Figure 6.8B). Equivalent levels of 
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plasma sCD40L were observed in patients treated with either imatinib or dasatinib when 
compared to the controls (Figure 6.8B).  
The observation that nilotinib induced increased soluble P-selectin levels confirms in vivo 
activation of both platelets and endothelial cells with platelets providing the major source 
of P-selectin. sP-selectin is promptly shed from the surface membrane of platelets and 
endothelial cells within minutes of activation and the circulating soluble P-selectin is 
known to bind to its ligand, PSGL-1 on leukocytes to promote microparticle release that 
potentiates thrombus formation in vivo [224, 447, 452]. Increased plasma levels of sP-
selectin have been reported in patients with PAOD [223], inflammation, thrombosis and 
atherosclerosis [521]. According to Romo et al. [229], they demonstrated that GPIbα is 
identified as a platelet counter-receptor for P-selectin on activated endothelial cells. This 
interaction between platelets and endothelium provides evidence that GPIbα has a 
tethering role to capture P-selectin on activated endothelium. The present results are 
consistent with our findings in Chapter four where nilotinib initiated platelet activation 
and/or endothelial cells in vivo via cleavage of P-selectin with a corresponding increase in 
soluble P-selectin in C57BL/6 wild-type mouse plasma. Based on these studies, nilotinib is 
indicated to have direct implication on reactivity of platelets and endothelial cells as 
recognised by increased plasma sP-selectin in both humans and mouse models. 
The finding that nilotinib-treated patients have elevated levels of sCD40L indicates 
activation of platelets and sCD40L release in vivo, either the presence or absence of aspirin 
treatment. Plasma levels of sCD40L were unaffected in patients with treatment of imatinib 
and/or dasatinib. Certainly, CD40 expressed on activated platelets can trigger pro-
inflammatory reactions in endothelial cells to promote secretion of adhesive molecules that 
induce leukocyte rolling at the site of vascular injury or atherosclerotic plaque [219]. The 
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expression of CD40L and its binding with CD40 also results in immediate up-regulation of 
P-selectin and numerous other protein mediators on the platelet surface [480], as well as 
up-regulation of ICAM-1, VCAM-1, and E- and P-selectin on endothelial cells [522].  
The sCD40L is secreted only when platelets are stimulated at the site of thrombosis [501]. 
High levels of sCD40L are reported in thrombotic and pro-inflammatory events [245] 
including PAOD and coronary artery syndrome, and in various cardiovascular diseases 
[247, 501]. Unlike sP-selectin, release of sCD40L was unchanged in plasma from mice 
treated with a single dose of nilotinib or imatinib (refer Chapter four), which would seem 
to indicate that release of sCD40L may require multiple doses rather than a single dose of 
nilotinib in mice. The literature indicates that cleavage of surface-expressed CD40L from 
activated platelets may occur in a few hours, producing sCD40L in vivo [242], whereas P-
selectin is cleaved over a period of minutes [43, 220]. Hence, more studies are warranted 
to evaluate nilotinib induction of sP-selectin and sCD40L in a chronic mouse model. 
Despite the fact that aspirin is commonly used for prevention of cardiovascular events, this 
claim remains controversial since the engagement of aspirin is reported to be a major risk 
of frequent vascular events-e.g. atherosclerosis and atherothrombosis in patients treated 
with aspirin persist at comparatively high rates [523, 524]. The reduced effectiveness of 
aspirin, term ‘aspirin resistance’ and the associated risk of cardiovascular disease was 
reported for thrombotic vascular events [525, 526]. A mechanism underlying aspirin 
resistance could involve different factors such as genetics and the environment but the 
exact mechanisms accounting for aspirin resistance remain unclear [526]. Interestingly, 
our current data clearly demonstrated augmented plasma levels of both sP-selectin and 
sCD40L among patients treated with nilotinib together with aspirin treatment. Other 
previous studies have reported that sP-selectin levels were not affected by aspirin therapy 
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in the absence of other drugs which indicated a limited protective capability of aspirin 
against prothrombotic progression [226, 527, 528]. Quinn et al. [529] showed that aspirin 
(compared with clopidogrel) did not attenuate surface expression of P-selectin and CD40L 
in patients with vascular disease. Andersen et al. [525] reported further evidence that 
levels of sP-selectin were increased in acute myocardial infarction patients despite aspirin 
therapy (75-160 mg/day). Similarly, Undas et al. [530] also stated that the secretion of 
plasma sCD40L levels was not affected in coronary artery disease patients treated with 100 
mg aspirin for at least four weeks. Accordingly, our results provide evidence with regard 
to a potential role for nilotinib, but not imatinib or dasatinib, in the induction of soluble 
plasma levels of P-selectin and CD40L, as indicated by the activation of platelets and 
endothelial cells in our CML patients. 
A calibrated automated thrombogram was used to measure thrombin generation 
parameters in plasma from CML patients treated with nilotinib, imatinib and or dasatinib 
to ascertain their impact on thrombin generation, which reflects the balance between pro- 
and anti-coagulant factors. The fact that nilotinib-treated patients showed increases in both 
thrombin peak and ETP levels in the presence or absence of aspirin treatment (Figure 6.9A 
and B) would suggest that the coagulation cascade is also activated to generate thrombin, 
leading to further platelet activation and potentiating the formation of blood clots. 
Evaluation of thrombin generation together with ex vivo thrombus formation may prove a 
useful screening test to determine which nilotinib-treated patients are more likely to have 
prothrombotic and procoagulant events. Note that thrombin generation measurement 
showed a trend towards increased concentrations of thrombin peak and ETP in imatinib-
treated patients, but no significant difference was noted when compared to the controls 
(Figure 6.9B). In contrast, the dasatinib-treated patients showed a reduction in thrombin 
peak and ETP levels, indicating suppression of the coagulation cascade in terms of 
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thrombin generation (Figure 6.9B). Although the coagulation cascade was altered by 
subsequent aspirin therapy was observed, thrombin formation decreased with the 
subsequent reduction of thrombin-mediated coagulant reactivity. Gum et al. [525] showed 
that decreased responsiveness to aspirin was observed in patients with elevated risk of 
cardiovascular events even at high doses. Furthermore, a previous study reported that 
thrombin generation was not inhibited in response to aspirin (100 mg/day) at the site of 
vascular injury [530] suggesting there are limited effects of aspirin on thrombin generation 
inhibition specifically among subjects with high risk of atherothrombosis. In this thesis, 
Chapter four showed that thrombin generation was not affected in mice following a single 
acute dose of nilotinib or imatinib thereby indicating alterations in coagulation factors that 
usually may occur following chronic but not acute modes of TKI treatment. Further studies 
will be warranted to investigate nilotinib induction of thrombin generation in a chronic 
mouse model. 
In the literature, clinical data indicate that patients treated with nilotinib but not imatinib or 
dasatinib develop a pro-atherogenic phenotype with hypercholesterolemia and increased 
oxLDL, which are major risk factors for atherosclerosis development [392, 400, 401]. In 
vivo, hypercholesterolemia and oxLDL exert a diversity of impacts on the vasculature 
which enhance persistent platelet activation and endothelial dysfunction leading to surface 
expression of P-selectin [218, 219] and CD40L as a consequence of the progression of 
vascular events [219, 243, 244, 531, 532]. Davi et al. [217] demonstrated that increased 
levels of plasma sP-selectin were correlated with hypercholesterolemia and oxLDL levels 
which indicates that oxLDL has an important role in the sequence of events that cause P-
selectin expression and secretion of its soluble form in vivo. Similarly, elevated levels of 
sCD40L were observed in patients with either hypercholesterolemia or oxLDL, which 
might have a direct effect that leads to release of sCD40L [219].  
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Hypercholesterolemia and elevated oxLDL are associated with promotion of the secretion 
of sP-selectin and sCD40L involved atherosclerotic development. However, the 
mechanisms of hypercholesterolemia- and LDL-mediated atherosclerosis are not fully 
understood [217, 219]. This Chapter showed a correlation between sP-selectin and 
sCD40L levels in patients with nilotinib treatment. It would appear that 
hypercholesterolemia and increased oxLDL levels are associated with increased levels of 
sP-selectin and sCD40L following nilotinib therapy, possibly triggering prothrombotic 
phenotypes. Further studies are warranted to investigate the extent of hypercholesterolemia 
and amounts of LDL in both CML patients and mouse models treated with nilotinib to 
identify any correlation with increased levels of sP-selectin and sCD40L. 
Endothelial cell activation has been associated with a diversity of CVD including 
atherosclerosis, coronary artery disease, arterial thrombosis and stroke [490, 533]. Upon 
endothelial activation, critical molecular machinery in the endothelium is activated, 
resulting in expression of proinflammatory cytokines and cell-surface adhesion molecules 
including VCAM-1, ICAM-1 and E-selectin, leading to enhance vasoconstriction, platelet 
aggregation and leukocyte rolling thereby promoting pathogenesis of the vascular 
pathology [219, 534]. Recent studies have revealed that nilotinib, but not imatinib, 
significantly induced the expression of the endothelial activation marker, E-selectin 
(CD62E) and potentiated the expression of other cytoadhesion molecules including 
VCAM-1 and ICAM-1 on HUVECs [448]. Furthermore, more recent observations indicate 
that nilotinib enhances secretion of pro-inflammatory cytokines and upregulation of 
adhesion molecules on the vascular endothelium [448, 535]. These findings by others and 
our observations provide a new insight into the potential influence of nilotinib on platelet 
thrombus formation and the release of adhesion molecules. The magnitude of these effects 
in contributing to the pathological thrombosis demonstrated in our experiments and 
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clinically in humans is still not known. However, nilotinib seems to stimulate an important 
priming event in the vascular endothelial cells and platelets. 
Nilotinib appears to potentiate platelet and endothelial activation that cause surface 
expressed P-selectin and CD40L leading to the release of soluble forms of P-selectin and 
CD40L in in vivo prothrombotic events. However, patients treated with dasatinib or 
imatinib seem to experience platelet and/or endothelial cell inhibition. In this study, results 
were obtained from a relatively small cohort of CP-CML patients treated with nilotinib, 
imatinib or dasatinib. In addition, CML is a relatively uncommon haematological disease 
compared to other types. Therefore, the major limitation of this study is the number of 
patients. Furthermore, most nilotinib-treated patients received aspirin therapy which is a 
direct anti-platelet therapy that can inhibit platelet aggregation an effect principally related 
to inhibition of TXA2 synthesis. Nevertheless, several studies have demonstrated the 
variability of patient responses to aspirin in different platelet function tests, indicating that 
many patients could be defective responders [509, 524, 525]. A similar variability was 
observed in the present study in the particular tests performed, including significant effects 
of platelet-monocyte aggregate and platelet-neutrophil aggregate formation in nilotinib-
treated patients in the absence of aspirin therapy but not in the presence of aspirin. 
Therefore, appropriate studies investigating the effects of these TKIs, and specifically 
nilotinib, on platelets, leukocytes and endothelial cells in modulating arterial thrombus 
formation in CML patients are warranted. In spite of this limitation in sample size, we 
consider that this study has shown the potential role of nilotinib to induce platelet 
thrombus formation, increased PLA tendency, increased thrombin generation and 
enhanced secretion of sP-selectin and sCD40L. Thus, patient recruitment is ongoing which 
would increase the power of the statistical analysis of patient data. 
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In conclusion, this study demonstrates the potential role of nilotinib TKI that triggers 
platelet and endothelial activation in vivo leading to release of sP-selectin, sCD40L and 
thrombin generation in patients with and without cardiovascular risk factors that can 
promote a prothrombotic state. It appears that nilotinib may potentiate atherogenesis via 
the global effects on physiological function of platelets, leukocytes and endothelial cells. 
Moreover, an augmentation in thrombotic tendency and increased reactivity of platelets 
and/or endothelial cells in nilotinib treatment among CML patients can provide further 
evidence and support the hypothesis that nilotinib has a different role to that of either 
imatinib or dasatinib which act as an inhibitory modulators in platelet thrombus formation. 
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7 CHAPTER SEVEN: GENERAL DISCUSSION AND 
FUTURE DIRECTIONS 
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7.1 GENERAL DISCUSSION 
The introduction of a targeted TKI in 2001, in the form of imatinib, confirmed its 
effectiveness as a front-line treatment for CML by its strong inhibition of the abnormal 
PTK function of Bcr-Abl fusion protein [337, 398]. Imatinib has shown much therapeutic 
success in producing long-term clinical remission in many CML patients. However, a 
significant proportion of patients (10-30%) develop resistance mostly due to Bcr-Abl 
kinase mutations and/or intolerance to the drug [339, 353, 356]. This has led to the 
development of the more potent second generation TKIs, nilotinib (an imatinib analogue) 
and dasatinib, which are more efficacious than imatinib at inhibiting Bcr-Abl kinase 
phosphorylation [331, 339, 366, 381, 391]. Nilotinib and dasatinib induce quicker and 
deeper molecular responses to achieve a durable CMR. The data suggest that a significant 
proportion of patients achieving a continued CMR (absence of detection of the Bcr-Abl 
transcript) to 2G TKI’s may be able to terminate treatment without relapse i.e. drug-free 
remission, with both patients and financial benefits (average cost per annum of TKI 
therapy is approx. $50,000) [339, 367, 378, 382, 397, 417]. Therefore, the focus of CML 
therapy and research has swapped to approaches to achieve durable CMR and CHR and as 
such, 2G TKI’s are now progressively used as front-line treatment in preference to 
imatinib. Nevertheless, the treatment of patients with these therapies is restricted due to 
serious complications that can arise [334, 401, 497]. 
Characteristic serious adverse events and CVD including sudden death, PAOD, 
myocardial infarction and spinal infarction, have been experienced by 6.1% (300 mg BID) 
and 12.5% (400 mg BID) of patients undergoing nilotinib therapy, particularly when used 
in long term treatment of CML. None of these complications had been reported in over ten 
years of experience using imatinib [343, 348, 392, 420]. Nilotinib also induced metabolic 
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disturbances, indicated by increased lipid profiles and fasting glucose levels. The existence 
of related cardiovascular risk factors (including smoking, arterial hypertension, diabetes 
mellitus, dyslipidaemia, obesity or male gender aged >60 years) was associated with an 
increased risk of PAOD in patients receiving nilotinib [400, 401, 420]. However, the risk 
is not fully explained by an adverse vascular risk profile, as adverse events occurred 
unexpectedly in patients with a low-risk profile and after a relatively short exposure to TKI 
therapy (within the first two years) [401, 420].  
The data from clinical trials thus far indicate that nilotinib may have specific additional 
prothrombotic/atherogenic effects not observed with other TKIs. Unlike the case for 
nilotinib, increased bleeding complications are documented in patients (40%) treated with 
dasatinib and less commonly in patients undergoing imatinib treatment [344, 388]. In a 
previous study, dasatinib showed potent inhibition of platelet function in vitro, ex vivo and 
in vivo, and it reduced thrombus growth under arterial flow conditions in both human and 
wild-type mouse models. Platelet thrombus formation was diminished in patients treated 
with imatinib but less potently than with dasatinib [399]. Previous studies have shown 
inhibition of the physiological function of platelets by TKIs through their disturbance of 
protein tyrosine kinase phosphorylation [536, 537].  
Platelets are dynamic cell fragments that freely circulate within blood vessels lined with 
endothelial cells in an inactive state under physiological conditions. Platelets are 
implicated as one of the essential blood components that form haemostatic thrombi at sites 
of vessel injury to maintain vascular integrity [158, 485, 538]. Following vascular injury, 
platelets adhere to exposed ECM proteins, in particular vWF and type I fibrillar collagen, 
through the binding of glycoprotein receptors and integrins expressed on the platelet 
surfaces. This induces platelet arrest, and following activation, the platelets initiate the 
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secretion of granule contents and the release of soluble and adhesive mediators. Platelet 
aggregation and thrombus formation results in plug formation that stops the bleeding and 
subsequently induces tissue factor release and activation of the coagulation cascade to 
produce haemostatic thrombi [10, 158, 163]. Platelets are key players in the development 
of atherosclerosis and arterial thrombosis due to their capacity to expedite the generation 
of proinflammatory cells at sites of inflammation or endothelial injury [206, 482]. 
Activation of circulating platelets promotes the secretion of several adhesive and pro-
inflammatory molecules from alpha granules which are translocated and expressed on the 
platelet surface. For instance, TGF-beta, platelet factor 4, the RANTES chemokine, and 
platelet-surface-expressed CD40L and P-selectin (which is cleaved after expression on the 
activated platelet surface to release sP-selectin and sCD40L) are commont molecules 
which are released from alpha granules upon platelet activation [206, 539].  
Platelet-leukocyte interactions are also involved in atherosclerotic plaque lesions that can 
arise from the attachment of leukocytes to the endothelial cells or from platelets associated 
with the endothelial cells, with participation of P-selectin-mediated rolling by the binding 
of PSGL-1 on leukocytes [10, 162]. Previous studies revealed that the interaction of 
platelets with leukocytes involved in atherosclerotic plaques can occur through cross-
linking of fibrinogen with αIIbβ3 and/or Mac-1 [540, 541]. As a consequence, the 
proatherogenic substances released from activated platelets induce a proinflammatory 
response and atherothrombotic events upon atherosclerotic plaque rupture or vascular 
injury [45, 162].  
The major aim of the studies undertaken for this thesis was to compare the effect of 
nilotinib with other TKIs in both human and mouse models in vitro, ex vivo and in vivo in 
order to determine its ability to induce a prothrombotic state. This thesis provides several 
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novel insights into the effects of nilotinib and other TKIs on platelet function and 
thrombus growth. The main findings here have extended the understanding the effects of 
nilotinib on the physiological functions of platelets and have revealed the potential 
mechanisms by which nilotinib induce a prothrombotic state. Variations in the 
mechanisms of nilotinib involving platelet thrombus formation in vivo have also been 
demonstrated. Moreover, this thesis has explored the broad influence of imatinib and 
dasatinib on platelet and thrombus growth development where both have inhibitory effects 
on platelets and thrombus formation in humans and mice. 
In Chapter three, the results demonstrated that in vitro platelet aggregation studies in 
normal humans demonstrated that nilotinib, even at high concentrations, had little effect on 
ADP-, CRP- or collagen-platelet aggregation, whereas dasatinib significantly and dose-
dependently inhibited agonist-induced platelet aggregation (Figures 3.1, 3.2 and 3.3). 
Significant inhibition of platelet aggregation in response to CRP and collagen but not ADP 
agonist was observed in imatinib at various concentrations (10-160 µM) (Figures 3.1, 3.2 
and 3.3). Previous clinical observations were consistent with our results where 59-80% of 
patients receiving dasatinib treatment showed substantially inhibited platelet aggregation 
responses, whereas 33% and 100% of the patients treated with imatinib or nilotinib, 
respectively, showed no changes in platelet aggregation responses following ADP (2 and 
20 µM), collagen (190 µg/mL), arachidonic acid (50 µg/mL) and epinephrine (100 µM) 
[388].  
The data reported in Chapter three demonstrated differential effects of TKIs on secretion 
of platelet granules (dense, alpha and lysosomes) in human platelets in a dose-dependent 
manner. No similar studies have been performed to date, apart from one carried out by 
Gratacap et al. [399], who reported that dasatinib (50 nM) inhibited agonist-induced alpha 
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granule release in human platelets. Analysis of dense granule secretion revealed that 
imatinib and nilotinib had no effect on the induction of dense granule release by thrombin, 
PAR-1, PAR-4 or CRP whereas dense granule release was inhibited in the presence of 
corresponding doses of dasatinib following agonist simulation (Figures 3.5, 3.6 and 3.7).  
Chapter three also provided the first evidence that nilotinib (at concentrations of 10-160 
µM) selectively potentiated platelet activation, displayed as increased PAR-1-mediated 
alpha granule exocytosis (Figure 3.10C). Also, a trend towards a greater increase in alpha 
granule release was seen in response to thrombin (0.5 and 0.25 U/mL), PAR-1 (2.5 µM) 
and CRP (0.5 and 0.25 µg/mL), but not PAR-4 (50 µM) in nilotinib-treated platelets 
(Figures 3.9, 3.10, 3.11 and 3.12). Both imatinib (10-160 µM) and dasatinib (dose-
dependently) inhibited alpha granule exocytosis, corresponding to a reduction in agonist-
induced platelet aggregation responses (Figures 3.9, 3.10, 3.11 and 3.12). This could 
indicate that the impairment of platelet aggregation by imatinib is at least in part regulated 
through the inhibition of alpha granule release. Finally, as shown in Chapter three, human 
platelets treated with various concentrations of TKIs showed no dose-dependent effects on 
lysosomal granule exocytosis (CD63 expression) in response to PAR-1 (2.5 µM) or PAR-4 
(100 µM) (Figure 3.14).  
Lysosomes enclosing acid hydrolytic enzymes are present in platelets with minimal copies, 
suggesting that they may have a phagocytic role but their exact role in platelets still 
uncertain [52, 53]. Furthermore, previous studies demonstrated that the release of 
lysosomal granules  requires a potent agonist (e.g. thrombin) at high doses to produce 60% 
secretion of lysosomal granules; however, release of platelet dense or alpha granules can 
occur in a few minutes following agonist stimulation at the lowest effective doses to give 
close to 100% exocytosis [435]. 
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As described in the first Chapter, platelets are densely populated with various localised 
granules including dense and alpha granules and lysosomes with dissimilar functional 
contents which are released upon platelet stimulation to play important roles in reinforcing 
platelet adhesion and aggregation as well as promoting thrombus growth [40]. It is also 
worth indicating that between the three categories of platelet secretory granules, the alpha 
granule is the most abundant with different proteins such as coagulation factors, adhesive 
molecules (P-selectin, vWF, CD40L), platelet ligands (fibrinogen) and cytokines [41, 42]. 
Therefore, alpha granules are exclusively collaborating in both primary and secondary 
haemostasis. Furthermore, there is evidence that alpha granule constituents are expressed 
on the platelet membrane surface and generate soluble proteins that are released into the 
extracellular plasma, where they function in inflammation, atherosclerosis, and 
angiogenesis [41].  
The current findings may therefore suggest that nilotinib is able to potentiate a selective 
platelet alpha granule pool but not dense granule exocytosis resulting in secretion of 
various proteins (e.g. P-selectin). On the other hand, imatinib (10-160 µM) selectively 
decreased agonist-mediated alpha granule, but not dense granule, secretion in response to a 
soluble agonist. Therefore, imatinib may partially inhibit platelet activation by affecting 
platelet proteins and receptors rather than by electron-dense granules. There is evidence 
further supporting the current observations that the mechanisms initiating platelet dense 
and alpha granule exocytosis are quite similar. Nevertheless, the alpha granule release and 
translocation to the platelet surface following agonist activation is much quicker than 
responses seen in dense granules [439]. This suggests a prospect for selective contributions 
of nilotinib to potentiate release of PAR-1 mediated alpha granule pool but not PAR-4 
while imatinib had all inhibitory effect on alpha granule release in response to soluble 
agonists. 
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Increasing evidence now indicates that elevations in circulating platelet-monocyte and/or 
platelet-neutrophil aggregates are risk factors for cardiovascular disease. Clinically, 
accumulation of PLAs is known to contribute to the pathogenesis of arterial thrombosis, 
making PLAs a potentially sensitive marker for platelet activation [407, 424, 542, 543]. In 
Chapter three, flow cytometry analysis of agonist-mediated platelet-monocyte and platelet-
neutrophil aggregates in vitro from whole blood from normal humans showed no dose-
dependent effects of nilotinib, imatinib or dasatinib (Figure 3.15 and 3.16). Furthermore, 
nilotinib had no observable effects on platelet-monocyte and platelet-neutrophil 
conjugation, despite the presence of protease inhibitors (Figure 3.17). As mentioned in 
Chapter 3, Barnard et al. [407] reported that the determination of PLAs in whole blood in 
vitro is limited because of several issues that can interfere with the analysis. 
Once again, this project hypothesis that nilotinib but not imatinib or dasatinib potentiate 
platelet-endothelial reactivity in vitro, ex vivo and in vivo in both human and wild-type 
mice. we investigated the effect of TKIs on C57BL/6 mouse platelets by comparing 
thrombus formation under in vitro, ex vivo and in vivo physiological flow conditions. As 
described in Chapter four, whole blood from C57BL/6 mice treated with different 
concentrations of imatinib or nilotinib showed no differences in in vitro thrombus growth 
over immobilised type I collagen at an arterial shear rate of 1800
-1
seconds, whereas 
thrombus formation was significantly inhibited over time in blood from mice treated with 
dasatinib (Figures 4.1, 4.2 and 4.3). Furthermore, pre-treatment of cohorts of wild-type 
C57BL/6 mice with a single acute dose of imatinib, nilotinib or dasatinib, 4 hours before 
blood collection, significantly enhanced the thrombus formation on type I collagen 
obtained under arterial shear flow conditions in whole blood in nilotinib-treated mice 
(Figure 4.5), while thrombus growth was reduced in mice treated with imatinib or 
dasatinib (Figures 4.4 and 4.5). Furthermore, the data in Chapter four of this thesis 
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demonstrated for the first time that P-selectin expression on platelets was reduced after 4 
hours of nilotinib treatment (Figure 4.9) in C57BL/6 mice with a corresponding two-fold 
increase in soluble plasma P-selectin levels observed (Figure 4.10). These results provided 
clear evidence for the ability of nilotinib to induce platelet and endothelial cell activation 
in vivo, as P-selectin is stored in the alpha granules of the platelets and to a lesser extent in 
the Weibel-Palade bodies of the endothelial cells. In addition, the results also showed that 
release of plasma sCD40L in mice was unaffected following nilotinib or imatinib therapy 
versus sham control (Figure 4.11). Mice treated with nilotinib, but not with other TKIs, 
promotes ex vivo thrombus growth and triggering the activation state of platelets and 
endothelial cells in vivo. Further studies are warranted to investigate the effect of these 
TKIs on platelet thrombus formation and release of adhesive molecules in a chronic mouse 
model. 
In Chapter five, the results provided some interesting observations about the influence of 
TKIs on in vivo thrombus formation. This study is the first to examine the involvement of 
TKIs on thrombus formation in the FeCl3-induced vascular injury of mesenteric arterioles 
or carotid arteries as a measure of microvascular thrombosis determination of arteriolar 
thrombosis in vivo in mice. Indeed, endothelial redox injury induced by oxidative FeCl3 
treatment exposes thrombogenic ECM substances (collagen and vWF). Consequently, 
circulating platelets bind and adhere to these exposed subendothelial regions which 
promote platelet activation, aggregation and thrombus growth [409, 411]. As shown in 
Figure 5.2 A-D and Figure 5.3A-D, pre-treatment of C57BL/6 mice with imatinib, 
nilotinib or dasatinib for four hours significantly enhanced thrombus growth and stabilised 
phenotype with nilotinib in vivo using FeCl3 induced vascular injury of mesenteric 
arterioles (Figures 5.2 A-D and 5.3A-D). However, smaller and less stable thrombi were 
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reported in mouse arterioles treated with either imatinib or dasatinib (Figure 5.2A-D and 
Figure 5.3A-D).  
In this study, the nilotinib-mediated prothrombotic effect in arterial thrombus formation in 
mouse arterioles was confirmed using an alternate model involving a different and higher 
shear rate vascular bed. Potentiation in thrombus growth following FeCl3-induced vascular 
injury of the carotid arteries was observed in nilotinib-treated mice, where a significantly 
shortened period to >95% vessel occlusion was observed. A significantly prolonged time 
to >95% vessel occlusion was reported in mice treated with dasatinib but not with imatinib 
(Figure 5.6). Interestingly, a reversibility of TKI action on in vivo thrombus formation was 
documented 48 hours after a single dose of drug ingestion (Figures 5.4 and 5.5), as 
expected from the rapid reversibility of the TKI effects, which is consistent with drug 
pharmacokinetics [350, 351, 365, 377, 491]. Treatment of wild-type mice with a single 
dose of imatinib or nilotinib caused no clearly detectable effects on in vivo primary 
haemostasis as the volumes of blood lost and bleeding times were quite similar to those of 
the controls (Figure 5.1A and B). In contrast, we and others [399] showed that reversible 
haemostatic instability, described as an elevated volume of blood lost and prolonged 
bleeding times, occurred in mice treated with dasatinib (Figure 5.1A and B). These results 
indicate that in acute model, nilotinib-treated mice have ability to induce both endothelial 
and platelet activation in vivo which leading to development of arterial thrombus 
formation. 
The findings presented in Chapter six demonstrated that blood from healthy humans 
showed negligible effects on thrombus growth on immobilised type I collagen when 
treated with different concentrations of imatinib or nilotinib, dasatinib treatment 
significantly reduced thrombus growth in real time (Figure 6.1, 6.2 and 6.3). Furthermore, 
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blood from CML patients treated with nilotinib, with or without aspirin therapy, formed 
much larger thrombi on immobilised type I collagen under arterial flow conditions, but 
smaller thrombi were reported in imatinib-treated and particularly in dasatinib-treated 
patients (Figure 6.4, 6.5 and 6.6). These observations are in agreement with similar results 
showing that thrombus formation on immobilised type I collagen was significantly 
decreased in whole blood from patients treated with imatinib or dasatinib [399]. Strikingly, 
the present findings indicated strong correlations between thrombus growth on collagen 
fibres under physiologic in vitro and ex vivo flow conditions in humans and in mice.  
In Chapter six, nilotinib-treated patients who received an anti-platelet agent (aspirin) 
showed unchanged levels of platelet-monocyte or platelet-neutrophil aggregate formation 
following agonist stimulation (CRP, PAR-1 and PAR-4) (Figure 6.6A), whereas there was 
a trend towards an increase reported in patients who received nilotinib therapy without 
aspirin (Figure 6.6B). However, patients treated with dasatinib, but not imatinib, showed 
slight inhibition of circulating platelet-monocyte and circulating platelet-neutrophil 
aggregates following treatment with soluble agonists but the differences were not 
statistically significant (Figure 6.6B). In the literature, some reports have pointed out 
controversies regarding the effect of aspirin on the interactions of platelets with 
leukocytes. Some studies have stated that platelet-monocyte and platelet-neutrophil 
conjugates were unaffected by aspirin but several conflicting findings have demonstrated 
an inhibitory role for aspirin in these interactions [514-517]. Based on the present data, 
aspirin treatment may interfere with and partially inhibit the formation of circulating 
platelet-monocyte and platelet-neutrophil aggregates; therefore, nilotinib would show no 
effect on PLAs in patients on aspirin therapy, specifically those with no risk factors for 
CVD.  
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The results in Chapter six demonstrated for the first time that levels of sP-selectin 
significantly increase in the plasma of patients treated with nilotinib with or without 
aspirin therapy (Figure 6.7A and B). Nevertheless, plasma levels of sP-selectin were 
unchanged in patients treated with either imatinib or dasatinib (Figure 6.7B). Furthermore, 
the results also displayed that plasma levels of sCD40L were significantly elevated in 
nilotinib-treated patients on aspirin therapy (Figure 6.8A), while a positive trend was 
observed in nilotinib-treated patients without aspirin (Figure 6.8B). On the other hand, no 
alterations in levels of sCD40L were observed in the plasma of patients treated with either 
imatinib or dasatinib (Figure 6.8B). Overall, these data provided supportive evidence for a 
direct effect of nilotinib in triggering platelet and/or endothelial cell activation and 
inducing secretion of soluble forms of adhesive molecules in vivo. 
Moreover, the data in Chapter six revealed that nilotinib-treated patients who received 
aspirin therapy showed increases in both the thrombin peak and ETP concentrations 
(Figure 6.9A and B). These findings suggest that the coagulation cascade is also activated 
to generate thrombin, leading to further platelet activation that potentiates the formation of 
blood clots. Evaluation of thrombin generation, together with ex vivo thrombus formation, 
may prove useful as a screening test to determine which nilotinib-treated patients are more 
likely to have prothrombotic and procoagulant events. In terms of future treatment 
strategies, the use of anticoagulants may prove to be beneficial in a subset of patients with 
increased thrombotic risk, in order to reverse this procoagulant potential induced by 
nilotinib. By contrast, dasatinib, but not imatinib, reduced the thrombin peak and ETP 
levels, indicating inhibition of the coagulation state in terms of thrombin generation 
(Figure 6.9B). As mentioned in Chapter six, aspirin treatment would probably reduce 
platelet-monocyte and platelet-neutrophil aggregate formation but not thrombus growth 
under flow shear [507, 508] following secretion of adhesive proteins [226, 527-530] and in 
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response to procoagulant  activity [525, 530]. Therefore, nilotinib appears to activate 
platelets and endothelial cells in vivo as well as trigger hypercoagulability. Further studies 
of these observations are required for verification. 
As described in Chapter three, nilotinib dose-dependently induces P-selectin exposure 
through potentiation of alpha granule release mediated by PAR-1 but not PAR-4 in healthy 
human donor platelets. Previous studies described that human platelets contain different 
alpha granule pools, including PAR-1-mediated alpha granule release VEGF and 
fibrinogen-containing pro-angiogenic proteins but not endostatin and PAR-4-mediated 
alpha granule release endostatin and vWF-containing anti-angiogenic proteins but not 
VEGF [207, 441]. Taken together, these results indicated that nilotinib potentiates the 
release of pro-angiogenic proteins, VEGF and fibrinogen. Nilotinib can potentiate 
selective alpha granule release in platelets, which leads to surface expression of P-selectin 
on platelets. This can then bind PSGL-1 on leukocyte surfaces which mediates the 
interactions of platelets and leukocytes as well as the interaction of platelet-leukocytes 
with activated endothelial cells [445, 446]. 
The PTKs are prominent components in platelets, where they play important roles in 
regulation of platelet activation and aggregation [402]. Most TKIs used thus far for 
leukaemia treatment are generally selective for Bcr-Abl kinase ATP binding pocket but off 
targeting effects can lead to problems of platelet and endothelial cell activation which 
significantly promote atherogenesis [399]. Indeed, imatinib and nilotinib target Abl, c-Kit 
and PDGFR [341, 418] whereas dasatinib targets Abl, c-Kit, PDGFR and SFKs. All these 
TKIs have significantly improved the therapy of patients with CML [382, 391]. A previous 
study reported that dasatinib is an effective reversible inhibitor of ITAM-mediated 
signalling pathways in platelets, particularly FcRIIa and collagen GPVI/FcR gamma 
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chain that involve tyrosine phosphorylation, PI3-kinase activation and PLC/DAG kinase 
activation. Dasatinib also negatively affected the active conformation state of integrin 
αIIbβ3 signalling pathways that are well identified to contribute SFKs [140, 399]. Literature 
reports indicate that imatinib triggers myelosuppression and induces reversible neutropenia 
and thrombocytopenia [334, 544]. Furthermore, a previous study by Seggewiss et al. [545] 
demonstrated that imatinib significantly inhibits TCR-mediated production and activation 
by reducing the maximum proximal signalling pathways via inhibition of SFKs, in 
particular Lck. As a member of the SFKs, Lck is present in both human and rodent 
platelets and plays an important role in activating many intracellular signalling pathways 
and mediated regulation of platelet activation [297, 298]. Based on these results, the 
present results and others [399] showed that imatinib inhibits platelet thrombus growth in 
humans and mice. Theoretically, imatinib may inhibit Lck-mediating signalling pathways 
in platelets and would be expected to impair platelet activation and reduce thrombus 
growth, so further study is warranted to verify this hypothesis.  
It is extensively acknowledged that platelets play a significant role in the emergence of 
cardiovascular disease and that they mediate arterial thrombus formation in both humans 
and mice [10, 162]. The platelets from humans differ slightly in their receptor repertoire 
from those of the mouse. For instance, FcγRIIa is present in human but not in wild-type 
mouse platelets, working as GPVI/Fcγ chain or CLEC-2 ITAM bearing receptors to 
activate platelet events upon phosphorylation [546]. Additionally, PAR-1 and PAR-4 G 
protein coupled receptors are both expressed on platelets as protease-stimulated targets for 
thrombin, which are potent activators of platelets. PAR-1 works as the predominant 
thrombin receptor in humans but to a lesser extent in mouse platelets which could be due 
to its greater affinity and higher sensitivity to thrombin in humans than in mice, while 
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PAR-4 has a low-affinity and sensitivity in response to thrombin in human platelets but 
predominates in mouse platelets [97, 98, 106].  
Once again, the results of this thesis demonstrated for the first time that nilotinib 
significantly induced thrombus formation under ex vivo and in vivo but not in vitro arterial 
flow conditions in both humans and mice. The observations confirmed the correlations 
between humans and mice in regard to increased thrombus growth in the presence of 
nilotinib therapy. Chapter four highlighted that mice treated with a single dose of nilotinib 
showed no upregulation of platelet glycoprotein expression-mediated platelet function 
(Figure 4.7) or induction of an active conformation of the major platelet integrin αIIbβ3 
complexes that would enhance platelet-platelet interactions (Figure 4.8). The results 
indicate that the effect of nilotinib on thrombus growth was independent of platelet 
glycoprotein expression. The presented results in this thesis therefore, suggest that the pro-
thrombotic effect of nilotinib treatment in humans or mice required the presence of 
endothelium to prime the platelets in vivo for potentiation of ex vivo thrombus formation 
under arterial shear. 
Dysfunction of endothelial cells plays a crucial role in the development of cardiovascular 
disease and is characterised by disturbed platelet function, recruited leukocyte adhesion 
and enhanced generation of pro-inflammatory mediators and adhesion molecules. 
Secretions of bioactive adhesive molecules, such as [490] P-selectin [224, 425] and 
CD40L [208, 242], from activated platelets play a fundamental role in the pathophysiology 
of multicellular vascular events, as these molecules have ability to mediate association 
between platelets, leukocytes, endothelium and the coagulation cascade in which 
significantly involve in atherosclerosis, inflammation and atherothombosis [45, 521]. 
Increases in plasma-soluble P-selectin and CD40L in vivo are widely acknowledged to 
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promote cardiovascular disease and atherothombosis. Therefore, these are commonly used 
as bioactive markers of platelets and endothelial cells in vivo [45, 208, 473, 501].  
One intriguing aspect of adverse vascular thrombosis development is the relatively short 
interval between commencement of nilotinib treatment and the incidence of arterial 
thrombosis, but the mechanisms through which nilotinib may induce prothrombotic events 
remain speculative [392, 401]. This thesis demonstrated interesting findings in support of 
the hypothesis that the occurrence of a prothrombotic state is likely to be triggered in the 
presence of a nilotinib regimen. Once again, results arising from this thesis reported that 
nilotinib has the ability to trigger platelet and endothelial activation in vivo, leading to the 
secretion of sP-selectin and sCD40L and thrombin generation; thereby predisposing to a 
prothrombotic state.  
One interesting aspect is that nilotinib is a structural analogue of imatinib and is highly 
efficacious in targeting and inhibiting Bcr-Abl phosphorylation [337, 339, 417]. Clinical 
data indicated an increased occurrence of higher fasting blood glucose (hyperglycaemia), 
hypercholesterolemia and LDL during nilotinib treatment; these effects were only rarely 
observed with imatinib [392, 394]. By comparison, several reports showed lower fasting 
blood glucose in imatinib-treated patients suggesting imatinib may have a vasoprotective 
role and protect against the formation of diabetes mellitus-mediated atherosclerosis plaque 
[547, 548].  
The increases in fasting glucose levels in response to nilotinib therapy may trigger 
endothelial dysfunction and platelet hyperactivity which contribute to induction of 
thrombogenic adhesive molecules resulting in the development of cardiovascular disease. 
It is now known that hyperglycaemia is also associated with reduced NO production and 
induces ROS generation which leads to endothelial dysfunction. In the literature, elevated 
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glucose levels among people in particular in type-2 diabetes are related with various 
pathological alterations including high blood cholesterol levels, high blood pressure, and 
increased coagulation factors [549, 550]. A previous study showed that hyperglycaemia 
accelerates platelet hyper-aggregation and induces arterial thrombus growth as well as 
hypercoagulability in humans [550, 551] and diabetic mice [552]. A study by Vaidyula et 
al. [553] demonstrated hyperglycaemia induced platelet stimulation in healthy people due 
to increases in surface-expressed P-selectin and CD40L. A further study by 
Gokulakrishnan et al. demonstrated increased levels of sP-selectin and sCD40L in 
individuals with impaired glucose tolerance or diabetes mellitus [554].  
In vivo, hypercholesterolemia and LDL exert a multiplicity of effects on the vasculature,  
enhancing persistent platelet activation and endothelial dysfunction, which leads to 
increased expression of pro-atherogenic cytoadhesion molecules such as P-selectin [218, 
219] and CD40L as a consequence the development of vascular events [219, 243, 244, 
531, 532]. Subsequently, elevated levels of sP-selectin and sCD40L were observed in 
patients with either hypercholesterolemia or LDL which might have a potentially direct 
effect that would lead to the release of sCD40L [217, 219]. The triggering of 
hypercholesterolemia and LDL in response to nilotinib regimen would therefore appear to 
be associated with increased levels of sP-selectin and sCD40L in the plasma as a 
consequence of the development of prothrombotic phenotypes. 
Another potential mechanism that could lead to arterial thrombosis nilotinib therapy could 
be vasospasms. The present observations indicate that nilotinib may induce 
vasoconstriction in the carotid arteries, mediated at least in part by platelet-activating 
factors and nilotinib would also appear to initiate an unexpected constriction of blood 
vessels. Stenotic artery events were frequently observed in patients undergoing nilotinib 
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therapy (a frequency of 25%) which suggested that nilotinib mediates vasospasms that 
induce platelet activation and PAOD development [392, 401].  
A further interesting aspect is that P-selectin associated with PSGL-1 in vivo triggers 
leukocyte recruitment and leukocyte-derived microparticles thus enhancing thrombus 
formation and fibrin deposition at sites of injured vascular endothelium resulting in 
atherosclerotic development [442]. Increased plasma levels of sP-selectin induces the 
generation of tissue factor mediated by leukocyte-derived microparticles and also activates 
endothelial cells to induce tissue factor exposure that mediates thrombus formation [232]. 
Further studies are required to investigate the effect of nilotinib on tissue factor secretion 
that trigger microparticle release and on tissue factor expression to address this limitation 
in the present study. 
As mentioned previously, the involvement of platelets in the early processes of arterial 
thrombosis is now extensively accepted. The association of platelets with leukocytes as 
well as endothelial cells induces autocrine and paracrine signalling pathway events that 
promote leukocyte recruitment to the endothelium which leads towards vascular 
thrombotic states. Propagation of pro-inflammatory mediators and adhesive molecules 
from activated platelets initiates endothelial cell stimulation, which encourages pro-
atherogenic phenotypes [206, 447, 481, 555]. Recent findings demonstrated that a pro-
atherogenic effect was initiated by nilotinib but not imatinib due to an increased expression 
of the endothelial activation marker, E-selectin (CD62E) and augmented expression 
cytoadhesion molecule including ICAM-1 and VCAM-1 in HUVECs [448]. Furthermore, 
recent clinical data demonstrated that nilotinib significantly induced upregulation of pro-
inflammatory cytokines and increased surface expression of adhesion proteins where 
showing raised levels of oxLDL, sCD40L and ETP in CML patients suggesting the 
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nilotinib treatment of patient increased risk of atherothrombotic vascular events [535]. 
Ultimately, potentiation of arterial thrombus formation could possibly have arisen from the 
synergistic influences of nilotinib on the physiological function of platelets and the 
endothelium coating of the vascular wall that triggered release of pro-inflammatory 
molecules, the formation of thrombogenic adhesive proteins and accelerated prothrombotic 
episodes; thereby increasing vessel occlusion (Figure 7.1). Importantly, assessment of 
thrombin generation, activation markers of platelets and endothelial cells together with ex 
vivo thrombus formation may be useful screening tests to identify which nilotinib-treated 
patients are at risk of developing prothrombotic events. 
7.2 CONCLUSION 
In this thesis, several studies successfully demonstrated differences in the behaviour of 
various types of TKIs and the ability of nilotinib, but not imatinib or dasatinib, to 
potentiate prothombotic phenotypes in vivo using complementary approaches. It has 
provided insight into the potential mechanisms of arterial thrombosis during nilotinib 
treatment which apparently triggers dysfunction of platelets and/or endothelial cells, 
leading to the induction of adhesive mediators, specifically P-selectin with a corresponding 
increase in plasma sP-selectin, in humans and mice. These findings have further revealed a 
crucial role for nilotinib promotion of an inflammatory mediator (CD40L), increased 
thrombin generation and a trend towards increased formation of platelet-monocyte and 
platelet-neutrophil aggregates among TKI treated CML patients.  
These findings presented in this thesis suggest that nilotinib may potentiate atherogenesis 
though the global effects on the physiological function of platelets, leukocytes and 
endothelial cells. Furthermore, the increased reactivity of platelets and/or endothelial cells 
in nilotinib-treated patients is further evidence and support for the working hypothesis that 
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nilotinib has a distinct role from both imatinib and dasatinib which have inhibitory effects 
on platelet function profiles and thrombus formation in both humans and mice. Overall, the 
results arising from this thesis have provided some insight into the possible mechanisms of 
nilotinib, imatinib and dasatinib in haemostasis or thrombosis. In particular, the data have 
further elucidated the potential role of nilotinib in platelets and endothelial cell function as 
well as arterial thrombus formation ex vivo and in vivo in both humans and wild-type mice. 
The significance of the outcomes made in the thesis on the crucial role of nilotinib in the 
development of thrombus growth in both humans and mice has improved our 
understanding of nilotinib in the potential mechanisms of atherothrombosis. This might 
illuminate the pro-thrombotic phenotypes observed in CML patients with nilotinib therapy. 
Based upon this study, these findings would prompt an evaluation of the beneficial use of 
anti-platelet drugs, anti-adhesive mediators (e.g. anti-P-selectin), anticoagulants and anti-
vasoplastic drugs in nilotinib-treated patients. Treatment of patients with inhibitory drugs 
such as anti-platelets and anti-adhesive mediators will contribute to reduce the potential 
adverse events of nilotinib and lead to improve the outcome of nilotinib-treated patients. 
The present challenge for physicians is to maintain the balance between life-saving 
leukaemia therapy and risks from adverse treatment-related vascular thrombosis effects, to 
avoid organ failure or destruction. Basic and clinical research is required to provide 
physicians with helpful guidelines and to understand the effects of these drugs on platelets 
in CML patients. This approach will help to establish individualised treatment and 
eventually provide the best outcomes by reducing the morbidity and mortality of 
cardiovascular disease. 
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Figure ‎7.1. Nilotinib induces platelet activation, endothelial dysfunction, inflammation and 
atherothrombosis. Nilotinib may trigger platelet and endothelial cell activation in vivo resulting 
upregulation of cellular adhesion proteins and release of soluble adhesion molecules including sP-selectin 
(sCD62P) and sCD40L that reinforcing the atherothrombosis. Nilotinib can further induce pro-atherogensis, 
increased ICAM-1 and VCAM-1 cytoadhesion expression. Nilotinib may exert a global effect on vascular 
endothelium and blood components, in particular platelets via multiple mechanisms and targets. Adapted 
from [219]. 
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7.3 FUTURE DIRECTIONS 
The studies performed in this thesis clearly demonstrated that nilotinib potentiates alpha 
granule expression (P-selectin) and increased plasma levels of sP-selectin in human and 
mice, suggesting platelet and endothelial cell activation in vivo. The results indicated a 
potential mechanism of action of arterial thrombosis by nilotinib that involves greater 
potentiation of alpha granule secretion in comparison to its effect on other platelet 
granules. Further studies are warranted to investigate the influences of TKIs on platelet 
secretion mechanisms, as well as on the release of alpha granule protein contents. 
Although sP-selectin is principally derived from activated platelets, it is also released from 
endothelial cells upon activation. Currently, we cannot differentiate cellular origin of sP-
selectin with current tests. Thus, further work is required to identify the origin of sP-
selectin in response to nilotinib treatment. The association of surface-expressed P-selectin 
from activated platelets and endothelial cells with PSGL-1 on leukocytes promotes the 
interactions of platelets and leukocytes on activated endothelial cells enhancing 
microparticle release that potentiates thrombus formation in vivo. Further studies therefore 
will be warranted to examine the ability of P-selectin binding and its ligand-mediated 
platelet-leukocyte interactions with the endothelium and to test microparticle release in 
humans and mice with TKI treatment. Further studies are warranted to measure markers of 
endothelial cell activation with greater specificity, such as E-selectin (CD62E) and pro-
inflammatory cytokines in C57BL/6 mice and human patient samples on nilotinib therapy.  
The results of this thesis indicate that humans or mice treated with nilotinib showed 
potentiation in ex vivo thrombus formation on type I collagen under arterial shear flow, 
while imatinib and dasatinib had an inhibitory role. Moreover, nilotinib-treated mice 
induced larger and more stable thrombi formed in vivo following FeCl3 mediated vascular 
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injury of mesenteric arterioles and carotid arteries, whereas smaller and less stable thrombi 
were reported with imatinib and dasatinib. However, further work is required to define the 
mechanism/s by which nilotinib potentiates human and mouse platelet activation, 
haemostatic potential and ex vivo thrombus formation under flow and platelet signalling 
profiling. Assessment of interactions of other ECM ligands such as fibrinogen or vWF 
with platelet receptors compared to type I collagen will provide evidence for a selective or 
global effect of nilotinib on ex vivo thrombus formation under flow. 
Nilotinib may activate the endothelial cell surface to express a thrombogenic phenotype 
inducing hypercoagulopathy. In this thesis, the results showed that nilotinib-treated, but 
not imatinib- or dasatinib-treated, human patients, but not mice, have elevated levels of 
thrombin generation. Thus, further studies will be warranted to evaluate coagulation 
profiles (PT, APTT, fibrinogen), microparticles, overall haemostatic potential (OHP), 
overall fibrinolytic potential (OFP) and thrombin generation in plasma of humans and 
C57BL/6 mice on nilotinib therapy to provide further insights into nilotinib mediated 
hypercoagulability.  
In this thesis, reduced thrombus formation was observed in nilotinib-treated mice received 
P-selectin blocking antibody, indicating that nilotinib has a direct role in modulating 
thrombus growth via inhibition of P-selectin expression in platelets and endothelial cells. 
However, the results demonstrated enhanced thrombus growth in nilotinib-treated mice 
with P-selectin blocking antibody versus mice treated with P-selectin blocking antibody 
alone indicating that nilotinib may have multiple off targeting effects on platelet thrombus 
formation. Further studies will be warranted to investigate the potential to ameliorate the 
nilotinib prothrombotic phenotype through anti-platelet agents, P-selectin blocking 
antibody (to demonstrate P-selectin), ADAM8, 10 or 17 (all expressed on platelets, 
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specific inhibitors to define possible cleavage protease), clopidogrel or aspirin (both anti-
platelet), atorvastatin (maintain lower cholesterol level) or calcium channel blockers. 
In the clinic, human CML patients are given a standard dose of nilotinib (300 mg BID), 
imatinib (400 mg/day) or dasatinib (100 mg/day), while in animal experiments in this 
research; a single acute dose of TKIs was given into wild-type mice that correlated with 
equivalent dosing used in patients for four or 48 hours prior to sample collection. 
Therefore, pre-treatment of mice with multiple doses (chronic dose model) are a subject 
for further studies. Additionally, in this study, healthy wild-type mice were used to study 
platelet mediated thrombus growth. This therefore requires further studies to examine the 
effect of these TKIs on platelet mediated arterial formation in a leukemic Ph+ mouse 
model treated with the TKI therapies. 
In this study, data achieved from a small cohort of CML patients were treated with 
nilotinib, imatinib or dasatinib; therefore, the major limitation is the number of patients. 
Furthermore, most nilotinib-treated patients received aspirin therapy, which has a direct 
anti-platelet effect that can reduce platelet aggregation responses through inhibition of 
TXA2 synthesis. Therefore, appropriate patients are needed to participate in studies for 
further investigation of the effect of these TKIs, and specifically nilotinib, on platelets, 
leukocytes and endothelial cells in mediating arterial thrombosis. Further studies are also 
required to perform correlation studies to investigate the association between risk factors 
(increased blood glucose and oxLDL levels) and thrombogenic potential among patients 
undergoing TKI treatments. 
Nilotinib is analogue of imatinib, a phenylamino-pyrimidine derivative, derived through 
rational drug design based upon the crystallographic structure of imatinib-Abl complex. 
Nilotinib varies structurally from imatinib with the amidobenzene substituted with the N-
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methylpiperazine moiety in imatinib, with an aminobenzene carrying trifluoromethyl and 
methyl imidazole substitutions. The adapted chemical structure has led to improved Bcr-
Abl binding activity and potency compared to imatinib. However, correspondingly 
nilotinib having a very dissimilar effect on platelet function and ex vivo thrombus 
formation compared to imatinib. Further studies are required to assess whether structurally 
nilotinib can potentiate selective release of alpha granules by a PAR-1 dependent P-
selectin exposure in platelets and ex vivo thrombus formation on type I collagen, using 
targeted synthetic strategy to obtain important structural analogues of nilotinib. This study 
will investigate structure-activity relationships resulting from the introduction of specific 
substitutions in the meta-positions of nilotinib’s aminobenzene moiety, which comprises 
the main differences from imatinib’s chemical structure. This approach will provide 
structural evidence on the importance of different nilotinib derivatives in inducing PAR-1-
mediated alpha granule release in platelets and ex vivo thrombus growth. Chemical 
derivatives identified that avoid the potentiation of platelet stimulation and arterial 
thrombus formation but retain potent Bcr-Abl kinase inhibition. 
Future work is required for investigating platelet signalling profiling in humans and 
C75BL/6 mice on TKI treatment. Platelets will be isolated from whole blood derived from 
untreated and TKI treated mice. Basal and collagen or CRP global tyrosine 
phosphorylation profiles over time will be by western blot analysis.  This will recognise 
the sizes of tyrosine phosphorylated proteins that are upregulated by TKI’s that can then be 
determined with phosphospecific antibodies in western blot analysis. Furthermore, 
evaluation by chemical proteomic profiling and phospho-array analysis of platelets 
isolated from untreated versus TKI treated mice will be carried out using a mouse 
phospho- RTK array that screens 39 different receptor tyrosine kinases to help identify the 
molecular RTK targets of TKIs in mouse platelets. As platelets are terminally 
  
 261  
differentiated and anucleate fragments in blood, TKIs in particular nilotinib and may have 
novel molecular targets or may show a broad off targeting effects compared to a cultured 
K562 cancer cell line where nilotinib was demonstrated to target Abl, PDGF, c-Kit and 
DDR1 [378, 556]. Different studies will be performed on platelets isolated from CP-CML 
human patients with no active disease that have imatinib resistance that are changed over 
to nilotinib compared with imatinib treatment alone. Assessment of various platelet 
signalling pathways will include human phospho-receptor tyrosine kinase array (49 
different RTKs), human phospho-MAPK array (24 kinases including Akt, Erk1, 2 and 
p38), human phospho-kinase antibody array (43 kinases) and human phospho-
immunoreceptor array (59 ITAM/ITIM associated immunoreceptors). However, the key 
issue is that nilotinib TKI has off targeting effects so signalling profiling may not reveal 
specific targets within a given signalling pathway. It may identify a range of upregulated 
or hyper-phosphorylated signalling molecules or receptors in platelets. Using this approach 
may help identify the molecular targets of these TKIs in human and mouse platelets. 
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